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Urinblærekreft er en av de hyppigste kreftformene i verden med høy frekvens av 
tilbakefall og progresjon. Omtrent 70-80 % av diagnostiserte tilfeller av urinblærekreft 
er ikke-muskel-invasiv blærekreft (NMIBC). Denne kreftformen er potensielt godt 
egnet for behandlingsformer som fotodynamisk terapi (PDT) eller fotokjemisk 
internalisering (PCI). Denne avhandlingen beskriver bruken av både PDT og PCI i fire 
prekliniske studier på urinblærekreft.  
 
I studien av PDT-effekt på proteinuttrykk og post-translasjonelle modifikasjoner (PTM) 
ble hexyl 5-aminolevulinate (HAL) brukt til å mediere PDT i en kreftcellelinje fra 
rotteblære (AY-27). Målet var å utvide vår forståelse av PDT-mekanismen. Ved å 
kombinere todimensjonal gel-elektroforese (2D-DIGE), immunopresipitering og 
massepektrometri identifiserte vi 40 proteiner som ble kartlagt for endringer knyttet til 
PDT, og identifiserte dessuten 10 proteiner med endret karbonylering. Det ble vist at 
PDT påvirket proteinuttrykk og induserte proteinmodifikasjoner. Dette tyder på at PDT 
utløser en kompleks cellulær respons som involverer flere biologiske prosesser, slik 
som transport, stressrespons, DNA-reparasjon, overlevelse og celledød.  
 
I den neste studien så vi på transportmekanismer for 5-aminolevulinate (ALA) og metyl 
aminolevulinate (MAL) via GABA-transportør (GAT) i forbindelse med PDT. Vi 
modellerte fire humane GAT-er ved molekylmodellering (ICM). Etter kvalitetssikring 
av modellene ble GABA, ALA og MAL dokket til bindingssetet i hver modell, og 
elektrostatiske potensialer (ESPs) i porene for translokasjon i modellene ble beregnet. 
Resultatene tyder på at ALA kan være substrat for alle GAT-ene, mens MAL er substrat 
for GAT-2, GAT-3 og BGT-1. I tillegg kan forskjeller i ESP mellom transportørene bli 
utnyttet i utviklingen av selektive inhibitorer, for eksempel for å redusere smerte i PDT 
ved bruk av ALA eller MAL. 
 
For å forbedre effekten av bleomycin som cytostatika ved blærekreft ble PCI kombinert 
med bleomycin i tre cellelinjer (T24, AY-27, A431), ved hjelp av en ny amfifil 
fotosensitizer tetrafenyl klorin disulfonat (TPCS2a). To nye strategier for å forsterke 
PCI-bleomycin effekten ble studert; et nytt peptid-basert medikament ATX -101, som 
kan svekke DNA- reparasjon, og en proteaseinhibitor E-64, som kan inaktivere 
bleomycin hydrolase. Våre resultater viser at PCI øker bleomycin-effekten, og at denne 
effekten blir ytterligere forsterket av ATX-101. Vi viser også at PCI øker 
DNA-skadenivået (studert med comet assay), noe som tyder på at den observerte 
effekten skyldes økt cellulær internalisering av bleomycin.  
 
For å etablere en protokoll for PCI-bleomycin i dyreforsøk med TPCS2a fotosensitizer 
ble kinetikk og lokaliseringen av TPCS2a studert i en etablert dyremodell for blærekreft i 
rotte, ved bruk av histologi og ex vivo fluorescensmålinger. Dette viser at TPCS2a har et 
overfladisk distribusjonsmønster i tumorvevet i rotteblæren, og at det er nesten 
fullstendig eliminert fra tumorvevet etter 72 timer. En optimal protokoll for TPCS2a ble 
utviklet for dyremodellen, inkludert et 24 timers TPCS2a-til-lys-intervall med en dose på 
3 mg/ml TPCS2a. 
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Background and introduction 
 
1. Photodynamic therapy 
 
Photodynamic therapy (PDT) is an effective treatment modality involving light and a 
photosensitizer used in conjunction with molecular oxygen to elicit cell death [1]. PDT 
is based on a two-stage process. The first stage is the selective accumulation of a 
photosensitizer in tumor cells in the absence of light. In the second stage, the 
photosensitizer is activated by light of the appropriate wavelength and intensity. 
Activated photosensitizer evokes responses in the tumor cells by reacting with 
molecular oxygen to produce reactive oxygen species (ROS). Subsequently, these ROS 
interact with cellular constituents causing biochemical disruption to the cell and 
induction of cell death in the mode of apoptosis, necrosis or autophagy. ROS produced 
by PDT can also cause direct cytotoxicity, destruction of tumor vasculature and 
induction of acute inflammatory response that further lead to activation of an immune 
response [2,3,4].  
 
 
1.1 Photodynamic therapy (PDT) in medicine 
 
De Rosa et al. and Juzeniene et al. have summarised the early history of PDT in several 
reviews [5,6,7]. The first attempts to use PDT to treat tumors and skin diseases were 
performed at the beginning of the twentieth century in Munich by the group of professor 
von Tappeiner. The discovery of oxygen-dependent photodynamic action was described 
and favorable results were reported using a number of dyes such as eosin and 
fluorescein [8]. However, there was no long-term follow-up, probably because of the 
advent of ionizing radiation in cancer therapy, until the application of hematoporphyrin 
derivative (HpD) for PDT in 1980s. Hematoporphyrin (Hp) was found to have a tumor-
localizing ability in a variety of human malignancies. The purification of Hp led to HpD 
which contains several porphyrin monomers, dimers and oligomers. Dougherty and his 
co-workers partly purified HpD by removing the monomers [9,10,11]. The resulting 
product was called Photofrin (Porfimer sodium) which is still the most widely used 
photosensitizer for clinical PDT. This pioneering work established the modern era of 
PDT [5,12]. 
 
Hans Fischer, who was awarded the Nobel Prize for his work on porphyrins, first 
reported in 1925 that uroporphyrin had similar phototoxicity as Hp although it is more 
water soluble than Hp [13]. PDT using 5-aminolevulinic acid (ALA, a precursor to 
heme synthesis) started in 1987 [14,15], when several investigators reported preferential 
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accumulation of porphyrins and porphyrin precursors in neoplastic tissue induced by 
exogenous ALA [5,6]. However, protoporphyrin IX (PpIX) was observed to be 
converted into heme and/or cleared from the body rapidly after systemic administration 
due to natural clearance mechanisms, which was problematic for practical use [5,6] . It 
was in 1990 that Kennedy and Pottier established successful clinical ALA-PDT by 
topical administration in the treatment of human skin tumors [16]. Since then, 
endogenously stimulated formation of PpIX has been one of the fastest developing areas 
in PDT and photodynamic detection (PDD) [5,6]. 
 
On the other hand, tetraphenyl porphine sulfonate (TPPS) and aluminum phthalocyanin 
sulfonates (AlPcS) were introduced in PDT with a better tumor-localizing ability than 
HpD. Moreover, they could be produced with different numbers of sulfonate groups, 
ranging from 1 to 4, attached to the aromatic ring structure resulting in different water 
solubilities, specific tumor uptake, tissue penetration and quantum yield. The sub-
cellular localisation of TPPS and AlPcS were observed in lysosome in 1989 [17]. Upon 
exposure to sub-lethal light, lysosomes were disrupted leading to leakage of the contents 
of the lysosomes into the cytosol by photochemical reactions [18,19,20,21,22]. The 
properties of the PSs were also used to release therapeutic molecules trapped by 
endosomes and lysosomes, termed in 1999 as photochemical internalization (PCI) [23]. 
Currently, a number of extremely promising applications of PCI to enhance the effect of 
therapeutic molecules have been proposed and demonstrated, as described in several 
papers (see recent reviews [6,24,25,26,27]). 
 
 
1.2 Photosensitizers in PDT 
 
PDT requires selective uptake and prolonged retention of a photosensitizer (PS) in 
diseased tissue, tracked by irradiation with a particular wavelength [2,28]. The PS is a 
natural or synthetic chemical compound that has the ability to absorb a photon of visible 
light and then transfers most of the absorbed energy to molecular oxygen nearby, 
inducing a series of photochemical reactions to produce lethal toxic agents, ROS. The 
physical-chemical properties of the PS are very important for the efficacy of PDT. The 
uptake and subcellular localization of the PS is dependent upon its chemical structure 
and physical nature of the PS, and the way it is administrated [29]. Different PSs will 
target different cellular compartments including mitochondria, lysosomes, endoplasmic 
reticulum (ER) and Golgi apparatus, cytosol and plasmatic membrane, or combinations 
of these sites. But most PSs tend not to accumulate in nuclei, as reviewed by Sanabria et 
al. [30].  
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The most important feature of a PS is selectivity, which means the capability of the PS 
to be taken up and retained in the tumor but not in normal tissue, thus leading to 
restricted photo-induced damage in surrounding tissue. The selective tumor uptake of 
the PS is probably due to differences in the physiology between tumors and normal 
tissues, as described in reviews by Juzeniene et al. and Plaetzer et al. [5,31]. Compared 
with normal tissue, tumors have a low pH which protonates PSs to become more 
lipophilic as they enter tumors via the blood supply, leading to preferential 
accumulation. Also, tumors contain many macrophages that can ingest and trap PSs, 
tumors have more low-density lipoprotein (LDL) receptors on the surface which favor 
the binding of lipophilic PSs, tumors have a leaky microvasculature providing high 
vascular permeability of the PSs and poor lymphatic drainage favoring retention of PSs, 
and tumors often have a larger interstitial space and a large amount of newly 
synthesized collagen which can help the uptake of PSs [5,31]. In addition, coupling of 
PSs to tumor-specific antibodies or other carriers can enhance the selectivity of a PS 
[32,33]. 
 
Finding a suitable PS is crucial for improving the efficacy of PDT. Some of the ideal 
characteristics of a good PS include chemical purity, easy synthesis from readily 
available materials, ability to be enriched in target tissue such as tumor, short half-life 
and rapid elimination from normal tissue to avoid prolonged photosensitization, 
absorption of light at a sufficiently long wavelength (within a range of 600-850 nm) so 
that light penetration in tissue is as deep as possible, and ability to produce a large 
amount of cytotoxic products upon light activation (high quantum yields), as described 
in reviews [2,34]. An ideal PS should not be toxic at typical doses in the absence of 
light. Most importantly, the PS should not cause mutagenic effects [35,36]. Finally, a 
short interval between administration of the drug and peak accumulation in the target 
tissue is required to establish a safe, low cost and reproducible clinical PDT protocol 
[35]. In addition to these characteristics, a PS should have reasonable stability to be 
useful in PDT. It should be stable enough to avoid degradation processes 
(photobleaching) during treatment, but some photobleaching tendency can be an 
advantage as it shortens the duration of general photosensitivity after PDT [34].  
 
Most PSs used in PDT are porphyrins or porphyrin-related compounds. During the past 
20 years, synthetic availability of PSs has expanded enormously. A great number of 
potential PSs for PDT have been developed [34], but only a few have been approved for 
therapy in humans (Table 1) [5,36,37,38,39].  
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Table 1. A selection of currently available photosensitizers/prodrugs in clinical PDT [38,39]. 
 
 
1.3 Light 
 
Each PS has a unique wavelength and intensity of light required for successful 
activation. Therefore, light dose required to achieve sufficient therapeutic effect is 
dependent on the PS used and on the optical properties of the tissue [34]. The light 
sources available for PDT belong to three major groups: broad spectrum lamps, diode 
lamps and lasers, as summarized by Issa et al. [2]. The introduction of lasers equipped 
with optical fibers revolutionized photosensitization and expanded its applicability in 
Photosensitizer 
 (prodrug) 
Chemical name 
and class 
Subcellular 
localization (Potential) indications  
Photofrin  
(porfimer sodium) 
Hematoporphyrin 
derivative (HpD) , 
porphyrin 
Golgi apparatus, 
plasma membrane 
Superficial bladder cancer, 
gastric, cervical, esophageal, 
lung and endobronchial cancer.  
Levulan 
5-aminolevulinic 
acid (ALA), 
endogenous PpIX, 
porphyrin 
Mitochondria, 
cytosolic 
membranes, 
cytosol 
Basal cell carcinoma, Actinic 
keratosis, Bowen's disease, head 
and neck cancer, superficial 
bladder cancer, esophageal 
Metvix  
Methyl ALA 
(MAL) , endogenous 
PpIX, porphyrin 
See above Basal cell carcinoma, Actinic keratosis 
Hexvix 
Hexyl ALA (HAL), 
endogenous PpIX, 
porphyrin 
See above Diagnosis of bladder cancer 
Visudyne 
(Vertiporfin) 
Benzoporphyrin 
derivative monoacid 
ring A, porphyrin 
Mitochondria, ER 
Basal cell carcinoma, age-
related macular degeneration, 
choroidal neovascularization 
Foscan  
(Temoporfin) 
Meso-tetrahydroxy-
phenyl chlorine (m-
THPC), chlorin 
Mitochondrial, 
ER  
Head and neck cancer, gastric 
and prostate, pulmonary,  
gastrointestinal  cancer 
Photochlor  
Hexylether 
derivative of 
pyroheophorbide 
(HPPH), chlorin 
Mitochondria, 
lysosome 
Basal cell carcinoma, 
esophageal cancer, and head and 
neck cancer  
Photosens  
Aluminum 
Phthalocyanine 
(AlPc), Dye 
Mitochondria Head and neck cancer, lung and gastrointestinal cancers 
NPe6 Mono-L-aspartyl chlorin e6, chlorin 
Lysosome, 
endosome 
Early lung cancer, cutaneous 
lesions, ophthalmic lesions 
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medicine, enabling the endoscopic delivery of light to almost every part of the human 
body [35]. In the case of tumors located within body cavities (e.g., bladder), light 
targeting is achieved through purposely manufactured, linear or spherical diffusive fiber 
tips [29,40].  
 
In addition to the accumulation of PS in tumor tissue, the specificity of PDT is also 
based on limiting the application of light to the target tissue. The penetration depth of 
light through the tissue depends upon the characteristics of the tissue and on the 
wavelength of the light [41,42]. The light penetration is limited by optical scattering 
within the tissue, the absorption by endogenous chromophores, and the absorption of 
light by the PS itself (self-shielding) [35,43]. The most important natural chromophores 
in tissue are water, oxyhemoglobin (HbO2) and deoxyhemoglobin, melanin and 
cytochromes. The absorption spectra of these molecules define the optical window for 
PDT in tissue (Figure 1). The optical window of living tissue is between 600 nm (above 
the absorption of heme) and 850 nm (for sufficient generation of the triplet state) where 
tissue penetration is quite high and quantum yield is sufficient for singlet oxygen 
production [36,44]. However, the oxygen concentration changes during PDT because of 
vessel damage and consumption of oxygen leading to a change of the penetration 
spectrum [5,45]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Optical window in tissue. The important tissue chromophores (oxy- and 
deoxyl-hemoglobinand melanin) have high absorption bands at wavelengths 
shorter than 600 nm. Water begins to absorb significantly at wavelengths greater 
than 1300 nm. This figure is reproduced from reference [44] with permission from 
Elsevier. 
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For clinical applications, the optimal light source is determined by several factors such 
as PS properties, disease, equipment cost and size; together with the delivery pattern of 
the light including total light dose, light exposure time, fluence rate and fractionation 
mode [46]. Light absorption leads to heat generation in tissue [47,48]. During PDT, the 
light intensity should be kept at a fluence rate of less than 150 mW/cm2 by which 
photochemical reactions can be triggered without hyperthermia [46,49]. 
 
The ideal light source in cutaneous PDT should be well absorbed by the PS, achieve a 
desirable penetration depth to reach target, be of adequate fluence and duration to drive 
PDT reaction, be rapid to administer, with minimal discomfort, and with minimal side 
effects including erythema, crusting and dyspigmentation [46]. Currently used light 
sources, such as pump dye lasers, diode lasers, lamps with appropriate optical filters and 
light-emitting diodes (LED), achieve some of these objectives, but often with significant 
side effects [3,50,51,52]. 
 
 
1.4 Mechanism of action 
 
The process starts with absorption of light by the photosensitizer (PS) at its excitation 
wavelength, resulting in excitation from its ground state (S0) to its first short-lived 
excited singlet state (S1) (Figure 2). The photosensitizer can return to S0 by emitting the 
absorbed energy in a radiative process of fluorescence or a non-radiative process of 
internal conversion. This fluorescing property can be used to evaluate the intracellular 
localizing of the PS and treatment effects on tumor cells, or utilized for cancer diagnosis 
[28,37]. Another route for deactivation of S1 is to convert to the first long-lived excited 
triplet state (T1) in a non-radiative process of intersystem crossing. T1 is the source of 
the photosensitizing effect. In the absence of other interacting molecules, the excited 
photosensitizer can return to S0 from T1 by emitting the rest of absorbed energy as 
phosphorescence (Figure 3) [37]. Or, it can react with neighboring molecules (e.g., 
molecular oxygen (3O2) or electron-rich substrates) leading to the production of ROS 
via two competing pathways, called type I and type II photochemical reaction [53,54]. 
Both reactions can take place simultaneously and the balance between the two reactions 
is determined by the surrounding substrates, the concentration of oxygen and the PS 
itself [36,55].  
 
Type I reactions involve electron or hydrogen-atom abstraction by the excited T1 
photosensitizer from the substrate molecules to produce substrate radicals, which after 
reaction with molecular oxygen can lead to cytotoxic ROS including superoxide anion 
(·O2-), hydroxyl radical (·OH), and hydrogen peroxide (H2O2). Type II reaction involves 
energy transfer from the excited T1 photosensitizer to ground-state (S0) molecular 
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oxygen. This transfer produces molecular oxygen in its first excited singlet state (S1) 
which is a powerful cytotoxic species. For most PSs employed in PDT, the Type II 
reaction is the dominant process [36,53]. In both reactions, the sensitizer returns to its S0 
state and can repeat the process. Thus, it can produce a continuous high level of ROS as 
long as there is light exposure. However, ROS can also attack the PS molecules, which 
become chemically modified or degraded leading to photobleaching of the PS [36]. 
 
PS (photosensitizer) + hv    1PS* (excited singlet state)  3PS* (excited triplet state) 
 
Type I reactions: 
 
 
3PS* + O2   •PS+ + •O2- 
1PS* + O2     PS  + •O2- 
 
3PS* + Substrate    •PS- + •Substrate+ 
 
Type II reactions:  3PS* + 3O2    PS   + 1O2 
 
 
 
 
Figure 2. The mechanism of action on tumors in photodynamic therapy. The 
photosensitizer (PS) is excited by light to a triplet state (PS*). The PS triplet 
transfers energy to ground-state triplet oxygen and molecules nearby, which 
produces reactive singlet oxygen (1O2) and other reactive oxygen species (ROS). 
ROS can directly kill tumor cells by the induction of necrosis, apoptosis and/or 
autophagy, can cause destruction of tumor vasculature and produces an acute 
inflammatory response. This figure is reproduced from reference [4] with 
permission from Nature Publishing Group. 
 
1O2, •O2-, H2O2, •OH, •O2 
3O2 
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The mechanism of action is clearly linked to the site where the PS is located, and the 
damaged area lies essentially within the tissue that has been exposed to light. This is due 
to the fact that the lifetime of the main active photoproduct, singlet oxygen, is short in 
cells, less than 0.05 μs. Thus, singlet oxygen can diffuse less than 0.02 μm from the site 
of production [5,56]. Action of PDT can cause various damages of cellular organelles, 
such as mitochondria, lysosomes, cell membrane and microtubules, depending on the 
subcellular location of PS, which is a key factor for the outcome of PDT, in addition to 
the determination of the photodamage site [5]. For instance, damages to cell membranes 
may reduce the metastatic potential of surviving tumor cells, damages to microtubules 
lead to accumulation of cells in mitosis and subsequently to death [5], and damages to 
lysosomes result in release of lysosomal enzymes, including endonucleases, proteases 
and hydralyses, into the cytosol in bioactive form which may induce either necrosis, 
apoptosis, or autophagy depending on the photo-oxidative level [57]. Since the cell 
nucleus is not a favorable accumulation site for most of the PSs, and due to the short 
lifetime of singlet oxygen, DNA damage caused by redistribution and/or relocation of 
PS after PDT is limited, resulting in low genotoxic potential [35,56]. Such damages will 
trigger cell survival or cell death signaling pathways.  
 
PDT causes not only direct destruction on tumor cells, but has also effect on tumor 
stroma [58]. Damage of the stroma may lead to destruction of surviving tumor cells, 
inhibition of tumor growth, delay of regression and cures, thus enhance the therapeutic 
effect of PDT [30,59]. The stroma is composed of extracellular matrix (ECM), 
vasculature and different cellular components including immune cells, fibroblasts and 
endothelial cells [30]. ECM is a dynamic and complex array of glycoproteins, collagens, 
glycosaminoglycans and proteoglycans secreted by the cells. PDT produces changes in 
the components of the ECM (such as damages in proteins and lipids), enhancing cell 
death by its secondary effect on tumor cells. Also, the cross-links of the collagen matrix 
produced by PDT reduce the migration of the malignant and stromal cells. The cell 
adhesion is also altered after PDT, by ECM injury or direct damage in the adhesion 
proteins (damage to cell membrane) [30]. 
 
ROS produced by PDT have been shown to destroy tumors by multifactorial 
mechanisms (Figure 2), as summarized in recent reviews [4,28]. Illumination and ROS 
production causes the shutdown of vessels and subsequently deprives the tumor of 
oxygen and nutrients. This is because endothelial cells of the vascular systems in tumor 
cells can concentrate PS. Upon illumination, PS in vasculature creates the 
photodynamic reactions causing tumor ischemia because of irreversible damage to 
tumor blood supply. In contrast, the surrounding normal vasculature in the non-
tumorous region may facilitate PS clearance [28]. The photodamage to the tumor 
vasculature has a marked contributing effect in PDT evoking the development of 
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vascular target PDT, such as the treatment of age-related macular degeneration (AMD) 
and prostate cancer [60,61]. 
 
PDT has a significant effect on the immune system, which can be either 
immunostimulatory or immunosuppressive, which have been described in reviews by 
Castano et al. and Sanabria et al. [4,30] and in papers referenced there. Antitumor 
immunity response is triggered by a series of events after PDT in which inflammatory 
response is considered to be an important initial step. Dying cells produce danger 
signals such as heat shock proteins and transcription factors which further induce the 
expression of cytokines, adhesion and co-stimulatory molecules, and immunologically 
important genes. The release of vasoactive mediators (e.g. histamine and serotonin) 
from damaged vasculature increases the permeability of blood vessels. Immune cells 
and inflammatory mediators are activated. Altogether, antitumor effect is enhanced after 
PDT by immunostimulation [4,30]. Furthermore, cancer vaccines using in vitro PDT-
treated cells or lysates take advantage of the immunostimulatory effects, and PDT-
generated vaccines have been shown to be tumor-specific [62,63,64,65]. 
 
 
1.5 Cell death induced by PDT 
 
PDT results in a sequence of photochemical processes in photosensitized cells. Cellular 
oxidative stress occurs when antioxidant mechanisms are overloaded due to high levels 
of ROS. This leads to cell death by apoptosis, autophagy or necrosis, and those are post-
transcriptional events that occur within a few hours after the treatment [12,66,67,68,69]. 
All kinds of cellular responses may be provoked in a strict dose-dependent manner, i.e. 
a transition from survival, over autophagy and apoptosis to necrosis depending on the 
applied PS concentration or light dose (termed photodynamic dose in this thesis) [66]. 
High light doses trigger necrotic pathways which may have implications for immune 
response. Low light doses allow for apoptosis and less inflammation and immune 
response [28,70]. Besides PDT dose, the mode of cell death also depends on PS 
properties and cell type [71]. Damage to organelles by PDT has been summarized in a 
review by Juzeniene et al. [5]. PS localized in mitochondria or ER generally promotes 
apoptosis. PS located in lysosomes can induce either necrosis or apoptosis, while in the 
plasma membrane it will initiate either rescue responses, apoptosis, or necrosis [5]. 
 
Recent evidence indicates that autophagy may be induced by PDT as an attempt to 
repair and survive photo-damaged organelles, and that this can be switched to a cell 
death signal if this initial response fails [37,72]. Autophagy offers protection from the 
photodamage at low PDT dose by enhancing survival for some cells, serving as a pro-
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survival response via the recycling of damaged organelles, but can serve as an alternate 
death mode when the PDT dose is increased [73]. 
 
 
1.6 PDT resistance 
 
Similar to drug resistance, there may also be induction of resistance to PDT, which 
recently has been reviewed by Casas et al. and Snabria et al. [30,73]. The mechanisms 
of resistance linked to the PS may be shared with general mechanisms of drug resistance, 
for instance different cellular uptake and efflux rates of the PS. The structure properties 
of the PS which determines its subcellular location is believed to be an essential factor 
in the development of resistance [73]. Under oxidative stress induced by PDT, an 
increased inactivation of ROS can occur via antioxidant enzymes (e.g. glutathione, 
superoxide dismutases) and up-regulation of heat shock proteins (HSPs) leading to cell 
survival by photo-damage repair [73,74,75]. Both oxidative stress and hypoxia induce 
autophagy [76,77]. The autophagy-lysosomal system represents a major protective 
mechanism for the clearance of ROS-damaged organelles and irreversibly oxidized 
cytosolic proteins by recycling proteins and cellular components, and contributes to 
tumor progression [30,78].  
 
PDT effect on tumor vasculature in combination with oxygen consumption by 
photoreactions can induce tissue hypoxia. This may limit the PDT efficacy because 
tumor hypoxia can enhance survival and tumor progression by induction of autophagy 
to overcome nutrient deprivation, to escape their hostile environment, or to induce 
changes in the proteome and genome of neoplastic cells [30,73].  
 
It is important to study the mechanisms of PDT resistance to maximize therapeutic 
outcome by developing new modalities, such as PDT in combination with surgery, 
chemotherapy, immunotherapy, or radiotherapy, and new strategies, such as increased 
oxygen supply (arterial flow focalization) and therapeutic inhibition of autophagy 
[3,73,79,80]. 
 
 
1.7 Applications of PDT  
 
PDT is either used as a single or combined therapy, or as an adjunct to conventional 
therapies. The main advantages of PDT over conventional therapies include good site-
specificity to the tumor, cosmetic outcomes in dermatological PDT, minimal invasion 
and systemic toxicity (except for skin photosensitivity), few secondary effects, the 
possibility to treat multiple lesions simultaneously, and to use repetitive cycles of 
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treatments, as described in reviews [30,35] and their references. PDT offers the 
remarkable advantage of stimulating an immune response in most cases [30]. Moreover, 
PDT is also effective in the treatment of chemo- and radio-resistant tumors, and there is 
very low potential for gene mutagenesis from the clinically approved PS [3].  
 
The clinical approvals for PDT include curative treatment of early or superficial cancers 
and palliative treatment of more advanced disease, as summarized by Norum et al. [27]. 
Originally used to treat individual malignances, current clinical PDT is often applied in 
dermatology and ophthalmology. The main applications consist of some types of pre-
malignant and malignant diseases such as age-related macular degeneration (AMD), 
head and neck cancer, basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs), 
actinic keratosis (AK), Bowen's disease, psoriasis, cutaneous T-cell lymphoma, acne 
and photo-rejuvenation of wrinkles. PDT is also applied in a number of other diseases 
such as superficial bladder cancer, prostate cancer, Barrett's oesophagus, early lung 
cancer, brain cancers, early gastrointestinal cancer, bile duct cancer, cervical and 
vaginal (see the review by Norum et al. [27] and references therein). Moreover, several 
PSs (Photofrin, temoporfin, verteporfin) have been licensed for use in PDT for the 
treatment of some advanced cancers including advanced bronchial carcinoma, 
oesophageal carcinoma, advanced head and neck cancer, and AMD with pathological 
myopia [27]. 
 
PDT is ideal for treating some superficial and early cancers. However, for palliative 
treatment with the purpose of symptom relief and local control, PDT has not achieved 
sustained local tumor control for most applied indications due to its limitations [27]. 
The most important limitation is the treatment side effects represented by residual and 
prolonged photosensitivity (systemic administration) or pain (topical administration). 
This may be why most PSs have not been approved for diagnostic purposes [3]. 
Limitation of efficient light penetration in human tissue restricts PDT effect mostly to 
the tumor surface, and this may cause tumor relapse from more deeply located parts 
[30]. The PDT protocol remains largely empirical because of the limitation of light 
dosimetry which is required to be optimized for every patient [3]. Therefore research 
has focused on the understanding of the fundamental mechanisms of PDT in a view of 
chemistry, physics, biology, and medicine. With the development of novel PSs and PS 
delivery system, and the improvement of light sources, PDT efficacy can certainly be 
improved [3,81,82,83]. 
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2. ALA-based PDT  
 
2.1 5-aminolevulinic acid (ALA) and its derivatives methyl and hexyl ALA 
 
ALA, the methyl ester (MAL), or the hexyl ester (HAL) serve as a biological precursor 
to produce excess amount of photosensitizing PpIX (Figure 4) via heme biosynthetic 
pathway, which is the basis for ALA-based PDT [84,85]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structure of Protoporphyrin IX (PpIX), 5-aminolevulinic acid (ALA), methyl- and hexyl ALA 
 
 
ALA is hydrophilic, and in mammalian cells it is taken up mainly by active transport 
mechanisms. This system requires energy, it depends on pH and temperature, and it is 
saturable and slow, being only slightly accelerated in tumor cells [2,86]. The low 
transport rate of ALA through the plasma membrane is the only limitation to the 
accumulation of PpIX in the treated cells. Therefore, high doses of ALA must be 
administered and only superficially located lesions can be treated because of the poor 
penetration. In an attempt to overcome the poor bioavailablility of ALA when using 
topical administration, a number of esterified ALA derivatives have been examined 
[84,85]. 
 
MAL is more lipophilic than ALA and is taken up by active mechanisms mainly 
through transporters of non-polar amino acids. Most importantly, MAL is transported 
both by active mechanisms and by passive diffusion through the membrane. The 
plurality and efficiency of these mechanisms determine the enhanced penetration of 
MAL in comparison to ALA, and the difference is even more significant in malignant 
cells. Soon after cell penetration, MAL is rapidly demethylated to free ALA which is 
then incorporated into heme biosynthesis [2,86]. MAL (Metvix) was approved in EU for 
the treatment of basal cell carcinoma (BCC) and actinic keratosis (AK) ten years after 
ALA was first approved in USA in 1991 for the treatment of AK (Table 1).  
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HAL is a hexyl ester of ALA. Because of the high lipophilicity of HAL, it has been 
shown that these molecules were about 50-100 times more efficient than ALA when 
inducing cellular porphyrin formation (mainly PpIX) with a high selectivity [87,88,89]. 
The exogenous HAL molecules enter into the cell membrane via passive diffusion. 
Soon after cell penetration, HAL is converted to free ALA by esterase and incorporated 
into the heme biosynthesis. HAL (Hexvix) was registered in EU in 2005 for the 
diagnosis of bladder cancer [90]. 
 
 
2.2 Cellular uptake of the prodrugs  
 
In contrast to HAL, both ALA and MAL are not sufficiently lipophilic to penetrate 
efficiently through lipid membranes [84,88,91], although MAL can show slight uptake 
by passive diffusion through the membrane. Thus, various transporter systems are 
involved in the uptake of ALA and MAL. Studies have indicated that active cellular 
uptake of ALA is via γ-aminobutyric acid (GABA) transporters (GATs) in mamma cells 
[91,92,93,94,95]. However, the uptake of MAL is shown to be cell type dependent, 
either via non-polar amino acid transporters, GATs, or other amino acid transporters 
[91,93,94,95]. Moreover, ALA is shown to be more potent for PpIX generation than 
MAL [89,94] due to a faster cellular uptake of ALA, possible due to higher substrate 
affinity to GATs, and a rate-limitation of MAL conversion to ALA by esterase [94,96]. 
 
 
2.3 PpIX selective accumulation 
 
PpIX is a member of the porphyrin derivatives. Porphyrins are a class of tetrapyrroles 
consisting of a highly conjugated, heterocyclic macrocycle and may also contain a 
central metallic atom such as ferrous iron (Heme), cobalt (Vitamin B12) or magnesium 
(Chlorophyll). Porphyrins are essential for the biological activity of all living organisms. 
Porphyrins absorb most efficiently at 410 nm, along with four smaller peaks near 510, 
540 and 635 nm, due to their highly conjugated skeleton (Figure 4), allowing for 
irradiation from multiple light sources (e.g. blue and red light) with diverse spectral 
yields [97]. Earlier research on the biochemistry of porphyria diseases showed that 
porphyrins can be endogenously produced via heme biosynthesis [98,99]. Exogenous 
administration of ALA in PDT results in preferential accumulation of PpIX in abnormal 
cells [16,100,101,102,103]. In addition to therapeutic use, the fluorescence of PpIX is 
applied for visualization of location and diagnosis of tumors [104,105,106,107].  
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The heme biosynthetic pathway comprises of eight enzymes, four in mitochondria and 
four in cytosol. The process starts in the mitochondria with the condensation of succinyl 
CoA and glycine to form ALA, catalyzed by ALA synthase. The next four steps take 
place in the cytosol. Two ALA molecules are condensed to form the monopyrrole 
porphobilinogen (PBG) by ALA deaminase (ALAD) and then four molecules of PBG 
are converted by PBG deaminase into the cyclic tetrapyrrole uroporphyringen III. 
Uroporphyrinogen decarboxylase then removes four acetic acid carboxyl groups to form 
coproporphyrinogen (COPRO) III. The last three steps occur in the mitochondria and 
involve modifications to the tetrapyrrole side chains of COPRO III and proto-porphyrin 
(PROTO) III by the oxidases. Finally iron is inserted into the center of protoporphyrin 
IX (PpIX) by ferrochelatase (Figure 5) [108,109,110]. 
 
The heme biosynthesis pathway is normally so tightly regulated that the concentrations 
of intermediates are below the threshold of photosensitization. There are two rate-
limiting steps in normal heme biosynthetic process: 1) synthesis of ALA catalyzed by 
the enzyme ALAD, which is regulated through negative feedback by heme, and 2) 
conversion of PpIX to heme by the enzyme ferrochelatase. Incubating cells with excess 
exogenous ALA, MAL or HAL bypasses the first rate-limiting step, causing 
accumulation of PpIX. Thus, the rate of production from MAL and HAL is instead 
limited by enzyme activity of the conversion [111].  
 
In addition to the differences with respect to physiological properties between tumors 
and normal tissues as mentioned in section 1.2, tumor selectivity of PpIX is based on 
decreased ferrochelatase activity and increased PBG deaminase activity in some 
malignant cells [112,113,114,115,116]. Other factors, such as uptake of the pro-drug 
ALA or its esters, esterase activity of the conversion of ALA esters to ALA, limited 
availability of ferrous iron due to the higher tumor proliferative activity, state of 
differentiation, mitochondrial content and cell type, etc. also play an important role in 
this process [102,117,118,119]. Intracellular localization of the PpIX is also considered 
as a factor that affects the PpIX accumulation. If an excess of PpIX is synthesized, it can 
diffuse from the mitochondria into ER, lysosomes and the plasma membrane 
[14,86,120,121,122]. But the accumulation is transient, because PpIX clearance is 
mostly complete by elimination within 24-48 hours, shortening the period of cutaneous 
photosensitivity [123].  
 
During PDT many molecules of PpIX are destroyed by reacting with the excited singlet 
oxygen [124]. However, radical attack leads to modification of side groups and/or the 
molecular skeleton of the PS. Photo-modification of PpIX typically creates chlorines 
which are more effective PSs than PpIX [36].  
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2.4 Cellular responses to ALA-based PDT 
 
PpIX is synthesized in the mitochondria and redistributes into the cytosol and 
membrane-rich organelles, e.g. ER and cell membrane, and reactive oxygen species 
(ROS) are produced at these sites. Cellular antioxidant mechanisms are apparently 
overloaded by high levels of ROS and radicals. This leads to ROS-induced protein 
modifications and dysfunction, and eventually affects pathways resulting in cell death 
[126]. The most thoroughly characterized oxidative modifications of proteins 
subsequent to PDT are irreversible and non-enzymatic carbonylation and oxidation of 
thiol groups [127,128]. At the molecular level, genes and their products can be either 
up-regulated or down-regulated after PDT. A strongly altered gene expression is found 
after ALA-PDT, and this includes immediate early genes and genes involved in cell 
proliferation, stress responses, apoptosis and cell adhesion, showing that PDT triggers a 
complicated cellular response involving several biological pathways 
[129,130,131,132,133,134]. 
 
 
2.5 Clinic applications and future perspectives 
 
ALA-based PDT is widely used in various pre-malignant and malignant cutaneous 
diseases in many countries. Topical application of ALA and its esters results in 
consistent PpIX uptake in the applied region. ALA-induced PpIX can accumulate in 
abnormal tissue at 2-10 fold higher concentration compared to normal tissue  [135]. 
However, with ALA and MAL only superficial lesions can be treated [84,136]. 
Therefore, improving tissue and depth penetration via various formulations and carriers 
of the prodrugs is an area of active research [137]. In recent years, a novel modality of 
ablative fractional laser has been developed for promoting drug delivery via skin by 
creating microscopic vertical channels in tissue [138]. The ablative fractional lasers 
have been used in animal models to facilitate intracutaneous uptake and distribution of 
topical MAL deeper into skin layers [139,140]. When blue light is employed, the 
penetration depth is only several millimeters [141] which is now utilized to treat non-
malignant skin pathologies such as inflammatory dermatoses, psoriasis, acne and warts, 
infectious cutaneous diseases caused by microbes [142,143].  
 
The earliest and most frequently used light sources in PDT for cutaneous diseases have 
been non-coherent broad-spectrum light sources in the red and blue wavelengths to 
activate porphyrins administered either systemically or topically [46,50]. The use of 
intense pulsed light (IPL) for PDT is promising because it spans wavelengths from the 
blue to the infrared range, thereby exciting PpIX along many of its successive 
absorption peaks [144,145]. Although lasers provide the ability to select a specific 
wavelength, in order to achieve higher irradiances and maximize penetration depth, they 
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are not suitable alternatives for cutaneous PDT because they are expensive, less reliable 
and portable, and give small illuminative area in the skin surface [46,146]. 
 
ALA may have a role in other applications in surgical oncology based on its ability to 
discriminate neoplastic tissue from adjacent normal tissue [107,147,148]. A number of 
efforts have been made to explore potential clinic applications of ALA-based PDT in 
non-cutaneous solid malignancies such as breast, bladder, ovarian, lung, gastrointestinal, 
head and neck cancers. However, further large studies are required to optimize the 
protocols and improve treatment efficacy [147]. Besides diagnostic purposes PpIX 
fluorescence images can be utilized either for a directed biopsy sampling or as an aid 
during surgery [5,149]. 
 
In contrast to skin photosensitivity as a main limiting factor of PDT with systemic PSs, 
pain is an important limiting factor for topical ALA-based PDT. In some cases pain is 
so severe that the treatment is discontinued [150,151]. In some clinical studies MAL is 
proposed to induce less pain than ALA [151,152,153]. But no significant differences in 
pain scores were observed between ALA- and MAL-PDT for actinic keratosis based on 
a clinic study of 600 patients [154]. Although the mechanism of pain has not been fully 
elucidated, several studies have suggested that it may be due to the uptake of ALA via 
GABA transporters into the mitochondria-rich sensory neurons and hence high-level 
accumulation of PpIX [155,156] which further induces nerve stimulation through tissue 
damage induced by ROS upon irradiation [155,157]. Current pain-reducing strategies 
include interrupted illumination, cooling of the affected area and local anesthesia 
[158,159].  
 
 
3. Photochemical internalization  
 
The rapid development of PDT includes many interesting perspectives. The most 
appealing one appears to the discovery and development of new PSs, which may 
progressively improve the efficacy and specificity of a particular therapy. However, the 
focus of the invention of PSs is not only on PDT itself. Another important field of study 
is the delivery technology known as photochemical internalization (PCI), which can 
efficiently release therapeutics accumulated in endosomes and lysosomes, by which the 
efficacy of some conventional therapies can be enhanced, with reduced side effects that 
are limited to the illuminated area.   
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3.1 Background of photochemical internalization (PCI) 
 
In the PCI technology a membrane-embedded photosensitizer is used together with a 
therapeutic macromolecule by endocytic delivery, a process known as endocytosis 
[23,160]. The endocytic pathway involves internalization of molecules from the plasma 
membrane and recycling them back to the surface or sorting them to degradation. In 
endocytosis, the cell engulfs extracellular substances, forms an intracellular bud by 
invagination of a portion of plasma membrane, and further forms an intracellular 
membrane-bounded vesicle, an endosome, by membrane fusion, containing the ingested 
substances. In general, molecules taken up by endocytosis are rapidly sorted, processed 
and directed to other organelles or to be subjected to enzymatic degradation in 
lysosomes [161]. In this way, cells can take up substances that do not readily pass the 
plasma membrane. The therapeutic macromolecules for PCI generally refer to 
oligonucleotides, peptides, protein toxins, chemotherapeutic agent and polymers  whose 
sizes are normally larger than 1k Dalton, and bio-availabilities are usually limited by the 
membrane barrier when used as traditional drugs (step 3 in Figure 6, the process without 
light exposure (dark)) [25,162,163].  
 
Lysosomes are dynamic membrane-bound organelles containing a large number of 
acidic hydrolases which can directly contribute to cell death through lysosomal 
destabilization and enzyme leakage into the cytoplasm [161]. Compelling evidences 
have shown that lysosomes can fuse with late endosomes, the plasma membrane, 
phagosomes and autophagosomes. Kissing events (kiss-and-run) and direct fusion with 
late endosomes are the means by which endocytosed macromolecules are delivered to 
lysosomes. The hybrid organelle fused by endosome and lysosome is the site of 
degradation of endocytosed macromolecules. Lysosomes are re-formed from the hybrid 
organelle by a maturation process [164,165]. As degradation of macromolecules in 
lysosomes after uptake by endocytosis is a major limitation for the therapeutic efficacy 
of the macromolecules, PCI has been established to liberate macromolecules trapped by 
the endocytic pathway before degradation by lysosomal hydrolases (Figure 6, the PCI 
process). This function of PCI has been demonstrated by a number of in vitro and in 
vivo studies [166,167].  
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Figure 6. Endolysosomal escape of therapeutics by photochemical internalization. (1) 
An amphiphilic photosensitizer (   ) and a drug ( ) bind to the plasma membrane 
after administration. To increase the uptake, the therapeutics are usually bound to 
targeting moieties (such as antibody or growth factor ligand); (2) The photosensitizer 
and the drug enter into the cell via endocytosis and co-localize in the endolysosomal 
compartments; (3) Without light exposure (dark), the enclosed drug is eventually 
hydrolyzed by lysosomal enzymes; While with light exposure (4) (PCI), the 
photosensitizer is activated leading to production of reactive oxygen species (mainly 
singlet oxygen) which further oxidizes the membrane. The free drug enters into the 
cytosol after the rupture of membrane, without degradation by the lysosomal enzymes. 
This figure is reproduced from  reference [25]  with permission from Elsevier. 
 
 
The selection of PSs for PCI is based on the property of membrane-localization at 
endocytic vesicles. The reason is simply to limit the photodamage to the vesicular 
membrane, thereby minimizing the possible destruction of the enclosed macromolecules 
in the lumen compartment. Thus, amphiphilic PSs are ideal for PCI [19]. Currently the 
most common PSs are porphyrins and chlorins, which have two favorable features with 
respect to PCI [168]. One feature is the possibility to modify the chemical structure at 
different loci and with various levels of complexity. The insertion of two polar 
substituents (e.g. sulphonate groups) on two adjacent rings of the macrocycle makes the 
PS an amphiphilic species. Another feature is the presence of absorption bands in the 
Dark 
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600-850 nm wavelength region, corresponding to maximal light penetration into 
mammalian tissue [168]. Compared to porphyrins, chlorins exhibit a high extinction 
coefficient and an absorption peak in the far red waveband and a rapid, high and 
selective accumulation in the target tissue [86]. To date, TPPS2a (disulfonated meso-
tetraphenylporphine) [169,170,171], TPCS2a (disulfonated meso-tetraphenyl chlorin) 
[169,170,171,172,173] and AlPcS2a (disulfonated aluminum phthalocyanine) [22,174] 
are the most efficient amphiphilic PSs for PCI, with two sulfonate groups on adjacent 
phenyl/phthalate rings (Figure 7). They primarily localize in the membranes of 
endocytic vesicles with their hydrophobic part inserted into the membrane and 
redistribute in the cytosol after irradiation [22,172,173,174,175,176]. It is of importance 
that these three amphiphilic PSs are not substrates to the ATP-binding cassette 
transporter ABCG2 [177]. 
 
 
Figure 7. Structures of chlorin, porphyrin, disulfonated meso-tetraphenyl chlorin 
(TPCS2a), and disulfonated meso-tetraphenylporphine (TPPS2a). 
 
 
3.2 Mechanism of action 
 
PCI is based on a three-stage process. The first stage is the selective accumulation of a 
photosensitizer in the tumor in the absence of light. The second stage is the 
accumulation of a therapeutic macromolecule in the tumor in the absence of light. In the 
last stage, the PS is activated by light of the appropriate wavelength and intensity [23]. 
Another three-stage process has also been suggested in which stage 2 and 3 is 
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exchanged. In this process, the macromolecules can leak out immediately from the 
newly formed endosome once it is fused with the photochemically damaged endocytic 
or lysosomal membrane [178]. However, this alternative process will not be further 
discussed in this thesis. The ability to release the content of the endosomal/lysosomal 
vesicles is a fourth novel effect in addition to PDT effects of direct cytotoxicity, 
vascular damage and activation of immune system [27,179]. The process of clinical 
application of the PCI technique is shown in Figure 8. 
 
 
Figure 8. The process of the photochemical internalization technique in clinical 
applications (A-D).  (1) The photosensitizer (S) and the drug (D) are systemically or 
locally administered into the body and transported or distributed to the target cell 
containing the therapeutic target molecule (T); (2) The photosensitizer and the drug are 
taken up by the target cell via endocytosis, but encapsulated in an endosome with 
photosensitizer localized in the membrane; (3) Illumination activates the photosensitizer 
and triggers photoreactions in the membrane of the endosome leading to the membrane 
rupture and then the drug release; (4) The drug molecule can now bind to its 
intracellular therapeutic target initiating a therapeutic response. This figure is 
reproduced from http://pcibiotech.no/content/basics-pci with the permission from PCI 
Biotech AS, Norway. 
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In the same way as for PDT, the process starts with the activation of the photosensitizer 
by light, but under PCI conditions the  photochemical reactions (Type I and II) are 
limited to the membrane where the activated PS is located [22]. Singlet oxygen causes 
mainly membrane damage by oxidizing amino acids including tryptophan, cysteine, 
histidine, methionine, phenylalanine and maybe guanine, unsaturated fatty acids and 
cholesterol [180]. Destruction of membrane constitutions results in membrane rupture 
and the liberation of the trapped macromolecules into the cytosol. The macromolecules 
exert their pharmacological actions after reaching their target sites [22].  
 
It has been reported that TPPS2a-PDT (associated with PCI) has effects on MAPK 
signaling pathway in NuTu-19 and WiDr cell lines [181]. Both extracellular signal-
regulated kinase (ERK) and p38 are activated immediately after PDT in these two cell 
lines. However, c-Jun NH2 terminal kinase (JNK) is only activated transiently in NuTu-
19 cells. Using selective inhibitors, p38 is shown to serve as a death signal, whereas 
JNK is a survival one. On contrast, the activation of ERK is not observed to have any 
influences on cellular response to the PDT-induced cytotoxity [181]. The epidermal 
growth factor receptor (EGFR) in NuTu-19 cells and mammalian target of rapamycin 
(mTOR) in WiDr cells are also targets of TPPS2a-PDT and AlPcS2a-PDT respectively 
[182,183,184]. 
 
In PCI it has been found that a large fraction of lysosomes may be ruptured without 
inducing significant cell death. This may be partly due to photochemical inactivation of 
the lysosomal hydrolases and to the action of their cytosolic inhibitors. On the other 
hand, upon illumination lysosomal contents can be released without losing their 
biological activity before degradation by lysosomal hydrolases [21]. It has been shown 
that endosomal photodamage induced by low photodynamic dose (including light dose 
and PS dose) can lead to impaired membrane trafficking processes without disrupting 
endosomes. As the photodynamic dose is increased endosomes are disrupted, triggering 
apoptosis. Necrosis occurs when the photodynamic dose is increased to even higher 
level [185]. Therefore, the photodynamic dose required for PCI is much lower (sub-
lethal) than the ones required for PDT modality. 
 
 
3.3 Perspectives of PCI  
 
Endocytosis is obligatory for PCI, but the environment of the endocytic vesicles may 
limit how much the therapeutic effect can be enhanced by PCI [27]. The hydrolases 
contained in the vesicles may degrade the endocytosed macromolecules. The PCI-
generated ROS may inactivate the nearby therapeutic macromolecules by oxidative 
reactions [27]. And the endocytic rate is cell type-dependent [161]. Nevertheless, the 
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outcomes of PCI with various macromolecules have revealed a synergetic effect. This 
indicates that photochemical inactivation of therapeutic macromolecules may be of 
marginal importance. The findings as described below have highlighted the potential 
clinical benefits of PCI [25].  
 
3.3.1 PCI for protein toxin and immunotoxin  
 
Ribosome-inactivating proteins (RIPs) are a group of protein toxins which inhibit 
protein synthesis. Among them, type I RIPs including gelonin and saporin have limited 
ability to enter the cells. It has been documented that PCI enhances the inhibitive effect 
of gelonin and saporin under selective PCI conditions [23,173,186,187]. To increase the 
uptake and specificity of protein toxins, both antibody-conjugated gelonin and saporin 
(immunotoxin) using antigens such as human epidermal growth factor receptor 2 
(HER2), vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) 
have been developed for PCI [26,79,188,189,190,191,192,193,194,195]. The efficacy 
and selectivity of these combinations of PCI indicate a benefit for cancer therapies in 
preclinical studies and clinical trials [26]. 
 
3.3.2 PCI for chemotherapy and multidrug resistance  
 
Many highly effective chemotherapeutic agents are large and water soluble and 
therefore do not easily penetrate plasma membranes, but are actively transported into 
cells by endocytosis [196]. PCI of several chemotherapeutic agents including bleomycin, 
doxorubicin, and mitoxantrone have been documented with significant effect 
[197,198,199,200,201] and with the ability to reverse any multiple drug resistance to the 
chemotherapeutic agents under selective conditions [198,202]. 
 
3.3.3 PCI for gene delivery  
 
The lack of efficient delivery systems is one of the main problems of gene therapy. 
Various delivery agents have been evaluated in PCI to mediate gene transfection 
[203,204]. It was found that PCI enhanced transfection using polycationic vectors (such 
as polylysine or polyethylenimine) and adenoviral vectors [205,206,207].  
 
3.3.4 PCI for other macromolecules and therapies  
 
A number of studies have also demonstrated that PCI represents an efficient delivery 
system for the release of other macromolecules such as peptide horseradish peroxidase 
[21,23], siRNA and peptide nucleic acids [208,209,210,211,212]. 
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3.3.5 Combination strategies of PCI  
 
Local recurrences are a major problem after inadequate surgery in cancer treatment. In 
order to explore the PCI effect on the remaining tumor cells after inadequate surgical 
resection, Norum et al. [213] used an infiltrative human fibrosarcoma in nude mice to 
test the effect of bleomycin, PDT, and PCI with bleomycin. Bleomycin was shown to 
significantly delay tumor regrowth after surgery, and this inhibition was further 
improved by PCI. The results indicate that PCI of bleomycin may be an efficient intra-
operative technique as an adjunct to surgery in cancer treatment [213]. PCI of 
bleomycin in combination with radiotherapy was also explored using a human soft 
tissue sarcoma in nude mice (TAX-1 tumor model) by the same research group [214]. 
The results indicate that radiotherapy in combination with PCI of bleomycin may reduce 
the total radiation dose necessary to obtain local tumor control by appropriate protocols.  
 
 
3.4 Differences between PCI and PDT 
 
As a technology for enhancing drug delivery, for instant chemotherapeutic 
macromolecules, PCI differs from conventional combination strategies of PDT. 
Although the treatment using PCI with chemotherapeutics is very similar to the 
combination of PDT and chemotherapy, photodynamic dose of PCI is sub-lethal with 
the main purpose to promote the cellular internalization of therapeutic molecules. The 
cell killing effect therefore results predominantly from the chemotherapeutics and not 
the photodynamic treatment. This is essential in PCI since the technique is designed to 
favor the delivery of a therapeutic macromolecule without inactivating the molecule or 
lethally damaging the cell. This is of particularly importance for the delivery of 
molecules which are not intended to be directly toxic to a cell, such as genes and siRNA 
[215]. 
 
It has been documented in several in vivo studies that PCI of therapeutic 
macromolecules increases both the necrotic depth and the fraction of complete 
remissions in treated tissue [179,186,216]. PCI has the potential to reduce the 
administered dose of chemotherapeutic agents, and hence the dose-dependent side 
effects. PCI may also reverse resistance to drugs such as bleomycin and doxorubincin 
[198]. 
 
 
  
36 
4. Bladder cancer 
 
 
4.1 An introduction to bladder cancer  
 
The bladder consists of three layers: a mucous layer of epithelial cells (urothelium), the 
underlying submucosa, and the outer muscular layer. A newly diagnosed bladder cancer 
is usually found in the epithelial lining and has high tendency to grow through the 
submucosa into the muscular layer, and then invade surrounding tissues and the lymph 
nodes, resulting in metastasis at last. Classification of bladder cancer by anatomic 
disease extent, i.e. stage, is important to determine the appropriate treatment strategy 
and predict outcomes. The most common classification is the TNM system (Table 2)  
describing tumor growth into the bladder (T), invasion in the lymph nodes (N) and 
metastasis (M) [217]. Non-muscle invasive bladder cancer (NMIBC), previously called 
as superficial bladder cancer includes carcinoma in situ (CIS, stage Tis), stage Ta and 
T1 tumors. NMIBC has a high risk of recurrence and a variable risk of progression. 
Invasive bladder cancer includes stage T2 or T3 tumors, where there is a higher risk that 
the cancer will spread to other areas of the body than for NMIBC. Advanced bladder 
cancer includes T4 bladder cancer, cancer in the lymph nodes, or cancer that has spread 
to another part of the body (Figure 9) [217].  
 
Bladder cancer is one of the most common cancers in the world and causes more than 
100 000 deaths every year [218,219]. In Norway bladder cancer has been one of the five 
most common cancer types for men during the last ten years [220] and in United States 
it is estimated that 72 570 new cases and 15 210 deaths will be reported in 2013 [221]. 
Approximately 70-80% of diagnosed bladder cancers worldwide are non-muscular 
invasive bladder cancer (NMIBC) for which intravesical chemotherapy and/or 
immunotherapy is used as an adjuvant treatment to the standard transurethral resection 
[218]. However, significant improvements in preventing disease progression and 
recurrence have not been obtained [218,219]. On the other hand, systemic therapy is 
typically reserved for higher stage, muscle-invading, or metastatic diseases [222]. The 
main risk factors for bladder cancer are cigarette smoking and occupational exposure to 
toxic chemicals. Age and chronic urinary tract infection are also involved. Due to 
frequent clinical follow-up, repeated cystoscopies, and often repeated transurethral 
resections, the treatment for bladder cancer becomes one of the most expensive cases in 
medical care. [223].  
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Table 2. Definitions of Tumor, Node, Metastasis (TNM) Staging System of urinary bladder. 
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, 
Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh 
Edition (2010) published by Springer Science and Business Media LLC, www.springer.com.  
 
 
 
Primary Tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ: “flat tumor” 
T1 Tumor invades subepithelial connective tissue 
T2 Tumor invades muscularis propria 
pT2a Tumor invades superficial muscularis propria (inner half) 
pT2b Tumor invades deep muscularis propria (outer half) 
T3 Tumor invades perivesical tissue 
pT3a Microscopically  
pT3b Macroscopically (extravesical mass) 
T4 Tumor invades any of the following: prostatic stroma, seminal 
vesicles, uterus, vagina, pelvic wall, abdominal wall 
T4a Tumor invades prostatic stroma, uterus, vagina 
T4b Tumor invades pelvic wall, abdominal wall 
  
Regional Lymph Nodes (N) 
Regional lymph nodes include both primary and secondary drainage regions. All 
other nodes above the aortic bifurcation are considered distant lymph nodes. 
NX Lymph nodes cannot be assessed 
N0 No lymph node metastasis 
N1 Single regional lymph node metastasis in the true pelvis 
(hypogastric, obturator, external iliac, or presacral lymph node) 
N2 Multiple regional lymph node metastasis in the true pelvis 
(hypogastric, obturator, external iliac, or presacral lymph node 
metastasis) 
N3 Lymph node metastasis to the common iliac lymph nodes 
  
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
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Stage I                                 Stage II                                     Stage III 
Stage IV  
(continued on next page)
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Figure 9. Definitions of anatomic stage/prognostic groups of urinary bladder. Used 
with the permission of the American Joint Committee on Cancer (AJCC), Chicago, 
Illinois. The original source for this material is the AJCC Cancer Staging Manual, 
Seventh Edition (2010) published by Springer Science and Business Media LLC, 
www.springer.com.  
 
 
4.2 Treatments for NMIBC 
 
NMIBC is normally removed by surgery during a cystoscopy under general anesthesia. 
This procedure is known as transurethral resection of bladder tumors (TURBT) which is 
the first-line treatment. Unfortunately, the high rate of recurrence and progression after 
TURBT demands the use of adjuvant treatments such as intravesical chemotherapy 
using mitomycin C (MMC), epirubicin, or doxorubicin [224]. If there is still a risk for 
development into invasive bladder cancer after the combination of surgery and 
chemotherapy, then treatment with the bacillus Calmette-Guérin (BCG) vaccine is 
required. BCG is the most effective use of cancer immunotherapy for preventing 
recurrence and progression in NMIBC [224,225,226,227]. However, recurrence rates 
still remain high and progression is not eliminated after BCG. In addition, BCG has 
some side effects such as bladder irritation, frequency, bleeding, and possibly with flu-
like symptoms, joint pain, and skin rash. The main side effect of chemotherapy is 
bladder irritation and skin rash. Slight chemical cystitis can occur, including dysuria, 
hematuria, frequency, occasional pyuria or suprapubic pain [228].  
 
Stage   T N M 
0a Ta N0 M0 
0is Tis N0 M0 
I T1 N0 M0 
II T2a 
T2b 
N0 
N0 
M0 
M0 
III T3a 
T3b 
T4a 
N0 
N0 
N0 
M0 
M0 
M0 
IV T4b 
Any T 
Any T 
N0 
N1-3 
Any N 
M0 
M0 
M1 
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To improve the total intravesical drug exposure and hence chemotherapeutic efficacy, 
various experimental approaches have been evaluated including enhancing the delivery 
of agents to bladder tissue (e.g. electromotive therapy), enhancing cell membrane 
permeability (e.g. intravesical hyperthermia), or prolonging the exposure (e.g. 
bioadhesive) [222]. Electromotive administration (EMDA) of chemotherapy may be 
applied if progress or recurrence occurs after chemotherapy or BCG as a single 
treatment. The electrical current applied increases the bladder lining permeability to 
absorb the chemotherapeutic molecules, thus enhances chemotherapeutic efficacy 
[229,230]. Another technique, called hyperthermic chemotherapy, is to heat the wall of 
the bladder with a microwave probe while intravesically administering a 
chemotherapeutic drug, e.g. MMC, on the purpose of enhancing the uptake 
[231,232,233,234].  
 
In the future, the perspectives for the treatment for bladder cancer seem to be focused on 
searching new modalities such as keyhole surgery (laparoscopic or robot cystectomy), 
multiple chemotherapeutics (e.g. MMC, gemcitabine, doxorubicin, epirubicin, thiotepa, 
cisplatin, ethoglucid, valrubicin, suramin and their combinations), radiotherapy and 
immunotherapy, and their optimal combinations [222,235]. Both PDT with potent PSs 
and PCI with selective chemotherapeutics are of great interest [236,237,238].   
 
 
4.3 PDT for bladder cancer 
 
NMIBC is potentially well suited for effective treatment by PDT because it is easily 
accessible for both intravesical instillation and illumination. It is possible to irradiate the 
whole bladder and thus provide access to multifocal tumors [158,239]. As no difference 
in light penetration is observed between tumor and normal bladder tissue, the 
photodynamic response upon diffuse illumination of the bladder will depend on the 
localization and accumulation of PS within the tumor [240]. PDT can be recommended 
as a second-line treatment or immediate therapy for patients with tumor recurrence after 
TURBT, chemotherapy, and/or BCG failure [241,242,243]. It has been shown that 
bladder PDT is effective in CIS, well-tolerated compared to adjuvant BCG therapy and 
enhances MMC efficiency as an adjuvant therapy [244].  
 
HpD (photofrin) was first approved for the treatment of NMIBC (superficial bladder 
cancer) in Canada in 1993. However, HpD itself has several drawbacks, such as 
contamination with impurities, and relatively low absorbance at 630 nm, where tissue 
penetration of light is not optimal. PDT for bladder cancer (bladder PDT) with 
intravenously administered HpD induces long-lasting skin photosensitivity for up to 6-8 
weeks. Because of accumulation of HpD in the bladder muscle, fibrosis and permanent 
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bladder contraction can be observed in some treated patients [245]. In addition, the 
onset of numerous side effects is sometimes triggered, including urinary frequency, 
urgency, nocturia, suprapubic pain, and bladder spasm. As a result, the light dose 
required for activation of HpD will vary largely from patient to patient [5,227,246]. Due 
to permanent bladder shrinkage induced by severe urgency symptoms and prolonged 
skin photosensitivity, bladder PDT has progressively been abandoned [237,247], until 
the introduction of ALA and HAL in bladder diagnosis. 
 
ALA and HAL have been approved for the diagnosis of NMIBC after intravesical 
instillation. Interestingly, fluorescence guided cystoscopy facilitates a more complete 
resection and prolongs recurrence-free survival [248]. This has caused regained interest 
in bladder PDT with intravesical administered PSs, especially to treat CIS. Some efforts 
have been made to improve ALA-based bladder PDT [103,249,250,251,252,253]. No 
patients revealed bladder contraction or systemic side effects. However, clinical trials of 
ALA-based bladder PDT have been extremely sparse, representing only small, single 
institution series [158,241,254,255,256].  
 
Owing to variable tumor responses and significant side effects such as phototoxicity and 
bladder contracture, lack of standard protocol, and limited number of appropriate 
patients, PDT has not become widely accepted as a treatment for human bladder cancer 
[238,257], demonstrating the need for improved approaches. Currently, a novel PS 
hypericin, extracted from plants of the Hypericum genus, has been developed for the 
detection of bladder cancer. Compared to white and blue light cystoscopy, hypericin 
shows minimal side effects and higher specificity and sensitivity [258]. Hypericin-
mediated PDT has been tested against bladder cancer in vitro showing significantly 
better photocytotoxicity and selective localization than HpD [259]. Bladder PDT using 
the new PS Radachlorin® has been shown to be a safe and effective treatment for 
NMIBC refractory or patients that are intolerant to BCG therapy [244,260].  
 
 
4.4 PCI for bladder cancer 
 
Very recently, both in vitro and in vivo studies of the treatment for bladder cancer using 
PCI combined with the chemotherapeutic agent bleomycin were independently set up 
by two research groups [236,261]. PCI-enhanced bleomycin effect has been observed in 
bladder cancer cells that were tested.  
 
In 2005, bleomycin was introduced for PCI. It was found that PCI with bleomycin 
induced a synergistic inhibition of tumor growth in vivo using several tumor models 
[201]. Later, in 2009, the same group reported that PCI of bleomycin was superior to 
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PDT and could be used as an adjunct to marginal surgery [179]. A PCI-enhanced 
bleomycin effect was also documented in malignant gliomas and breast cancer cells 
[262,263]. These results have shown that PCI has the potential to lower both drug doses 
and the number of repetitive doses required to achieve sufficient therapeutic effect 
compared to the single drug dose. Therefore, the toxic side effects of bleomycin can 
potentially be greatly reduced by using the PCI technique [262]. Altogether, the benefits 
of PCI with bleomycin encourage further research into bladder cancer treatment. 
 
 
5. Aims of the study 
 
The use of prodrugs 5-aminolevulinic acid (ALA) and its hexyl ester in bladder 
diagnosis has stimulated great interest in ALA-PDT clinical trials. However, the number 
of clinical trials is extremely sparse and PDT has not become widely accepted as a 
treatment for bladder cancer as yet, demonstrating the need for more studies towards 
improved strategies.  
 
Based on this purpose, we aimed to: 
 
(1) investigate protein carbonylation, signaling pathways, and biological processes 
induced/affected by hexyl ALA-PDT, to improve our understanding of 
biological processes affected by PDT (Paper 1); 
 
(2) study the uptake mechanism of ALA and methyl ALA via the γ-aminobutyric 
acid (GABA) transporters, searching for a potent pain-reducing strategy for 
ALA-based PDT (Paper 2);  
 
As a novel drug delivery tool, photochemical internalization (PCI) has the potential to 
improve the total intravesical therapeutic agent uptake and hence therapeutic efficacy 
for bladder cancer. Based on this purpose, using a novel photosensitizer TPCS2a 
(Amphinex®, PCI Biotech AS, Norway), we aimed to:  
 
(3) explore the effect of PCI of the chemotherapeutic agent bleomycin in vitro 
(Paper 3); 
 
(4) establish a research protocol for the photosensitizer TPCS2a in a rat bladder 
tumor model (Paper 4). 
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6. Summary of publications and manuscripts included in the thesis 
 
6.1 Paper 1: Photodynamic therapy with hexyl aminolevulinate induces 
carbonylation, posttranslational modifications and changed expression of proteins 
in cell survival and cell death pathways 
 
Yan Baglo, Mirta M. L. Sousa, Geir Slupphaug, Lars Hagen, Sissel Håvåg, Linda 
Helander, Kamila A. Zub, Hans E. Krokan and Odrun A. Gederaas* 
 
Journal of Photochemical & Photobiological Sciences, 2011 
 
In this study, we examined protein expression levels, post-translational modifications, 
and protein carbonylation in rat bladder cells (AY-27) after PDT mediated by hexyl 5- 
aminolevulinic acid (HAL) and blue light (435 nm).  
 
Modern proteomic methods, including immunoprecipitation, two-dimensional 
difference gel electrophoresis (2D-DIGE), two-dimensional gel electrophoresis (2D-
GE), and mass spectrometry (MS), were used in this study (Figure 10). We obtained 
proteomic maps of AY-27 cells and identified 40 proteins and 10 carbonylated proteins 
with altered protein expression and/or modification at 2h post-PDT. These proteins were 
associated with cellular cytoskeleton, transport, oxidative stress response, protein 
biosynthesis and stability, and DNA repair. The results indicate that HAL-mediated 
PDT triggers a complex cellular response involving several important biological 
pathways, such as cell motility, energy metabolism, and signaling pathways for survival 
and cell death. 
 
This study has extended our understanding of the clinical effects associated with ALA-
based PDT, and may pave the way for potential new adjuvant drugs or for targeted use 
of other treatment modalities.  
 
Remarks:  
The work on identification of 40 proteins with altered protein expression (Figure 1-3) 
was included in the master degree of the candidate. The work on identification of 10 
carbonylated proteins and protocol development, classification of 50 identified proteins, 
pathways affected by PDT, and article writing has only been included in the doctoral 
degree of the candidate. 
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Figure 10. Outline of the experiments of paper 1  
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6.2 Paper 2: Homology modeling of human γ-butyric acid transporters and the 
binding of pro-drugs 5- aminolevulinic acid and methyl aminolevulinic acid used in 
photodynamic therapy 
 
Yan Baglo, Mari Gabrielsen, Ingebrigt Sylte and Odrun A. Gederaas* 
 
Journal of PLOS ONE, 2013 
 
In this study a novel structure-based approach, homology modeling and molecular 
docking, was employed to investigate the uptake of ALA and MAL via GABA 
transporters (GATs). We constructed in silico models of four human GAT subtypes 
(GAT-1, GAT-2, GAT-3, and BGT-1) using three x-ray crystal structures of the 
homologous leucine transporter (LeuT) as templates. The LeuT crystal structures are 
available in outward-occluded, inward- and outward-open conformations. Homology 
modeling and docking was performed using ICM software version 3.7 
(www.molsoft.com). The alignment was adjusted according to the comprehensive 
alignment of prokaryotic and eukaryotic NSS transporter sequences published by 
Beuming et al. [264]. After construction, the models were energy refined and quality 
checked using the programs PROCHECK, ERRAT and VERIFY-3D 
(http://nihserver.mbi.ucla.edu/SAVES/). 
 
Binding of the native substrate GABA and the possible substrates ALA and MAL was 
investigated by molecular docking of the ligands into the central putative substrate 
binding sites in the evaluated outward-occluded GAT models. Electrostatic potentials 
(ESPs) of the putative substrate translocation pathway of each subtype were calculated 
using the outward-open and inward-open homology models. The outline of the 
experiment is show in Figure 11. 
 
Our results suggest that ALA is a substrate of all four GATs and that MAL is a substrate 
of GAT-2, GAT-3 and BGT-1, based on docking scores and the calculation of the ESPs. 
Uptake via GATs into peripheral sensory nerve endings may also account for one of the 
few adverse side effects of ALA-based PDT, namely pain. In addition, the ESP 
calculations indicate that differences are likely to exist in the entry pathway of the 
transporters (i.e. in outward-open conformations). Such differences may be used to 
search for therapeutic inhibitors that selectively target specific GAT subtypes, and this 
may be used to reduce ALA- and MAL-induced pain. 
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Figure 11. Outline of the experiment of paper 2. 
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6.3 Paper 3: Enhanced efficacy of bleomycin in bladder cancer cells by 
photochemical internalization 
 
Yan Baglo*, Lars Hagen, Anders Høgset, Finn Drabløs, Marit Otterlei and Odrun A. 
Gederaas 
 
Journal of BioMed Research International (submitted) 
 
This work was performed to explore the effect of PCI with bleomycin in bladder cancer 
cells using the photosensitizer disulfonated tetraphenyl chlorin (TPCS2a). Bleomycin is 
a cytotoxic chemotherapeutic agent widely used in cancer treatment. But its efficacy in 
bladder cancer is low, possibly due to limited cellular internalization. We investigated 
cellular sensitivity to photosensitizer uptake, bleomycin and photodynamic dose, and 
DNA repair capacity by fluorescence measurement, resazurin survival assay, and comet 
assay, respectively, in three cell lines (Table 3, Figure 12). The results showed that PCI 
enhanced bleomycin cytotoxicity up to 20% independent of cell type, and elevated 
bleomycin-induced DNA damage levels in all three cell lines. We further explored two 
additional strategies to enhance the PCI-bleomycin effect. One strategy was to impair 
DNA damage responses using the peptide ATX-101. The other was to inhibit activity of 
bleomycin hydrolase using the protease inhibitor E-64. The results showed that ATX-
101 enhanced the PCI-bleomycin efficacy with 14.7%, 30.5%, and 20.7% in A431, T24, 
and AY-27 cells respectively, whereas E-64 did not have a similar effect. 
 
 
Table 3. Cellular responses to bleomycin treatment and photodynamic treatment 
 
 
 
Cellular response AY-27 T24 A431 
TPCS2a uptake low low high 
Sensitivity to light strong weak middle 
Sensitivity to 
bleomycin  
low middle high 
DNA damage repair high low middle 
BLMH expression high low low 
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Figure 12. Outline of the main experiments of paper 3. 
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6.4 Paper 4: Studies of the photosensitizer disulfonated meso-tetraphenyl chlorin 
in an orthotopic rat bladder tumor model 
 
Yan Baglo*, Qian Peng, Lars Hagen, Kristian Berg, Anders Høgset, Finn Drabløs, and 
Odrun A. Gederaas 
 
Journal of Photodiagnosis and Photodynamic Therapy (manuscript) 
 
In this study, patterns of uptake, retention and localization of the photosensitizer 
disulfonated tetraphenyl chlorin (TPCS2a) were explored to establish a protocol with 
TPCS2a in an orthotopic rat bladder tumor model. AY-27 transitional carcinoma cells 
were intravesically inoculated in rat bladder. Two weeks later, the photosensitizer 
TPCS2a was intravesically instilled at different concentrations to determine an optimal 
concentration by ex vivo fluorescence measurement. This measurement was performed 
from bladder inner wall in tumor node(s) after bladder dissection as described by 
Gederaas et al. [261]. With this optimal concentration of TPCS2a, bladders were excised 
at different times to determine an optimal TPCS2a-to-light time interval by ex vivo 
fluorescence measurement. The tissue retentive TPCS2a was activated by red light 
(652 nm, 0.5 J/cm2) under the presumed optimal protocol determined by fluorescence 
measurement (3 mg/ml TPCS2a and TPCS2a-to-light time interval of 24 h) in the rat 
bladder tumor model (Figure 13). Necrotic area induced was histologically examined. 
The results obtained from both fluorescence microscopes and histological examination 
of the necrotic area showed that the location and penetration of TPCS2a was superficial 
in the mucosal layer of the bladder wall. The retentive TPCS2a was maximal at 24 h, 
eliminated thereafter and cleared from the tissue after 72 h. 
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                              Figure 13. Outline of the experiments of paper 4. 
  
 
   
72 h after TPCS2a 
instillation with 1, 2, 3, 
and 5 mg/ml 
Protocol A Protocol B Protocol C 
23 rats  19 rats  8 rats  
AY-27 inoculation, 14 days  AY-27 inoculation, 14 days  AY-27 inoculation, 14 days  
4, 24, 48, and 72 h after 
3 mg/ml TPCS2a 
instillation  
Illumination at 24 h after 
3 mg/ml TPCS2a 
instillation  
Fluorescence ex vivo 
measurement  
Fluorescence ex vivo 
measurement  
Housing for 19 days  
Optimal concentration:  
3 mg/ml  
Optimal TPCS2a-to-light:  
24 h  
Histology of necrotic 
area with paraffin 
section 
Fluorescence microscopy with frozen tissue sections  
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Discussion 
 
 
This thesis describes preclinical studies of the treatment effects of bladder cancer. This 
is done at the level of molecules and proteins using photodynamic therapy (PDT) with 
prodrugs including 5-aminolevulinic acid (ALA) and its esters, and at the level of cells 
and tissue using photochemical internalization (PCI) of the chemotherapeutic agent 
bleomycin mediated by the photosensitizer disulfonated tetraphenyl chlorin (TPCS2a). 
 
 
7. PDT for bladder cancer 
 
7.1 Differential protein expression and modifications induced by HAL-PDT 
 
The presence of carbonyl groups is the most widely used marker for oxidative damage 
to proteins. PDT triggers a sequence of photochemical reactions in photosensitized cells 
producing high level of reactive oxygen species (ROS) and radicals. Cellular 
antioxidant mechanisms are apparently overloaded leading to ROS-induced protein 
modifications and dysfunction, and this eventually affects pathways resulting in cell 
death [126]. 
 
At the molecular level, genes and their products (proteins) have been observed to be 
either up-regulated or down-regulated after ALA-PDT in human A431 skin cancer cells. 
This was observed by Verwanger et al. and Ruhdorfer et al. using cDNA arrays, 
identifying genes involved in cell proliferation, stress responses, apoptosis and cell 
adhesion [129,132]. Recently, Demyanenko et al. evaluated 112 proteins associated 
with epigenetic regulation in mouse brain tumor after ALA-PDT, using proteomic 
antibody microarrays. The PDT alters expression of proteins involved in epigenetic 
regulation of transcription, histone modification, DNA repair, nuclear protein import, 
and proliferation [265]. By using modern proteomic methods of 2D-DIGE and MS, we 
have obtained differential proteomic maps of protein pI-shift induced by HAL-PDT in 
AY-27 rat bladder cancer cells, and identified 40 proteins from the maps. Further study 
on the proteins with acidic pI-shift indicated that alternative oxidations such as cysteine 
sulfinic acid, or secondary enzymatic modifications such as phosphorylation, may be 
present. In contrast, carbonylation does not mediate a change in pI, which is one of the 
most used markers for oxidative damage to proteins. Elevation in the total level of 
protein carbonyls after PDT has previously been documented by Magi et al. and 
Kirdaite et al. [266,267]. In order to identify proteins modified by carbonylation after 
PDT in our study, we developed a protocol of labeling carbonylated proteins with 2,4-
dinitrophenyl hydrazine (DNPH) after PDT. Control and PDT samples were derivatized 
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with DNPH and immunoprecipitated using an anti-DNP antibody prior to separation by 
2D-GE and identification by MS. Nine proteins were identify with increased 
carbonylation and one protein with reduced carbonylation.  
 
We classified the identified proteins by cellular localization demonstrating that the 
majority of the modified proteins by HAL-PDT were from mitochondria, ER and 
membranes where the endogenous photosensitizer protoporphyrin IX (PpIX) is 
synthesized or accumulated. This indicates that these cellular compartments are major 
targets for HAL-PDT. Although nuclear localization of PpIX has not been observed, we 
found that several cytoplasmic and nuclear proteins were shown to be affected, likely 
caused by indirect oxidation or intracellular translocation subsequent to HAL-PDT. 
 
Overall, our results indicate that HAL-mediated PDT triggers a complex cellular 
response involving several biological pathways. This study has extended our 
understanding of PDT effects at the protein level. Our findings are relevant for the 
elucidation of mechanisms modulated by PDT, paving the way to improved clinical 
PDT efficacy. 
 
The proteomic methods used in this study will not detect proteins at very low 
concentration, due to the presence of more highly abundant proteins. However, we can 
use an enrichment strategy with removal of known abundant proteins, or a more specific 
strategy with immunoprecipitation of a protein of interest from a large amount of lysate. 
Another suggestion for future work is to repeat the study with a photosensitizer for PCI 
in order to explore differences between PDT and PCI effects at the protein level. 
 
 
7.2 The transport of ALA and MAL via human γ-butyric acid transporters 
 
Previous in vitro studies have indicated that 5-aminolevulinic acid (ALA) is a substrate 
for human γ-butyric acid (GABA) transporters (GATs), while its methyl ester MAL is 
more ambiguous, as this compound seemingly is transported via GAT in some cell 
types, but not in others [91,92,94,95,268]. Our in silico results suggest that ALA is a 
substrate of all four GATs and that MAL is a substrate of GAT-2, GAT-3 and BGT-1, 
based on structural analysis of ligand-protein interactions. However, further studies are 
needed to verify these findings, such as molecular dynamics simulations or wet-lab 
experiments. 
 
The GATs play an essential role in regulating neurotransmitter signaling and 
homeostasis by mediating uptake of released GABA from the extracellular space into 
neurons and glial cells. For ALA-based PDT, the uptake of ALA or MAL via GAT-2, 
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GAT-3 and BGT-1 (GAT-1 is only found in CNS) into peripheral sensory nerve 
endings may account for one of the few adverse side effects, namely pain [155,156]. 
ALA-based PDT in combination with selective inhibitors of the GATs may be an 
attractive approach to develop pain-reduce strategy and improve the PDT efficacy in the 
future. 
 
 
8. PCI for bladder cancer  
 
8.1 PCI enhances bleomycin effect in bladder cancer cells  
 
To improve the total intravesical agent uptake and hence chemotherapeutic efficacy for 
non-muscle invasive bladder cancer, various experimental approaches have previously 
been evaluated, including enhancing the agent delivery to bladder tissue using 
electromotive therapy, and enhancing cell membrane permeability using intravesical 
hyperthermia [222,269,270]. In this study we employed a novel drug delivery approach 
consisting of PCI technique in combination with the chemotherapeutic agent bleomycin 
in rat and human bladder cancer cells (AY-27 and T24 cell lines). Although bleomycin 
has not shown good clinic efficacy in bladder cancer [271,272,273], we demonstrate 
that PCI enhances the bleomycin effect in vitro, in agreement with a related study 
reported by Arentsen et al. [236]. We further show that PCI elevates bleomycin-induced 
DNA damage levels in all three cell lines, strongly suggesting that more bleomycin 
molecules entered the nuclei compared to treatment with bleomycin as a single agent. 
Thus, the membrane barrier seemed to be bypassed by bleomycin when using the PCI 
technique. 
 
 
8.2 Combination strategy of PCI, bleomycin, and an inhibitor of DNA repair 
 
The membrane barrier, degradation by bleomycin hydrolase (BLMH), and elevated 
DNA repair capacity in cells are considered as main factors towards bleomycin 
resistance in cells lines with low bleomycin effect [274,275,276]. We demonstrated that 
a novel peptide drug ATX-101 increases bleomycin efficacy by impairing DNA repair 
response in treated cells, strongly suggesting that the cellular DNA repair capacity is a 
crucial factor of bleomycin efficacy. The combination of TPCS2a, blue light, bleomycin, 
and ATX-101 dose used has no or low toxicity, but reaches a promising therapeutic 
effect in bladder cancer cell lines AY-27 and T24. This shows a potential for reducing 
possible side effects of bleomycin at high dose in clinical application. 
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8.3 Studies of TPCS2a in an orthotopic rat bladder tumor model 
 
The photosensitizer TPCS2a displays a superficial distribution pattern in bladder tumor 
tissue. This may be due to AY-27 cells having low ability to take up the photosensitizer. 
The retentive TPCS2a is almost cleared from the tumor tissue at 72 hours after 
instillation. Based on fluorescence measurement of the tissue retentive TPCS2a, an 
optimal TPCS2a protocol has been achieved, including a 24-hour TPCS2a-to-light time 
interval and a dose of 3 mg/ml TPCS2a. This protocol will be utilized for further in vivo 
studies of PCI-enhanced therapeutic effects on non-muscle invasive bladder cancer, 
using a potent chemotherapeutic under an optimal light dose. 
 
As the location and penetration of TPCS2a are shown to be superficial in the rat bladder 
tumor model, further studies on improvement of tissue penetration of TPCS2a and 
optimization of light dose are required. 
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Conclusions 
 
This project has been a preclinical study of PDT/PCI-based treatment effects, with focus 
on bladder cancer.  
 
1. The state-of-the-art proteomic experiments outlined may be a useful tool for the 
study of treatment effects on proteins and associated signaling pathways. Our 
findings provide an overview of biological effects at the protein level after HAL-
PDT in rat AY-27 bladder cancer cells, and supplement our understanding of the 
mechanisms of PDT action.  
 
2. The homology models of GABA transporters (GATs) presented here may provide 
an important tool for designing potential therapeutic inhibitors for handling 
treatment effects related to the transporters. For ALA/MAL-PDT, these models may 
provide future druggability for a pain-reduce strategy based on our findings that 
ALA/MAL is a potential substrate for the GATs. 
 
3. The observations presented in this thesis indicate that more bleomycin molecules 
enter the nuclei when using the PCI technique and that the cellular DNA repair 
capacity is a crucial factor of the PCI-bleomycin efficacy. This study gives basis for 
a promising combined strategy of PCI-bleomycin and ATX-101 (a peptide inhibitor 
of DNA repair) in future animal and clinical studies. 
 
4. The orthotopic rat bladder tumor model is a good model for studying enhanced 
bleomycin treatment of bladder cancer by PCI. This work has developed important 
parts of a novel and practical protocol for TPCS2a-PCI in the animal model. 
Importantly, the histological findings of superficial distribution of the 
photosensitizer TPCS2a show a limitation for the approach. The challenge for future 
study is how to increase the penetration depth of the photosensitizer in tissue. 
 
In summary, this project has developed a highly useful set of tools for studying the 
effect of PDT and PCI, in particular on bladder cancer, and application of these tools 
has both generated novel information, and indicated important challenges for future 
research. 
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Photodynamic therapy with hexyl aminolevulinate induces carbonylation,
posttranslational modiﬁcations and changed expression of proteins in cell
survival and cell death pathways
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Photodynamic therapy (PDT) using blue light and the potent precursor for protoporphyrin IX, hexyl
aminolevulinate (HAL), has been shown to induce apoptosis and necrosis in cancer cells, but the
mechanism remains obscure. In the present study, we examined protein carbonylation, expression levels
and post-translational modiﬁcations in rat bladder cells (AY-27) after PDT with HAL. Altered levels of
expression and/or post-translational modiﬁcations induced by PDT were observed for numerous
proteins, including proteins required for cell mobility, energy supply, cell survival and cell death
pathways, by using two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry
(MS). Moreover, 10 carbonylated proteins associated with cytoskeleton, transport, oxidative stress
response, protein biosynthesis and stability, and DNA repair were identiﬁed using immunoprecipitation,
two-dimensional gel electrophoresis and MS. Overall, the results indicate that HAL-mediated PDT
triggers a complex cellular response involving several biological pathways. Our ﬁndings may account
for the elucidation of mechanisms modulated by PDT, paving the way to improve clinic PDT-efﬁcacy.
1. Introduction
5-Aminolevulinic acid (ALA) is an endogenous precursor for pro-
toporphyrin IX (PpIX) formed via the heme biosynthetic pathway.
It has been shown that certain tumor cells have a large capacity
to synthesize the photosensitizer PpIX in mitochondria when
exposed to adequate concentrations of exogenous ALA because
of low activity of ferrochelatase and elevated porphobilinogen
deaminase.1 Hexyl aminolevulinate (HAL) is an ester of ALA
that is effectively converted into free ALA by esterases in cytosol
before entering into the heme biosynthetic pathway.2,3 The uptake
mechanisms of ALA and ALA methyl ester have been extensively
studied in human colon carcinoma cells (WiDr).4–6
In recent years, a number of studies on HAL-mediated PDT
have been conducted. The improved penetration of HAL due
to its high lipophilicity was demonstrated by comparison of
distribution of ALA, whilst kinetics and intracellular localization
ofHAL-induced PpIXwere investigated in human and rat bladder
cancers in vivo and several human cancer cell lines.7–18 The
effect of illumination was examined in rat ovarian cancer and
porcine bladder mucosa.19,20 Moreover, tissue response to HAL-
PDT was monitored in rat bladder. The results revealed a clear
treatment response in vivo including decreased tissue oxygenation
Department of Cancer Research and Molecular Medicine, Norwegian
University of Science and Technology, N-7491, Trondheim, Norway.
E-mail: odrun.gederaas@ntnu.no; Fax: +4772576400; Tel: +4772573015
and PpIX photobleaching.21 Later, PpIX photobleaching was
proven to be a useful tool to predict the tissue response to HAL-
PDT.22 A clinical study comprising 24 patients demonstrated
that HAL-PDT was a non-invasive, repeatable procedure for
cervical intraepithelial neoplasia and no severe side effects were
encountered.23 Mechanisms of cell killing in PDT remain obscure,
but are most likely complex and apparently involve both caspase-
dependent and -independent apoptotic pathways.24–26
PDT results in a sequence of photochemical processes in pho-
tosensitized cells. Cellular antioxidant mechanisms are apparently
overloaded by high levels of reactive oxygen species (ROS) and
radicals. This leads toROS-inducedproteinmodiﬁcations anddys-
function, and eventually affects pathways resulting in cell death.27
The most thoroughly characterized oxidative modiﬁcations of
proteins subsequent to PDT are irreversible and non-enzymatic
carbonylation and oxidation of thiol groups.28,29 Magi et al. found
that a speciﬁc set of proteins, including structural proteins and
chaperones, were carbonylated and their results supported the
concept that oxidative damage to proteins was selectively induced
by PDT with Purpurin-18.30
The aim of the present study was to identify proteins with
altered expression levels and/or altered post-translational status
2 h subsequent to HAL-mediated PDT in rat bladder cancer
cells (AY-27), using 2D difference gel electrophoresis (2D-DIGE)
and mass spectrometry (MS). To detect protein carbonylation
and altered expression in less abundant proteins, carbonylated
proteins were labeled with 2,4-dinitrophenyl hydrazine (DNPH)
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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and immunoprecipitated with anti-DNP antibody prior to 2D-
GE and MS.31,32
2. Materials and methods
2.1 Cell culture and HAL-mediated light treatment
Rat bladder cancer cells (AY-27) were maintained in RPMI-
1640 culture medium (BioWhittaker) supplemented with 5% L-
glutamine, 1% penicillin/streptomycin, 0.1% fungizone and 10%
fetal bovine serum (FBS) in a humidiﬁed atmosphere of 95% air
and 5% CO2 at 37 ◦C.
About 3.5 ¥ 106 cells were seeded per Petri dish (diameter:
10 cm) and cultured for one day. Subsequent to wash cells with
PBS twice, RPMI-1640 culture medium (FBS-free) containing 10
mM HAL (PhotoCure AS, Norway) was added to cells and kept
in the dark for 3.5 h. The medium was then replaced with PBS,
and the cells were exposed to blue light (435 nm) for 35 s (0.45 J
cm-2, Lumi Source, PCI Biotech AS, Norway). Subsequent to 2 h
incubation in the dark in FBS-free medium, cells were harvested
by scraping in ice-cold PBS and centrifuged (450 g, 5 min, 4 ◦C).
Three groups of cell samples were analyzed in parallel: HAL;
cells incubated with HAL only. PDT; cells treated with blue
light after HAL incubation, and controls; without any treatment,
neither HAL incubation nor light exposure.
This protocol was chosen based on our earlier unpublished
results that the HAL-incubation time (3–3.5 h) gave a stable
production of PpIX inside the AY-27 cancer cells and light
treatment at the same experimental conditions led to about LD80
close to clinic target.
2.2 Protein extraction
Cell pellets were resuspended in 0.3¥ packed cell volume (PCV) of
buffer I (10 mM Tris-HCl pH 8.0, 200 mM KCl, 1 mM DTT, 1%
phosphatase inhibitor cocktail 1 and 2 (Sigma), 2% Complete
protease inhibitor cocktail (Roche) and mixed with a volume
of buffer II (10 mM Tris-HCl pH 8.0, 200 mM KCl, 2 mM
EDTA, 40% glycerol, 0.5% NP40, 1 mM DTT and phosphatase-
and protease inhibitors as above) corresponding to the combined
volumes of the pellet and buffer I. The mixture was incubated on
a roller (45 min, 4 ◦C) and sonicated (2 min, dark) using Branson
Soniﬁer250 (output 2, duty cycle 20). Subsequent to centrifugation
(10 min, 16100 g, 4 ◦C) supernatants (control, HAL and PDT)
were collected and protein concentrations were determined using
the Bio-Rad protein assay (BioRad Laboratories, USA).
2.3 Two dimensional difference gel electrophoresis (2D-DIGE)
Protein lysates (Control, HAL and PDT), 50 mg of each, were
diluted in 2¥ lysis buffer (7 M urea, 4% CHAPS, 30 mM Tris, 2 M
thiourea pH 8–8.5) and labelled with a speciﬁc CyDye (Cy2, Cy3
and Cy5, respectively), according to manufacturer’s instructions
(GE Healthcare). The reaction was quenched by adding 10 mM
lysine (1 ml) following incubation for 10 min on ice in the dark.
Each labelled protein sample was diluted 2-fold with 2¥ sample
buffer (7 M urea, 4% CHAPS, 30 mM Tris, 130 mM DTT) and
incubated on ice for 10 min. The three protein samples were mixed
together and 1¥ sample buffer was added to reach a ﬁnal volume
of 450 ml. Then, 1% IPG buffer pH 3–11 (GE Healthcare) was
added to the sample and rehydrated overnight into an IPGstrip
(pH 3–11, 24 cm). Isoelectric focusing (IEF) was carried out
according to the manufacturer’s instructions (GEHeathcare). For
the second dimension, strip was ﬁrst incubated with equilibration
stock buffer (50 M Tris-HCl pH 8.8, 6 M urea, 30% glycerol
and 2% SDS) containing 1% DTT for 15 min and then with
the equilibration stock buffer containing 2.5% iodoacetamide for
15min under agitation at room temperature. The equilibrated strip
was sealed on top of a 10% polyacrylamide gel using colorless
liquid agarose. The electrophoresis was run overnight using Ettan
DALT electrophoresis system (400 V, 20 mA, 2 W/gel, 20 ◦C).
Spots were visualized using the TyphoonTM Trio Imager (GE
Healthcare) at wavelengths of 520 nm, 580 nm and 620 nm. Images
were analyzed using DeCyderTM 2D software, which provides a
3D view of each protein spot. The spots are plotted as peaks
that represent directly both the distribution (peak area) of the
spot in the gel and its amount (peak volume). The relative peak
volumes of protein spots were used to calculate the volume ratio
of protein spots pairs (Cy3 and Cy5). Changes in volume ratio of
protein spots pairs were used to determine proteins differentially
expressed due to PDT treatment. Proteins of interest were then
selected using DeCyderTM 2D software and picked using Ettan
Spot Picker.
2.4 Two dimensional gel electrophoresis (2D-GE)
The HAL and PDT lysates (300 mg of each) were mixed together
and DeStreak rehydration solution (GEHealthcare) was added to
reach a ﬁnal volume of 450 ml. The IPGstrip (pH 3–11, 24 cm) was
rehydrated and protein separation by IEF and SDS-PAGE was
performed as described above.
After 2D-GE separation, the gel was stained with silver
according to the protocol established by Shevchenko33 with minor
modiﬁcations. Spots of interest were excised manually.
2.5 Protein identiﬁcation by mass spectrometry (MS)
Protein spots were in-gel digested with trypsin as described by
Shevchenko.33 Peptides were extracted from the gel and desalted
using StageTIP.34 The eluted peptides were mixed with HCCA (a-
cyano-4-hydroxycinnamic acid) matrix (7 g l-1 in 50%Acetonitrile,
50% ethanol) and loaded onto a MALDI-plate. Peptide mass
ﬁngerprints andMS/MS spectra were obtained using anUltraﬂex
IIIMALDI-TOF/TOF instrument (BRUKERDaltonicsGmbH,
Germany). Protein identiﬁcation was performed by MSDB
database searches using the Mascot software (Matrix Science).
2.6 Carbonylated protein labeling with 2,4-dinitrophenyl
hydrazine (DNPH)
Protein lysates (1.5 mg each) were diluted (1 : 1) with 10% SDS
and incubated for 5 min prior to addition of an equal volume of
10 mM DNPH in 10% TFA and further incubation for 30 min
at room temperature under rotation. Reactions were stopped and
the products (DNP-protein) precipitated by adding 2 volumes of
20% ice-cold trichloroacetic acid (TCA) and incubation on ice for
45 min. Precipitated DNP-proteins were pelleted (20 min, 5900 g,
4 ◦C), and pellets were washed three times with acetone (5 min,
4500 g, 4 ◦C) and resuspended in 600 ml of a 1 : 1 mixture of buffer
I and II.
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Fig. 1 Proteomic map of HAL and PDT lysate samples of AY-27 cells. (A) Proteins under-expressed (green spots) or over-expressed (red spots) in the
PDT sample (HAL and light treatment) compared to control (only HAL treatment); (B) spot with lower Cy3/Cy5 ratio (DeCyder analysis) shown as
red in the proteomic map was up-regulated in the PDT sample. This spot together with other 3 spots to the right were identiﬁed as heat shock protein
60 kDa later by MS indicating pI-shift.; (C) Spot with higher Cy3/Cy5 ratio shown as green in the proteomic map was down-regulated in the PDT
sample.
2.7 Immunoprecipitation using anti-DNP antibody
Anti-DNP antibodies were covalently coupled to paramagnetic
Dynabeads protein A beads according to the manufacturer’s
protocol (Dynal). DNP-labelled protein samples were incubated
with crosslinked beads (150 ml) overnight at 4 ◦C with constant
agitation. The beads were washed three times with 10 mM Tris-
HCl (pH 8.3), 50 mM KCl (pH 8.3) and DNP-proteins eluted
with 1¥ Novex LDS loading buffer (13 ml, Invitrogen) and the
beads were further incubated overnight in 1¥ sample buffer
(117 ml). The combined eluates were then subjected to 2D-GE
using 7 cm IPGstrip (pH 3–11) and a 4–12% gradient NuPAGE
gel (Invitrogen). The gel was stained with Krypton protein stain
according to the manufacturer’s protocol (Pierce, USA) and the
spots were visualized using a Typhoon scanner (GE Healthcare).
3. Results and discussion
3.1 PDT treatment causes marked changes in protein expression
and apparent post-translational modiﬁcation status
Alterations in the apparent post-translationalmodiﬁcation (PTM)
status of proteins two hours subsequent to HAL alone or
HAL/PDT treatment of rat bladder cancer cells (AY-27) were
monitored in three parallel experiments using 2D-DIGE. Since
our primary objective was to identify alteredmigration of proteins
that could indicate differential PTM status, a Cy2-labelled internal
control was not included in the experiments. Nevertheless, a
marked difference in the overall expression level of several
proteins was evident from the Cy3/Cy5 ratios. Moreover, the
proteomic maps obtained from the parallel experiments were very
similar, indicating that the procedure is highly reproducible. A
representative proteomic map of HAL and PDT lysate samples is
shown in Fig. 1 (a), in which clear red spots represent up-regulated
proteins (Fig. 1, b) and clear green spots represent down-regulated
proteins (Fig. 1, c) in the PDT-treated cells as compared to cells
treated with HAL only. Yellow spots represent proteins expressed
at similar level in both samples. The 2D-DIGE image clearly
demonstrates that additional exposure of the HAL-treated cells
to blue light causes a striking change in the expression of some
proteins.Moreover, several proteins exhibited apparently different
migration in the 2D-gel, typically in the form of species having an
acidic pI-shift (Fig. 1, b). Such acidic shifts might be the result
of enzymatic modiﬁcations mediating gain of negative charge by,
for example, phosphorylation, or loss of positive charge by, for
example, acetylation. However, shifts towards the acidic side may
also result from non-enzymatic oxidative modiﬁcations, such as
oxidation of cysteine to cysteine sulfenic- or sulﬁnic acid.
In order to increase protein concentration and enhance protein
identiﬁcation in MS analysis, a 2D-GE was run with higher
amount of both HAL and PDT lysate samples (Fig. 2), and
proteins were excised from the silver-stained gel using the 2D-
DIGE gels as reference. A total of 40 proteins were identiﬁed
and assigned in the 2D-DIGE gel (Fig. 3). Among these, 15
proteinsweremarkedly up-/down-regulated or displayedmodiﬁed
post-translational status, as suggested by their altered migration.
As shown in Table 1, heterogeneous nuclear ribonucleoprotein
(hnRNP) L and pre-mRNA-processing factor 19 were markedly
up-regulated, while pyruvate kinase isozymes M1/M2, vimentin,
and tubulin alpha-1 chain were markedly down-regulated. The
remaining 10 proteins displayed acidic pI-shifts, as illustrated for
HSP60 (Fig. 1, b).
Apparent down-regulation of vimentin could be a consequence
of vimentin cross-linking resulting from carbonylation. This has
previously been observed in A549 cells subsequent to acrolein-
induced carbonylation,35 and would mediate a loss of vimentin
monomers in 1D-GE and 2D-GE gels. Interestingly, several of
the most abundant cytoskeletal and chaperone proteins such as
b-actin, protein disulﬁde-isomerase A6 and A3, HSP70/90 and
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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Table 1 Proteins and biological processes/pathways inAY-27 cells affected byHAL-mediated PDT, based on the 24 proteins subject to post-translational
modiﬁcation and differential expression, analyzed using Uniprot and PANTHER software (www.pantherdb.org)
Gene ID Name of protein Cellular location PDT responsea
Main molecular
function
Main biological
process/pathway Reference
P11980 pyruvate kinase isozymes
M1/M2
cytosol D carbohydrate kinase glycolysis/pyruvate
metabolism
P68370 tubulin alpha-1A chain microtubule D tubulin intracellular
protein trafﬁc, cell
structure and
motility, cell cycle,
developmental
process, etc.
30,37,38
P31000 vimentin nucleus, cytoplasm D structural protein ectoderm
development; cell
structure
35,39
Q5U1Y5 hnRNP Lb nucleus U ribosomal protein mRNA splicing
Q9JMJ4 pre-mRNA-processing
factor 19
nucleus U RNA-binding
protein
mRNA splicing
Q63081 protein disulﬁde
isomerase (PDI) A6
ER P other isomerase disulﬁde-isomerase
reaction
43,52
P11598 PDI A3 (p58) ER P isomerase disulﬁde-isomerase
reaction
43,52
P11884 aldehyde dehydrogenase mitochondria P dehydrogenase phenylethylamine
degradation
(carbon
metabolism)
Q66HD0 endoplasmin (GRP94,
HSP90)
ER P chaperone protein folding,
stress response
43–46,50,51
P63039 60kDa heat shock protein
(HSP60)
mitochondria P chaperonin protein folding 30,43–47,49–51
P10719 F1-ATPase beta chain mitochondria P other ion channel,
hydrogen
transporter, ATP
synthase; hydrolase
purine metabolism,
electron transport
(ATP synthesis)
Q6P136 hyou1 protein cytosol P chaperone stress response
P48721 stress-70 protein (GRP75) mitochondria P chaperone protein folding;
Stress response
(apoptosis
signaling pathway)
43–46
P14659 heat shock cognate
71kDa protein (HSP70)
cytosol, organelles P chaperone protein folding;
Stress response
(apoptosis
signaling pathway)
30,43–46,48–51
P60711 b-actin cytoplasm C, P, U actin and actin
related protein
transport;
cytokinesis; cell
structure, etc.
30–40
P15178 aspartyl-tRNA
synthetase
cytoplasm C, U aminoacyl-tRNA
synthetase
protein
biosynthesis
P02563 myosin-6 heavy chain cytoplasm C, U motor protein,
muscle protein
muscle contrac-
tion/development,
(Wnt signaling
pathway, cytokine
signaling pathway,
etc)
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Table 1 (Contd.)
Gene ID Name of protein Cellular location PDT responsea
Main molecular
function
Main biological
process/pathway Reference
P32089 tricarboxylate transport
protein (TCC)
mitochondria,
membrane
C, U mitochondrial
carrier protein
small molecule
transport
A7VJC2 hnRNP A2/B1 nucleus, cytoplasm C, U ribonucleoprotein mRNA splicing
P04256 hnRNP A1 nucleus, cytoplasm C, U ribonucleoprotein mRNA splicing,
mRNA transport
Q7TP52 carboxymethylene-
butenolidase homolog
cytoplasm C, U hydrolase; other
miscellaneous
function protein
carbohydrate
metabolism
Q5M7T9 threonine synthase-like 2 cytosol C, U synthase threonine
biosynthesis;
vitamin B6
metabolism
P54758 ephrin type-A receptor 6 membrane C, U tyrosine protein
kinase, receptor;
transferase
protein
phosphorylation;
cell proliferation
and differentiation;
receptor protein
tyrosine kinase
signaling pathway
Q06226 serum and glucocorticoid
-regulated kinase (sgk1)
ER, nucleus,
cytoplasm
C, D kinase activity Protein
phosphorylation;
Inhibition of
apoptosis; Other
homeostasis
activities and
intracellular
signaling cascade
a D: down-regulated; U: up-regulated; P: pI-shift; C: carbonylated. b hnRNP: heterogeneous nuclear ribonucleoprotein.
Fig. 2 Silver-stained gel. HAL and PDT lysate samples (300 mg of each)
of AY-27 cells were mixed and subjected to IEF in a 24 cm IPGstrip pH
3–11 and separated in a 10% polyacrylamide gel. Proteins selected from
the DIGE reference gel were excised from the silver stained gel for MS
identiﬁcation.
Grp75 all display marked acidic pI-shifts after HAL-mediated
PDT. It is tempting to speculate that these abundant proteins
may be quantitatively dominating targets for direct oxidative
attack within the cell during HAL-mediated PDT, and that the
observed pI-shifts may represent such covalent modiﬁcations that
are not reversed by the reducing conditions employed during 2D-
DIGE. Cysteine sulfonic acid is such an irreversible modiﬁcation,
whereas cysteine sulfenic acid and reaction products thereof
such as glutathioylations, are reversible,36 and would most likely
have been reverted during the procedure of two dimensional
gel-electrophoresis. Moreover, carbonylation should not mediate
pI shifts since they do not introduce charge differences in the
proteins. An alternative explanation would be that these proteins,
at least in part, are modiﬁed enzymatically as part of the oxidative
stress response. At least the protein disulﬁde isomerases, b-actin,
HSP70/90 may become phosphorylated as a consequence of
various forms of cellular stress, and for the chaperone group
of protein this apparently is part of a regulatory mechanism
modulating the substrate speciﬁcity.
Damage to several structural proteins induced by PDT was
previously reported using other cell lines and photosensitizers.
Moor et al. andLee et al. stated that cellular structures having high
sensitizer and a high oxygen concentration would be preferentially
damaged upon illumination.37,38 Belichenko et al. investigated
the role of vimentin in apoptosis after PDT with the silicon
phthalocyanine Pc4 in human Jurkat T cells and found that
the full-length vimentin confers resistance to nuclear apoptosis.39
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Fig. 3 Mapping of 40 identiﬁed proteins in AY-27 cells (DIGE, 10% polyacrylamide gel). Protein spots of interest were picked from both 2D-DIGE gels
and silver stained 2D-GE gels and identiﬁed by MALDI-TOF/TOF (Ultraﬂex III, BRUKER Daltonics GmbH, Germany).
Later, Tsaytler et al. concluded that more structural proteins
were oxidatively modiﬁed in human epidermoid carcinoma cells
A431 after Pc4-PDT,40 and Magi et al. described that tubulin a-1
chain and b-actin were modiﬁed via carbonylation after PDTwith
Purpurin-18 in human HL60 cells.30
It has been demonstrated that some cell lines can respond
to photodynamic damage by initiating a rescue response41,42 to
induce expression of stress proteins containing a number of heat
shock proteins (HSPs) and glucose-regulated proteins (GRPs).43–46
The contribution by HSP60 increased the resistance to Photofrin-
mediated PDT in human colon cancer cell line (HT29),47 while
HSP70 was demonstrated to inhibit apoptosis mediated by PDT
with either dihematoporphyrin ether or Purpurin-18 in human
leukemia cells (HL60).48 Elevated expression of both HSP60 and
HSP70 after ALA-PDT was observed in several human cell lines
by Yanase et al.,49 and these proteins were carbonylated during
Purpurin-18mediated PDT, as reported byMagi et al.30 Moreover,
it has been demonstrated that the amounts of HSP60, HSP70
and GRP94 (endoplasmin, HSP90) increased at the cell surface,
contributing to enhanced immune responses in mouse tumor
cells (SCCVII) after Photofrin-mediated PDT.50,51 Our results
show that several rescue/stress proteins were modiﬁed in the
rat cell line AY-27 after HAL-PDT, including HSP60, HSP70,
GRP94,GRP75andhyou1protein. These proteins have important
chaperone functions in the cell and apparently may shield the
cells from oxidative damage. Interestingly, Magi et al.30 hypoth-
esized that cellular chaperones may actually bind to oxidized
proteins and that a protein-protein radical transfer can occur
from oxidized proteins to chaperones. Thus, certain chaperones
trying to reduce the toxic effect of oxidative stress are themselves
oxidized.
Among proteins involved in energy metabolism, pI-shift was
observed for hyou1 protein and F1-ATPase beta chain. Addi-
tionally, pyruvate kinase isozymes M1/M2 were shown to be
down-regulated. These modiﬁcations might contribute to energy
insufﬁciency and cell death by inhibiting the hypoxia responses.
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Fig. 4 Mapping of carbonylated proteins of AY-27 cells 2 h subsequent to HAL-mediated PDT. Nine up-regulated proteins are shown in PDT sample
(right) and one down-regulated is shown inControl sample (left). Each sample (1.5mg)was labeledwith 10mMDNPH in 10%TFAand immunoprecipited
with 150 ml cross-linked protein A beads with anti-DNP antibodies before 2D-GE separation. Protein spots of interest were excised from krypton-gels
and 10 carbonylated proteins were identiﬁed by MALDI-TOF/TOF.
Moreover, the modiﬁcations on the rescue/stress proteins might
lose their protective effect against oxidative stress triggering the
suicide mechanism after PDT.
Three proteins associated with Ca2+ signaling pathways were
shown to be affected by ALA-PDT,43,52 including calreticulin
precursor, protein disulﬁde isomerase (p55) and protein disulﬁde
isomerase A3 (p58).43 In our study, although protein p58, p55 and
calcineurin subunit B have been identiﬁed, only p58was conﬁrmed
to be modiﬁed by showing a pI-shift. More experiments are
required to identify possible HAL-PDT effects on this signaling
pathway.
3.2 Detection of carbonylated proteins
The most widely used marker for oxidative damage to proteins
is the presence of carbonyl groups. Carbonyls can be introduced
into proteins either by direct oxidation of Pro, Arg, Lys, and Thr
side chains or by Michael addition reactions with products of
lipid peroxidation or glycol-oxidation. Elevation in the total level
of protein carbonyls has been documented after PDT, but the
identities of the proteins modiﬁed by carbonylation or other types
of oxidation remain largely incompletely understood. Since car-
bonylation, in contrast to oxidation of cysteine to cysteine sulfonic
or sulﬁnic acid, do not mediate a change in pI, control and PDT
samples were derivatized with DNPH and immunoprecipitated
using an anti-DNP antibody prior to separation by 2D-GE. By
using this experimental outline we were able to identify 9 proteins
with increased carbonylation and, surprisingly, one protein with
reduced carbonylation (Fig. 4).
According to our results, b-actin was conﬁrmed to be carbony-
lated after HAL-PDT, in agreement with results after PDT with
Purpurin-18 in HL60.30 However, carbonylation is apparently
not the only modiﬁcation induced in b-actin by HAL-PDT.
The pI-shift towards the acidic side indicates that alternative
oxidations such as cysteine sulﬁnic acid, or secondary enzymatic
modiﬁcations such as phosphorylation, may be present.
Moreover, protein hnRNP A1 and hnRNP A2/B1 were con-
ﬁrmed to be up-regulated and oxidized. Together with pre-mRNA
processing factor 19 and hnRNP L (Table 1), four up-regulated
proteins in our results are related to DNA-repair, pre-mRNA
processing and mRNA splicing. These results may suggest that
transcription, translation or stability may have been increased
in response to protein and DNA damages under oxidative stress
induced by HAL-mediated PDT.
Interestingly, mitochondrial tricarboxylate carrier protein
(TCC) and serum and glucocorticoid-regulated kinase 1 (sgk1)
were found to display altered expression or modiﬁcation after
PDT. Both of them are supposed to play a key role in oxidative
stress conditions in rat brain.53,54 Our results demonstrate that
both proteins were carbonylated. TCC was up-regulated, while
sgk1 was down-regulated already at 2 h post-PDT.
3.3 Proteins, pathways and processes affected by HAL-PDT
ROS-inducedmodiﬁcationsmay changeprotein functions, thereby
affecting biological processes and signaling pathways.27 A total
of more than 200 post-translational modiﬁcations have been
identiﬁed.55 Furthermore, increasing evidence suggests that many
proteins carry multiple and distinct modiﬁcations. These may in
some cases antagonize or synergize each other, with important
biological consequences.55 Thus, the PANTHERclassiﬁcation sys-
tem was used to gain information of potential affected biological
processes afterHAL-PDT.Clearly, the complex responses indicate
that no single mechanism can be responsible for the effects of
HAL-PDT (Table 1).
In AY-27 cells the endogenous photosensitizer PpIX is syn-
thesized and accumulated in mitochondria, and moves to
other membrane-rich organelles when a certain concentration
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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is reached.1 Classiﬁcation of proteins by cellular localization
(Table 1) demonstrates that the majority of the modiﬁed proteins
by HAL-PDT were from mitochondria, ER and membranes.
However, in the study of Pc4-PDT,40 the majority of affected
proteins were cytosolic, likely reﬂecting a somewhat different
cellular targeting of PpIX and Pc4.56 So far, nuclear localization
of PpIX has not been observed. Nevertheless, several cytoplasmic
and nuclear proteins were shown to be affected in our study,
likely caused by indirect oxidation or intracellular translocation
subsequent to HAL-mediated PDT.
4. Conclusions
Our results demonstrate that a number of proteins in AY-27
cells are differentially expressed or chemically or enzymatically
modiﬁed after HAL-mediated PDT, thus most likely affecting
important processes, such as cell motility, energy metabolism,
and signaling pathways for survival and cell death. The results
support previous studies employing other photosensitizers,30,40 in
that numerous cellular pathways are likely to be affected by PDT.
The majority of proteins identiﬁed subsequent to 2D-DIGE dis-
played acidic pI-shifts, indicating altered phosphorylation status
or oxidative thiol modiﬁcations. Notably, these proteins mainly
belong to the mitochondrial/ERmolecular chaperones and stress
proteins, indicating that these cellular compartments are major
targets for HAL-mediated PDT. These results have extended our
understanding of the clinic effects associated with ALA-PDT, and
may pave the way for potential new adjuvant drugs. Our further
studies are, however, warranted to elucidate to what degree these
modiﬁcations are associated with the apoptotic signaling events
induced by HAL-PDT. By better understanding mechanisms of
PDT-mediated cytotoxicity in AY-27 bladder cancer cells, we aim
at improving efﬁcacy of PDT in the in vivo rat model21 and
ultimately in treatment of human bladder. This may also pave
the way for targeted use of other treatment modalities, such as
siRNA and photochemical internalization (PCI).57
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Abstract
Photodynamic therapy (PDT) is a safe and effective method currently used in the treatment of skin cancer. In ALA-based
PDT, 5-aminolevulinic acid (ALA), or ALA esters, are used as pro-drugs to induce the formation of the potent photosensitizer
protoporphyrin IX (PpIX). Activation of PpIX by light causes the formation of reactive oxygen species (ROS) and toxic
responses. Studies have indicated that ALA and its methyl ester (MAL) are taken up into the cells via c-butyric acid (GABA)
transporters (GATs). Uptake via GATs into peripheral sensory nerve endings may also account for one of the few adverse
side effects of ALA-based PDT, namely pain. In the present study, homology models of the four human GAT subtypes were
constructed using three x-ray crystal structures of the homologous leucine transporter (LeuT) as templates. Binding of the
native substrate GABA and the possible substrates ALA and MAL was investigated by molecular docking of the ligands into
the central putative substrate binding sites in the outward-occluded GAT models. Electrostatic potentials (ESPs) of the
putative substrate translocation pathway of each subtype were calculated using the outward-open and inward-open
homology models. Our results suggested that ALA is a substrate of all four GATs and that MAL is a substrate of GAT-2, GAT-3
and BGT-1. The ESP calculations indicated that differences likely exist in the entry pathway of the transporters (i.e. in
outward-open conformations). Such differences may be exploited for development of inhibitors that selectively target
specific GAT subtypes and the homology models may hence provide tools for design of therapeutic inhibitors that can be
used to reduce ALA-induced pain.
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Introduction
Photodynamic therapy (PDT) is an innovative treatment
modality for cancer that involves systemic or topical administra-
tion of a photosensitizer pro-drug, or the photosensitizer itself, and
activation of the photosensitizer by light of appropriate wave-
lengths, resulting in generation of reactive oxygen species (ROS)
and toxic responses [1–3].
One commonly used PDT pro-drug is 5-aminolevulinic acid
(ALA). Topical (dermal) administration of ALA or the ALA methyl
ester (MAL) (ALA-based PDT) is approved for treatment of non-
melanoma skin cancers including superficial basal cell carcinoma
(BCC), actinic keratosis (AK), Bowen’s disease (BD), and squamous
cell carcinoma in situ (SCC) in many countries [2]. In these
cancers, ALA-based PDT may also be used in replacement or to
reduce the extent of surgery [4]. Furthermore, the use of ALA-
based PDT for the treatment of other types of cancer, e.g. in the
brain, stomach and bladder, are currently being evaluated in
clinical trials [3]. ALA-based PDT may also be used for the
treatment of acne, psoriasis, scleroderma, viral warts, photoaging
and cutaneous lymphoma [2].
ALA is an endogenous precursor of the potent photosensitizer
protoporphyrin IX (PpIX), which is synthesized in the heme
biosynthetic pathway of nucleated cells [5]. By administration of
exogenous ALA the first rate-limiting step of the heme biosynthetic
pathway, which is regulated by negative feedback of heme, is
bypassed [6,7]. Studies have furthermore indicated that PpIX
accumulates in greater amounts in tumor cells than in normal cells
following the administration of exogenous ALA [5]. The main
reasons for the selective accumulation in cancer cells are the
changes in the activity of two enzymes of the heme biosynthesis
pathway, namely increased activity of porphoblinogen deaminase,
which catalyzes an early step of the heme biosynthetic pathway,
and decreased activity of ferrochelatase, catalyzing the conversion
of PpIX to heme in the last step of the biosynthetic pathway [6].
MAL was developed to increase the hydrophobicity and hence
skin penetration of the pro-drug. Once inside the cell, intracellular
esterases catalyze the cleavage of the ALA esters to ALA, which
then enters the heme biosynthetic pathway [7].
Due to the selective accumulation of PpIX in cancer cells, ALA-
based PDT does not cause the serious adverse side effects often
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e65200
seen with conventional chemotherapy. The main limiting factor
for successful clinical ALA-based PDT is pain, which in some cases
is so severe that the treatment is discontinued [8,9]. Although the
mechanism of pain has not fully been elucidated, several studies
have suggested that it may be due to nerve stimulation and tissue
damage induced by ROS [10,11]. Interestingly, clinical studies
have shown that MAL may induce less pain than ALA [9,12,13].
Studies by our group and others have indicated that active
cellular uptake of ALA is via c-aminobutyric acid (GABA)
transporters (GATs) [14–18], of which four human subtypes,
GAT-1, GAT-2, GAT-3 and BGT-1 (betaine-GABA transporter-
1), have been identified [19-22]. The uptake of MAL, however,
seems to be cell type dependent [15–17]. In adenocarcinoma
WiDr and LM3 cells, studies have indicated that MAL is
transported via non-polar amino acid transporters rather than
GAT [15,18]. MAL uptake was also recently suggested to be via
GATs and other amino acid transporters in rat peripheral DRG
sensory neurons [16] and in human A431 and CCD skin cells [17].
The GATs belong to the neurotransmitter/sodium symporter
(NSS) transporter family [23] of the solute carrier 6 (SLC6)
superfamily [24]. The NSS family members mediate Na+-
dependent uptake of a wide array of substrates, including
dopamine (DAT), serotonin (SERT), noradrenaline (NET), glycine
(GlyT) and GABA (GATs) [23], using an alternate access
mechanism [25,26]. During transport, the substrate binding site,
which has a central location midway between the extracellular
environment and the cytoplasm, is sequentially exposed to either
side of the membrane through permeation pathways [25,26].
Substrate transport thus involves cycling between outward-open,
outward-occluded and inward-open conformational states of the
transporters.
Only one member of the NSS family, namely the prokaryotic
Aquifex aeolicus leucine transporter (LeuT), has so far been
crystallized. In support of the alternate-access hypothesis, howev-
er, the LeuT crystal structures are available in outward-open,
outward-occluded and inward-open conformations [27–29]. Co-
crystallized with substrates the transporter is stabilized in an
outward-occluded state [29]. In contrast, the crystal structure of
LeuT in complex with the competitive inhibitor tryptophan (Trp)
shows that Trp stabilizes LeuT in an outward-open conformation
[29]. The LeuT crystal structures hence suggest that in order for
transport to occur, the substrates must be able to induce a
conformational change in the transporter from outward-open to
outward-occluded.
In this study, homology models of the four human
transporters in outward-occluded, outward- and inward-open
conformations were constructed using three x-ray crystal
structures of LeuT as templates [27–29]. To investigate the
binding of GABA, ALA and MAL, the compounds were docked
into in the central putative substrate binding sites in the
outward-occluded GAT models. Furthermore, the electrostatic
potentials (ESPs) of the putative translocation pathways leading
from the extracellular environment to the central substrate
binding site (termed the ‘entry’ pathway) and from the central
substrate binding site to the cytoplasm (termed the ‘exit’
pathway) were calculated in the outward- and inward-open
homology models, respectively. Our results suggest that whereas
ALA most likely is a substrate of all four GAT subtypes, MAL
may only be a substrate of GAT-2, GAT-3 and BGT-1.
Furthermore, the results suggest that the major differences
between the transporter subtypes most likely are located to the
entry pathway. This region may hence be the most interesting
to study with the aim of obtaining subtype-selective GAT
inhibitors.
Methods
Homology Modeling
The amino acid sequences of GAT-1, GAT-2, GAT-3 and
BGT-1 (UniProt accession numbers P30531, Q9NSD5, P48066
and P48065, respectively) [30] were aligned with LeuT using the
Internal Coordinate Mechanics (ICM) version 3.7 software [31].
The alignment was adjusted according to the comprehensive
alignment of prokaryotic and eukaryotic NSS transporter
sequences published by Beuming et al. [32] (Figure S1).
Based on the alignment, outward-open GAT models were
constructed using the 3F3A LeuT x-ray crystal structure [29] as
template, while the outward-occluded and inward-open GAT
models were generated based on the 2A65 [27] and 3TT3 [28]
crystal structures, respectively. The ICM BuildModel macro was
used to construct the models [31]. This macro uses a rigid body
approach to transfer the conformation of the structurally
conserved regions from the template to the target and constructs
the non-conserved loop regions either by ab initio modeling (,
seven amino acids) or by PDB loop searching (. seven amino
acids) [31]. The final models consisted of the twelve TMs and the
connecting intra- and extracellular loops, but did not include the
N- and C-termini and parts of EL2.
The Na1 and Na2 sodium ions were copied into the outward-
open and outward-occluded GAT models from their correspond-
ing LeuT templates as the amino acids coordinating the two
sodium ions are highly conserved [32]. Although Rud et al. [14]
have suggested that three sodium ions are needed for the
transmembrane transport of ALA, a Na+: Cl- stoichiometry of
Figure 1. Outward-occluded GAT-2 model. Membrane view of the
outward-occluded GAT-2 homology model (grey ribbon representa-
tion). Orange wire: the putative substrate binding site detected by ICM
PocketFinder; blue spheres: Na1 and Na2 sodium ions; green sphere:
chloride ion; dotted line: missing EL2 residues.
doi:10.1371/journal.pone.0065200.g001
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2:1 was applied in this study due to the lack of positional
knowledge of the putative third sodium ion. In addition, a chloride
ion was placed in the position corresponding to the carboxylate
carbon of LeuT amino acid E290 in the outward-open and
outward-occluded models [33,34].
Energy Refinement
The ICM RefineModel macro (default settings) [35] was used to
remove possible close contacts between amino acids in the models
and to relax the structures. The macro performs 1) side chain
sampling using the program module Montecarlo-fast [35], 2)
iterative annealing with tethers, and 3) a second side chain
sampling. Iterations of Montecarlo-fast consist of a random move
followed by local energy minimization and the iteration is either
accepted or rejected based on the energy [35].
Structure Quality Check
The programs PROCHECK, ERRAT and VERIFY-3D,
available through the Structural Analysis and Verification Server
(SAVES, http://nihserver.mbi.ucla.edu/SAVES/), were used to
perform structure quality checks of the models before and after the
refinement step.
Evaluation of the Outward-occluded Models by Docking
To evaluate whether the outward-occluded GAT models could
separate binders from decoys, an evaluation test set containing 17
binders and 170 decoys was established (Figure S2; S3). The 170
decoys were selected using ICM Molcart [31] based on their
structural similarities with the binders (Figure S3). The compounds
were charge labeled using default ECEPP/3 partial charges [36]
before docking.
The ICM PocketFinder macro (default settings) [37] was used to
define the central putative substrate binding site of the outward-
occluded GAT homology models into which the evaluation test set
was docked. The PocketFinder algorithm uses the 3D protein
structure to detect possible ligand binding pockets and does not
require knowledge about potential ligands [37].
The test set database was docked using the ICM batch docking
method and a semi-flexible docking approach in which the
transporter, represented as 3D grid potential maps accounting for
van der Waals (vdw), electrostatics, hydrophobic and hydrogen
bonding interactions, was kept rigid while the ligands were fully
Table 1. Central substrate binding site.
GAT-1 GAT-2 GAT-3 BGT-1 Position
Y60 E48 E66 E52 1.42
A61 I49 I67 I53 1.43
I62 I I I 1.44
G63 G51 G69 G55 1.45
L64 L52 L70 L56 1.46
G65 G53 G71 G57 1.47
N66 N54 N N 1.48
L136 L125 L143 L129 3.46
Y140 Y129 Y147 Y133 3.50
F294 F288 F308 F293 6.53
S295 S289 S309 S294 6.54
G297 A291 A311 A296 6.56
L300 L294 L314 Q299 6.59
S396 S390 S410 S395 8.60
Q397 Q Q Q 8.61
C399 V393 V413 V 8.63
T400 C394 C414 C399 8.64
172.2 145.2 161.1 118.6 Volume (A˚3)
156 140.4 150.3 121.4 Area (A˚2)
Amino acids detected by ICM PocketFinder in the outward-occluded GAT
models; in italics: amino acids not detected in the respective models.
doi:10.1371/journal.pone.0065200.t001
Figure 2. Evaluation docking results. ROC curves obtained from docking of 17 binders and 170 decoys into the central putative substrate
binding sites of detected in the outward-occluded GAT models.
doi:10.1371/journal.pone.0065200.g002
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flexible. ICM uses a Monte Carlo global energy optimization
algorithm to dock the ligands [31]. Due to the stochastic nature of
the docking procedure three parallel docking runs were per-
formed.
The ICM VLS scoring function was used to score the resulting
ligand-protein complexes. The scoring function uses steric,
entropic, hydrogen bonding, hydrophobic and electrostatic terms
to calculate the score and also include a correction term
proportional to the number of atoms in the ligand to avoid bias
towards larger ligands [38].
Following docking, receiver operating characteristic (ROC)
curves for each GAT model were generated using the best scored
orientation of each ligand from the three parallel docking
simulations, and the normalized ‘area under curve’ (noAUC)
value for each transporter was calculated.
Full-atom Docking Refinement of ALA, MAL and GABA
Following semi-flexible docking of ALA, MAL and GABA, full-
atom refinement of the complexes was performed. During the
refinement, energy minimization and sampling of the side chain
torsional angles of the amino acids within 5 A˚ of the ligands using
ICM biased probability Monte Carlo (BPMC) [31] was per-
formed. To score the complexes following the full-atom refine-
ment, the ICM scanScoreExtrenal macro was used [35].
Electrostatic Potentials (ESPs)
ICM PocketFinder [35] was used to detect the substrate
translocation pathways in the outward-open and inward-open
GAT models (Table S3; S4). The identified amino acids were
selected and the ESPs of the amino acids were calculated using the
ICM Rapid Exact-Boundary Electrostatics (REBEL) algorithm
with a potential scale value of 5 kcal/e.u. charge units (default
values) [31]. The Na1 and Na2 ions (with a charge of +1) were
included in the ESP calculations in the outward-open homology
model. The ESP of GABA, ALA and MAL were also calculated
using the ICM-REBEL [31].
Indexing of Residues
To facilitate comparison of amino acid positions between the
four GAT subtypes, a generic numbering scheme developed for
the NSS transporters [32,39] is used in this paper. The most
conserved residue in each of the twelve TM segments is given the
number 50, and the other residues are numbered according to its
position relative to this most conserved residue. Hence, a residue
with a generic position number lower or higher than 50 indicates
that it is located N- or C-terminal to the most conserved residue in
the TM helix, respectively. The reference GAT-1 residues are as
follows: W681.50, P962.50, Y1403.50, T2174.50, P2475.50, Q2916.50,
F3397.50, F3868.50, Y4329.50, Y45310.50, P50511.50, and P54912.50
(Table S1).
Figure 3. Orientations of GABA, ALA and MAL in the central
substrate binding pocket. a) GABA in all four GAT models, b) GABA
and ALA in GAT-2, and c) GABA and MAL in GAT-2. Amino acids in
positions 1.47 (G), 3.50 (Y) and 6.53 (F) are conserved among the GAT
subtypes, whereas the amino acids in positions 1.42 (Y in GAT-1; E in the
others) and 6.59 (Q in BGT-1, L in the others) are non-conserved.
Intermolecular hydrogen bonds are shown as dotted lines; the
thickness of the lines representing the energy of the interaction. Amino
acid side chains are shown in wire representation, ligands in yellow
xstick representation, and Na1 sodium ion as blue sphere. Color coding
of atoms: blue: nitrogen; red: oxygen.
doi:10.1371/journal.pone.0065200.g003
Table 2. Docking scores (kcal/mol) of GABA, ALA and MAL.
Ligand GAT-1 GAT-2 GAT-3 BGT-1
GABA 230.12 228.37 220.51 236.14
ALA 232.10 223.40 227.62 235.77
MAL 7.11 219.10 219.72 219.00
doi:10.1371/journal.pone.0065200.t002
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Results
Homology Modeling
In this study, homology models of the four human GATs were
constructed in outward-open, outward-occluded and inward-open
conformations based on LeuT x-ray crystal structures (PDB id
3F3A, 2A65 and 3TT3, respectively). The stereochemical quality
of the homology models both before and after energy refinements
were evaluated using the PROCHECK [40], ERRAT [41] and
VERIFY 3D [42,43] programs and compared with LeuT template
structures (Table S2). The ERRAT scores revealed that some
atoms in the unrefined models had overlapping van der Waals
surfaces, and these models were hence discarded. For the refined
models, the ERRAT scores were similar to that of their
corresponding templates and Ramachandran plots provided by
the PROCHECK were found to be satisfactory (Table S2). The
VERIFY 3D scores were lower for the refined structures than the
corresponding LeuT, but acceptable (Table S2). The structure of
the outward-occluded GAT-2 homology model is shown in
Figure 1.
Evaluation of the Outward-occluded Models by Docking
To further evaluate the outward-occluded models, an evalua-
tion test set containing 17 binders and 170 decoys was docked into
the central substrate binding site detected by ICM PocketFinder
[35] (Table S3; S4). The compounds included as binders were
either substrates or presumed substrates (i.e. compounds that only
have been tested in some of the GATs but likely interact with all
four transporter subtypes) and small-size inhibitors that presum-
ably bind in the central substrate binding site (Figure S2). The
decoys were selected based on their structural similarities with the
binders (Figure S3). Specifically, all decoys contained at least one –
COO- or –SO3
- moiety.
The putative substrate binding site was formed by amino acids
in TM 1, 3, 6, and 8 and the majority of the amino acids were
conserved among the four GAT subtypes (Table 1). Some
interesting differences were also seen between the transporters.
For instance, GAT-2, GAT-3 and BGT-1 contained a negatively
charged glutamate in position 1.42 which in GAT-1 was an
aromatic tyrosine (Table 1). The GAT-1 pocket was identified as
the largest of the four (Table 1). With the exception of L3006.59, all
the identified amino acids have previously been shown by site-
directed mutagenesis studies to play roles in the GABA binding
and/or transport in GAT-1 [44,45]. The localization of the
Figure 4. Entry pathway ESPs. ESPs of the entry pathways detected in the outward-open GAT models (grey ribbon representation). a) GAT-1, b)
GAT-2, c) GAT-3, and d) BGT-1. Blue spheres: Na1 and Na2 sodium ions. Color coding: red: negative ESP; blue: positive ESP; grey: neutral ESP.
doi:10.1371/journal.pone.0065200.g004
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putative GAT substrate binding site furthermore corresponded
well to the position of the substrate binding site seen in the LeuT
crystal structures and also with the results of Dodd and Christie
[45]. Dodd and Christie showed that substitutions of the amino
acids in positions 1.42, 3.46, 6.56 and 8.64 of the creatine
transporter (CRT) to the corresponding GAT-1 amino acids
results in the loss of creatine and gain of GABA transport activity
[45].
Following docking, ROC curves and noAUC values of each
model were obtained (Figure 2). A noAUC value of 100 represents
a perfect separation between binders and decoys. The results
showed that the GAT-1 model was the least specific with a
noAUC value of 68.8, whereas the noAUC values for other three
subtypes were excellent (noAUC values of 95.7, 94.0 and 90.4 for
GAT-2, GAT-3 and BGT-1, respectively) (Figure 2). Analysis of
the docking results in GAT-1 showed that the lower noAUC value
obtained for this transporter was due to more decoys rather than
fewer substrates being selected. This was not surprising as the
GAT-1 model had the largest binding pocket of the four models
(Table 1). The evaluation docking hence suggested that the models
were acceptable for docking of substrates.
Docking of GABA, ALA and MAL
To study the interaction of PDT pro-drugs ALA and MAL and
the native substrate GABA in the GAT models, the ligands were
docked into the central putative substrate binding site of the
outward-occluded GAT models using a regular semi-flexible
docking approach, followed by refinement of the GAT substrate
binding site amino acids within 5 A˚ of the three ligands. The
results showed that GABA, ALA and MAL had favorable (i.e.
negative) docking scores in all four GATs, except MAL in GAT-1
(Table 2). The orientations of GABA, ALA and MAL in the
central substrate binding site can be seen in Figure 3.
The docking results showed that the carboxyl group of GABA
coordinated the Na1 ion and formed hydrogen bonds to the side
chain hydroxyl group of Y3.50 and to the main chain nitrogen
atom of G1.47 in all four GAT subtypes (Figure 3). The amine
moiety of GABA formed a hydrogen bond to the main chain
oxygen of F6.53 in GAT-1, GAT-2 and GAT-3, whereas it in
BGT-1 was involved in a hydrogen bond to the side chain oxygen
of Q6.59, which is a leucine residue in the other GATs (Table 1).
The GABA orientations are in accordance with the results of
docking of GABA in GAT-1, GAT-2 and GAT-3 published by
other groups, in which the orientation of the carboxyl moiety of
GABA was very similar to the present orientation whereas the
localization of the amine moiety was more variable [46–49]. This
was not surprising as the same template was used for homology
modeling in all studies, and comparison of GABA in the GAT
models and Leu in the template structure showed that GABA
occupied the same regions of the binding pocket as Leu in the
template structure [27] (results not shown).
The carboxyl moiety of ALA had a similar orientation as that of
GABA, interacting with Na1, Y3.50 and G1.47 (Figure 3).
Furthermore, like GABA, the amine moiety in ALA was found
in two localizations in the transporter models: in GAT-1 and
GAT-2 the amine moiety interacted with the backbone oxygen
Figure 5. GAT-1 exit pathway ESPs. GAT-1 in grey ribbon
representation. Color coding of ESPs as in Figure 4.
doi:10.1371/journal.pone.0065200.g005
Figure 6. GABA (a), ALA (b) and MAL (c) ESPs. Color coding of
ESPs as in Figure 4.
doi:10.1371/journal.pone.0065200.g006
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atom of F6.53, whereas it in GAT-3 and BGT-1 the moiety formed
an ionic interaction with the side chain of E1.42 (which is a tyrosine
in GAT-1) (Figure 3).
MAL occupied the same region as GABA and ALA in the
GATs (Figure 3). However, as MAL contains an ester moiety
whereas GABA and ALA have a carboxylate moiety, MAL was
not able to coordinate the Na1 ion (Figure 3). In GAT-1, a
hydrogen bond was formed between the ester and amine moieties
of the ligand and to the backbone oxygen atom of F6.53 (results not
shown). In GAT-2, GAT-3 and BGT-1, hydrogen bonds were
present between the ester and amine moieties of MAL and
between the ester moiety and the side chain hydroxyl of Y3.50
(Figure 3). Furthermore, in the latter transporters, the amine
moiety of MAL in addition formed ionic interactions with E1.42
(Figure 3), while the corresponding amino acid in GAT-1 was
tyrosine (Table 1). The ionic interaction with E1.42 probably
accounted for the relatively high scoring of MAL in GAT-2, GAT-
3 and BGT-1 (Table 2).
Electrostatic Potentials (ESP) of Outward- and Inward-
open Homology Models
The ESPs of the funnel-shaped entry pathway extending from
the extracellular environment to the central substrate binding
pocket in the outward-open homology models varied considerably
(Figure 4). Whereas the GAT-1 entry pathway and central
putative substrate binding site was highly positive in nature, the
corresponding areas in GAT-2, GAT-3 and BGT-1 consisted of
positive, negative and hydrophobic sub-regions (Figure 4). The
major differences between the GAT subtypes in the entry pathway
were the amino acids in position 1.42, 6.59 and 8.64, located in
the central substrate binding site region, and the amino acids in
positions 1.54, EL4 and 10.45, located in the vestibule leading
from the extracellular environment to the central substrate binding
site (Table S3; S4). In contrast, only minor differences in the ESPs
of the exit pathway reaching from the central substrate binding site
to the cytoplasm in the inward-open GAT models were observed,
and this region was highly negative in all four GAT subtypes
(Figure 5). The ligand ESPs indicated that the surface of MAL is
more positively charged than that of GABA and ALA which had
zwitterionic charge distribution (Figure 6).
Discussion
Whereas studies have suggested that the PDT pro-drug ALA is
a GAT substrate [16,17], studies regarding MAL are more
ambiguous as this compound seemingly is transported via GAT in
some cell types but not in others [15,17]. Molecular insight into
the binding interactions of GABA, ALA and MAL in the central
substrate binding site of the four GAT subtypes may help shed
light on this question.
GABA is the primary inhibitory neurotransmitter in the central
nervous system (CNS) and a native substrate for the GATs. The
GATs play an essential role in regulating neurotransmitter
signaling and homeostasis by mediating uptake of released GABA
from the extracellular space into neurons and glial cells. Abnormal
levels of GABA can result in inappropriate neural signaling and
underlie CNS disorders such as epilepsy, depression, schizophre-
nia, drug addiction, and acute and chronic pain [50–54]. GAT-1
for instance plays an important role in the treatment of epilepsy
being targeted by the antiepileptic tiagabine [55]. The GATs may,
however, also play important roles in non-CNS and non-neuronal
diseases. In contrast to GAT-1, which is exclusively expressed in
the CNS, GAT-2 and BGT-1 are also expressed in the peripheral
nervous system (PNS), and has been found in several other tissues,
including the kidneys, liver, heart, lungs, and testis [21,22,27,56].
GAT-3 was also recently shown to be expressed in human skin
cells [17]. Molecular insight into the structure and function of the
GATs is important for an increased understanding of GABAergic
neurotransmission and may be important for drug development in
several therapeutic areas.
In the present study, the outward-occluded GAT models, in
which the central substrate binding site is closed from either side of
the membrane, were chosen for docking of the native substrate
GABA and the putative substrates ALA and MAL as x-ray crystal
structures show that LeuT in the presence of substrates adopts this
conformation [29]. Based on the orientations of GABA, ALA and
MAL in the substrate binding site, as well as the docking scores,
our results suggest that ALA may be a substrate in all four GATs
whereas MAL may be a substrate in GAT-2, GAT-3 and BGT-1.
However, whether a compound is transported or not via GAT is
also dependent on other factors than the ability to bind to and
induce the outward-occluded conformation of the transporter.
Dodd and Christie have for instance shown that though the
creatine transporter activity can be changed from creatine to
GABA by substitution of a few amino acids in the central substrate
binding site, the substitutions alone are not sufficient for efficient
GABA transport [45]. Hence, though the obtained docking
orientations and scores suggested that ALA and MAL may be
substrates of all or some GAT subtypes, further studies are needed
to verify these findings.
The ESPs of the translocation pathways may reveal electrostatic
forces involved in substrate binding and translocation and
highlight differences between the four GAT subtypes. The ESPs
of the putative entry and exit permeation pathways in the
outward- and inward-open GAT homology models, respectively,
were hence calculated (Figure 4; 5). The x-ray structure of LeuT in
complex with the competitive inhibitor tryptophan (Trp) [29]
shows that Trp prevents the extracellular gate from closing, hence
stabilizing the transporter in a conformation in which the central
substrate binding site is accessible from the extracellular environ-
ment [29]. The outward-open GAT models constructed based on
this LeuT structure were hence used to illustrate the entry
pathways. The inward-open LeuT crystal structure was used as a
template for modeling the GAT subtypes used to calculate the
ESPs of the exit pathway extending from the central substrate
binding site to the cytoplasm. In this structure, the extracellular
gate has closed, an intracellular vestibule has opened and the Na1
and Na2 sodium binding sites seen in the outward-open and
outward-occluded structures have been disrupted [28]. These
changes has occurred due to large conformational changes,
including reorientation of TMs 1, 2, 5, 6 and 7, hinge bending
of the intracellular half of TM1 and occlusion of the extracellular
vestibule by EL4 [28].
The ESP calculations indicated that the major differences
between the GAT subtypes were located in the outward-open
models, hence in the entry pathway region of the transporters
(Figure 4). The ligand ESPs also showed that GABA and ALA had
a zwitterionic charge distribution, whereas the MAL charge
distribution was cationic in nature due to the replacement of the
carboxyl moiety found in GABA and ALA with an ester group
(Figure 6). The ESPs hence support the notion that MAL may not
be a GAT-1 substrate, as the results suggest that the entry pathway
of this GAT subtype is highly positive in nature (Figure 4).
The amino acids in the entry region are the first to come in
contact with the substrates and hence play crucial roles in ligand
recognition and binding. The finding that the major differences
between the GAT subtypes are located in this region may be of
clinical importance as it has been suggested that the pain often
Homology Modelling of GABA Transporters
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e65200
observed during ALA-based PDT may result from uptake of ALA
via GAT-2 and BGT-1 into the mitochondria-rich sensory
neurons and hence high-level accumulation of PpIX [11,57].
Current pain-reducing strategies include interrupted illumination,
cooling of the affected area and local anesthesia [58,59]; however,
in some cases the pain is severe and the treatment is discontinued
[8,9]. Exploitation of the differences in the entry pathways to
develop inhibitors that can be used to selectively inhibit the uptake
of ALA into the sensory neurons may hence be used clinically to
reduce ALA-induced pain.
In summary, this study pioneers in structure-based character-
ization of ALA and MAL transports via the four GABA
transporters using the homology modeling approach. Although
ALA-based PDT has been used successfully for the treatment of a
variety of skin cancers, pain is a limiting factor. ALA-based PDT
in combination with selective inhibitors of the GAT may be an
attractive approach to develop pain-reduce strategy and improve
the PDT efficacy in the future.
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Table S1. 
Position LeuT GAT-1 GAT-2 GAT-3 BGT-1 
1.50 L29 W68 W56 W74 W60 
2.50 P57 P96 P84 P102 P88 
3.50 Y108 Y140 Y129 Y147 Y133 
4.50 V171 T217 C211 C231 C216 
5.50 L202 P247 P241 P261 P246 
6.50 Q250 Q291 Q285 Q305 Q290 
7.50 S298 F339 F333 F353 F338 
8.50 F345 F386 F379 F400 F385 
9.50 F387 Y432 F428 Y448 Y433 
10.50 W406 Y453 Y449 Y469 Y454 
11.50 P457 P505 P501 P521 P506 
12.50 T498 P549 P546 P566 P551 
 
Table S1. NSS numbering scheme. 
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Table S2.  
 
 Template Template Template 
GAT-1 2A65 3F3A 3TT3 
Ramachandran plot 95.3 / 4.7 / 0 94.7 / 5.3 / 0 95.5 / 4.2 / 0.3 
Errat 87.931 92.391 86.726 
Verify-3D 75.26 % 77.40 % 74.51 % 
GAT-2 2A65 3F3A 3TT3 
Ramachandran plot 94.2 / 5.5 / 0.3 94.8 / 5.2 / 0 95.5 / 3.9 / 0.6 
Errat 92.308 94.828 89.956 
Verify-3D 81.55 % 78.86 % 67.02 % 
GAT-3 2A65 3F3A 3TT3 
Ramachandran plot 94.2 / 5.5 / 0.3 94.7 / 5.3 / 0 94.9 / 4.5 / 0.6 
Errat 93.162 87.931 90.749 
Verify-3D 79.25 % 79.92 % 71.73 % 
BGT-1 2A65 3F3A 3TT3 
Ramachandran plot 94.0 / 6.0 / 0 94.8 / 5.2 / 0 94.5 / 4.7 / 0.8 
Errat 92.949 93.966 88.210 
Verify-3D 83.23 % 78.22 % 67.88 % 
LeuT 2A65 3F3A 3TT3 
Ramachandran plot 94.5 / 5.5  / 0 94.9 / 5.1 / 0 92.3 / 6.7 / 0 
Errat 93.028 94.400 87.889 
Verify-3D 93.15 % 90.18 % 90.06 % 
 
Table S2. SAVES results. Ramachandran plot: most favored/additional allowed/generously 
allowed regions.  
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Table S5.  
 
GAT-1 GAT-2 GAT-3 BGT-1 Position 
Y60 E48 E66 E52 1.42 
A61 I49 I67 I53 1.43 
I62 I50 I68 I54 1.44 
G63 G51 G69 G55 1.45 
L64 L52 L70 L56 1.46 
G65 G53 G71 G57 1.47 
N66 N54 N72 N58 1.48 
W68 W56 W74 W60 1.50 
R69 R57 R75 R61 1.51 
Y72 Y60 R78 R64 1.54 
L136 L125 L143 L129 3.46 
Y139 Y128 Y146 Y132 3.49 
Y140 Y129 Y147 Y133 3.50 
I143 V132 I150 I136 3.53 
W146 W135 W153 W139 3.56 
F294 F288 F308 F293 6.53 
S295 S289 S309 S294 6.54 
Y296 F290 Y310 F295 6.55 
G297 A291 A311 A296 6.56 
L300 L294 L314 Q299 6.59 
A357 A351 A371 A356 EL4 
A358 E352 E372 E358 EL4 
G360 G354 G374 G361 EL4 
P361 P355 P375 P362 EL4 
L363 L357 L377 L364 EL4 
A364 A358 A378 A365 EL4 
F365 F359 F379 F366 EL4 
S396 S390 S410 S395 8.60 
T400 C394 C414 C399 8.64 
F447 F443 F463 F448 10.44 
K448 Q444 Q464 Q449 10.45 
D451 D447 D467 D452 10.48 
L460 L456 L476 L461 10.57 
 
Table S5. Amino acids of the entry pathway, outward-open models. 
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Table S6.  
GAT-1 GAT-2 GAT-3 BGT-1 Position 
S56 S44 S62 S48 1.38 
G59 G47 G65 G51 1.41 
Y60 E48 E66 E52 1.42 
A61 I49 I67 I53 1.43 
I62 I50 I68 I54 1.44 
G63 G51 G69 G55 1.45 
L64 L52 L70 L56 1.46 
G65 G53 G71 G57 1.47 
N66 N54 N72 N58 1.48 
F98 F86 F104 F90 2.48 
L136 L125 L143 L129 3.46 
Y140 Y129 Y147 Y133 3.50 
V240 V234 V254 V239 5.43 
Y241 Y235 Y255 Y240 5.44 
S243 T237 T257 T242 5.46 
A244 A238 A258 A243 5.47 
T245 T239 T259 T244 5.48 
F294 F288 F308 F293 6.53 
S295 S289 S309 S294 6.54 
Y296 F290 Y310 F295 6.55 
G297 A291 A311 A296 6.56 
L300 L294 L314 Q299 6.59 
S302 C296 C316 C301 6.61 
L303 L297 L317 L302 6.62 
L306 L300 L320 L305 6.65 
V323 L317 L337 L322 7.34 
N327 N321 N341 N326 7.38 
M391 L385 F405 F390 8.55 
L392 L386 L406 L391 8.56 
D395 D389 D409 D394 8.59 
S396 S390 S410 S395 8.60 
F398 F392 F412 F397 8.62 
C399 V393 V413 V398 8.63 
T400 C394 C414 C399 8.64 
 
Table S6. Amino acids of the exit pathway, inward-open homology models.  
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Bleomycin is a cytotoxic chemotherapeutic agent widely used in cancer treatment. However, its 
efficacy in different cancers is low, possibly due to limited cellular internalization. In this study, 
a novel approach known as photochemical internalization (PCI) was explored to enhance 
bleomycin delivery in bladder cancer cells (human T24 and rat AY-27), as bladder cancer is a 
potential indication for use of PCI with bleomycin. The PCI technique was mediated by the 
amphiphilic photosensitizer disulfonated tetraphenyl chlorin (TPCS2a) and blue light (435 nm). 
Two additional strategies were explored to further enhance the cytotoxicity of bleomycin; a 
novel peptide drug ATX-101 which is known to impair DNA damage responses, and the 
protease inhibitor E-64 which may reduce bleomycin degradation by inhibition of bleomycin 
hydrolase. Our results demonstrate that the PCI technique enhances the bleomycin effect under 
appropriate conditions, and importantly we show that PCI-bleomycin treatment leads to 
increased levels of DNA damage supporting that the observed effect is due to increased 
bleomycin uptake. Impairing the DNA damage responses by ATX-101 further enhances the 
efficacy of the PCI-bleomycin treatment, while inhibiting the bleomycin hydrolase does not.  
 
 
1.  Introduction 
 
Bladder cancer is one of the most common cancers in the world and causes more than 
100 000 deaths every year [1,2]. In Norway bladder cancer has been one of the five 
most common cancer types for men during the last ten years [3] and in United States it 
is estimated that 72 570 new cases and 15 210 deaths will be reported in 2013 [4]. 
Approximately 70-80% of diagnosed bladder cancers worldwide are non-muscular 
invasive bladder cancer (NMIBC) for which intravesical chemotherapy is used as an 
adjuvant treatment to the standard transurethral resection [1]. However, significant 
improvements in preventing disease progression and recurrence have not been obtained 
[1,2]. Due to high intrinsic cytotoxicity and low myelosuppression and 
immune-suppression, bleomycin is used in the treatment of cancers such as malignant 
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lymphomas, testicular carcinomas, and squamous cell carcinomas (see review by 
Ramotar and Wang [5] and references therein). However, good clinic efficacy has not 
been found in bladder cancer [6,7,8]. This could be due to low uptake into the cells as 
bleomycin consists of rather large water-soluble glycopeptidic molecules that are most 
likely unable to cross cell membranes by passive diffusion, and thus rely on endocytosis 
and/or transporters [9,10]. Studies have shown that cellular responses to bleomycin are 
cell type-dependent. In cell lines with low sensitivity to bleomycin, the drug resistance 
is considered mainly to be due to membrane barrier, degradation by hydrolases in 
lysosomes or bleomycin hydrolase (BLMH) in the cytosol, elevated DNA repair 
capacity, and low activity of bleomycin transporters [9,10,11,12,13]. Severe side effects 
of bleomycin at high dose are therefore limiting its clinical applications [5]. In an effort 
to overcome the membrane barrier for bleomycin, electro- permeabilization was shown 
to enhance the efficacy [14,15].  
The PCI technology has been developed from photodynamic therapy (PDT) as an 
efficient drug delivery tool to enhance the effect of several types of therapeutic 
molecules [16]. In the PCI technology a membrane-embedded photosensitizer is used 
together with a therapeutic agent by endocytotic delivery [17,18]. The photosensitizers 
used in PCI, such as meso-tetraphenyl chlorin disulfonate (TPCS2a) used in this study, 
are specially designed as amphiphilic molecules that initially localize to the plasma 
membrane, but are later incorporated into the endosomal membranes by endocytosis 
[19,20,21]. When used together with bleomycin, the bleomycin molecules are enclosed 
in the endocytotic vesicles, and exposure to light leads to endosomal rupture by 
phototoxic damage and release of bleomycin molecules into the cytosol [22,23]. Side 
effects often seen in the conventional systemic therapeutic strategies can also be 
reduced by PCI because the enhanced effect is localized to the area exposed to light 
[24,25]. Enhanced efficacy of PCI with bleomycin has been documented in several 
preclinical studies and clinical trials [24,25,26,27,28]. A phase I clinical trial of 
TPCS2a-mediated PCI of bleomycin showed no severe side effects associated with the 
treatment, and the efficacy and safety of the modality are currently being evaluated in a 
phase II interventional clinical trial [27,29]. 
Once inside the nucleus, bleomycin-induce DNA strand breaks are leading to 
apoptosis, extended cell cycle arrest, mitotic cell death, and increasing risk of 
chromosome aberrations if not properly repaired [30,31,32]. A novel designed 
cell-penetrating peptide named ATX-101, containing the AlkB homolog 2 
PCNA-interacting motif (APIM), has been shown to enhance cytotoxicity of several 
chemotherapeutic drugs [33]. The APIM-motif mediate interaction with proliferating 
cell nuclear antigen (PCNA) in many proteins involved in DNA repair, apoptosis, restart 
of replication and cell cycle regulation after DNA damage. Impairing the interactions 
between these proteins and PCNA by ATX-101 impairs the cellular DNA damage 
responses and thus sensitizes the cells to chemotherapeutic drugs [33,34,35,36,37]. In 
this study, cytotoxicity of TPCS2a-mediated PCI of bleomycin (PCI-bleomycin) was 
studied in rat bladder cancer cells (AY-27) and human bladder cancer cells (T24) using 
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the PCI strategy of illumination after bleomycin treatment [38,39]. For all experiments, 
a human epidermoid carcinoma cell line (A431) was used as reference due to its 
sensitivity to PCI [40]. Furthermore, we examined the effects of inhibiting the DNA 
damage response and bleomycin degradation in combination with PCI-bleomycin. The 
levels of induced DNA damages were investigated using the comet assay. Our results 
demonstrate that PCI enhances bleomycin efficacy in human and rat bladder cancer 
cells under optimal conditions. Combination therapy using PCI-bleomycin and 
ATX-101 further enhanced the observed cytotoxicity.  
 
 
2. Materials and Methods 
 
2.1 Cell culture 
 
Rat bladder transitional carcinoma cells (AY-27) were maintained in the same RPMI 
culture medium and conditions as described in our earlier study [41]. Human 
epidermoid carcinoma cells (A431) and human bladder carcinoma cells (T24) were 
maintained in Dulbecco’s Modified Eagle’s Medium (D6429) supplemented with 2 mM 
L-glutamine, 1% penicillin/streptomycin, 10 mM HEPES, 1 mM natrium pyruvate 
(Lonza), and 10% (v/v) fetal bovine serum. All medium chemicals were purchased from 
Sigma except noted. 
 
2.2 Chemicals 
 
TPCS2a (30 mg ml-1, Amphinex®) dissolved in Tween 80 and 50 mM Tris buffer was 
provided by PCI Biotech AS (Oslo, Norway) and stored at 4 °C in aliquots. The stock 
was first diluted with 50 mM Tris phosphate buffer (pH 8.5) to 0.06 mg ml-1 and further 
diluted with fresh culture medium immediately before use. All work with TPCS2a was 
performed under subdued light or light protection. 
Bleomycin powder (15000 IU, Baxter, Norway) was dissolved with 0.9% salt water 
as stock (1000 IU ml-1) and stored at -20 °C in aliquots. Peptide drug ATX-101 (1 mM) 
was supplied by APIM Therapeutics AS (Trondheim, Norway) and stored at 4 °C in 
aliquots. Protease inhibitor E-64 powder (Sigma), a known inhibitor of bleomycin 
hydrolase [42,43], was diluted with de-ionized water as stock (1 mM) and stored at 
-20 °C in aliquots. Resazurin sodium salt powder (Sigma) was dissolved with PBS to 
2.5 mM followed by filtering and sonication under subdued light. Resazurin stock was 
stored at -20 °C in aliquots. These chemical stocks were further diluted to desired 
concentrations with fresh culture medium immediately before use. 
DRAQ5TM solution (5 mM, BioStatus Limited, UK), a novel DNA-detecting 
far-red- fluorescing dye [44], was stored at 4 °C under light protection and diluted with 
PBS (1:10000) under subdued light immediately before use. 
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2.3 Light source 
 
Blue light with λmax of 435 nm used in this study was available from a LumiSource® 
lamp (PCI Biotech AS, Norway). The lamp is designed specifically to provide stable 
and homogenous fluency with an irradiance of 12.9 mW cm-2 over a defined 
illumination area, allowing attached living cells to be illuminated from the bottom of 
culture dishes or plates. With the light doses used in the PCI experiments, the 
photosensitizer is not likely to be affected by photobleaching [45]. 
 
2.4 Cellular uptake of TPCS2a 
 
Cells were seeded out into 96-well plates (6000 cells/well, CytoOne, USA Scientific, 
Inc). Attached cells were incubated with TPCS2a at a series of concentrations (18 h). 
Subsequent to removal of TPCS2a-medium, fluorescence intensity of cellular 
accumulated TPCS2a was measured using FLUOStar Omega microplate reader 
(410 nm/650 nm, BMG Labtech GmbH, Germany). The cells were immediately washed 
with cold PBS, fixed with fresh 2% paraformaldehyde (150 µl/well, 15 min, on ice, no 
shaking), and stained with 0.5 µM DRAQ5 (50 µl/well, 20 min, RT, gentle shaking, in 
the dark). The plates were dried out after washing with cold PBS. Fluorescence intensity 
of DNA binding DRAQ5 was measured using Odyssey Imager at 700 nm channel 
according to the user manual (Li-Cor® Infrared imaging system, LI-COR Biosciences, 
Ltd, UK). Cellular accumulation of TPCS2a was determined by dividing relative 
fluorescence intensity (normalized with control cells) of TPCS2a with fluorescence 
intensity of DRAQ5 (DNA content in the same well). 
 
Table 1 Therapeutic drug and light doses (used in Figure 3b and 4b) 
 
 
 
 
 
 
 
 
 
2.5 Resazurin survival assay 
 
Control and treated cells were incubated with resazurin medium (200 µM, 130 µl/well, 
2-3 h, 37 °C) under light protection and fluorescence intensity was measured using the 
FLUOStar Omega microplate reader (544 nm/590 nm). Cell survival fraction was 
determined after normalization with fluorescence intensity of resazurin medium and 
control cells. 
Cell line TPCS2a (µg ml-1) 
Light 
(J cm-2) 
Bleomycin
(IU ml-1) 
ATX-101 
(µM) 
E-64 
(µM) 
  A431 0.2 0.387 5 5 10 
  T24 0.2 0.774 5 5 10 
  AY-27 0.1 0.387 50 5 50 
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2.6 Cytotoxicity assays  
 
Cells were seeded out into 96-well plates (6000 cells/well). Attached cells were treated 
using one of the protocols below: 
Protocol A (photodynamic treatment): the cells were incubated with TPCS2a for 
18 h. Subsequent to removal of TPCS2a-medium, cells were washed with culture 
medium twice and chased (4 h) in fresh drug-free medium before exposure to blue light 
at different intervals [26].  
Protocol B (drug treatment): the cells were (co-)incubated with drug(s) (bleomycin, 
ATX-101 or E-64) for 4 h and then washed once with culture medium.  
Protocol C (PCI-bleomycin treatment): here protocol B was incorporated into 
protocol A after TPCS2a-treatment. The treated cells were (co-)incubated with 
bleomycin (and ATX-101/E-64) for 4 h instead of being chased in drug-free medium. 
The cells were washed once before illumination. Therapeutic drug and light doses used 
are listed in Table 1. 
Finally, cell survival fraction was determined by resazurin survival assay after 
post-incubation for 48 h. The time point of 48 h was selected based on bleomycin effect 
measured at each day from 1 to 7 days after bleomycin treatment in theses cell lines (see 
Figure 1S, Supplementary Information). Cell survival fractions showed the same 
relative relationship among the three cell lines across the time series. Considering the 
subsequent studies on bleomycin effects in different combined treatments, cell growth 
measured at 48 h after bleomycin treatment seemed to be an optimal time point which 
could show clear differences in treatment effect in all cell lines that were used. 
Clonogenic assay was also performed in T24 and AY-27 cell lines as method control, 
showing that T24 had weaker colony forming capacity than AY-27. However, due to 
possibly misleading results caused by differences in colony forming capacity rather than 
drug effects, clonogenic assay was not used for the actual study (see Figure 2S, 
Supplementary Information).  
Using protocol C, the cells were washed one additional time compared to protocol 
A. This could eliminate cellular TPCS2a and thereby reduce the photodynamic 
cytotoxicity to a small extent in PCI-drug(s) treated cells (see Figure 3S, Supplementary 
Information). However, this matched the PCI strategy using sub-lethal photodynamic 
dose. 
 
2.7 Analysis of BLMH expression by Western blot 
 
Protein lysate was extracted from (treated) cells using the same protocol described in 
our earlier study [41]. Briefly, cell pellet was resuspended in lysis buffer followed by 
sonication. Protein concentration was determined using Bio-Rad protein assay after 
centrifugation. 
Expression of bleomycin hydrolase (BLMH) was analyzed by 1D Western blot 
using a standard protocol (Invitrogen). As described [34], protein lysates (100 µg) were 
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separated on 10% Bis-Tris gel (NuPAGE, Invitrogen) and transferred onto PVDF 
membrane (Immobilon, Millipore). Proteins were further detected using anti-BLMH 
primary antibody (ab77111, Abcam), HRP-conjugated rabbit anti-mouse secondary 
antibody (p0260, Dako Denamark) and anti-PCNA antibody (ab29, Abcam) as loading 
control. K562 whole cell lysate (30 µg, ab7911, Abcam) was used as positive control of 
the primary antibody.  
 
2.8 Comet assay 
 
Cells were seeded out into 6-well plates (5×104 cells/well, CytoOne). Bleomycin or 
PCI-bleomycin treated cells were washed with PBS and then detached with accutase 
(15 min, 37 °C, Sigma) immediately after treatments or after an interval of 
post-incubation (15 min and 30 min, respectively) in culture medium. DNA damage 
level was further evaluated using a standard protocol of single cell gel electrophoresis 
[46,47,48]. As described [48], the cells were resuspended at 37 °C in 1% low-melt agar 
after centrifugation and loaded on a pre-coated microscope slide which was 
immediately cooled down on ice. The embedded cells were lysed in fresh cold lysis 
buffer [48] overnight and then electrophoresed in cold alkaline buffer (pH 13.3). DNA 
fragments stained with ethidium bromide were visualized in an inverted fluorescence 
microscope (Zeiss Axiovert 200M, Germany) equipped with a Sony XCD-X700 camera. 
Several hundreds of comets in each sample were evaluated using Komet 5.5 imaging 
software (Andor Technology).  
 
  
7 
 
3. Results and discussion 
 
3.1 Cellular uptake of TPCS2a and dose responses to blue light and bleomycin 
 
The uptake of TPCS2a to the endosomal membrane is essential for drug delivery. To 
assess the uptake capacity in the skin cancer cell line A431 and the bladder cancer cell 
lines T24 and AY-27, fluorescence intensity of cellular TPCS2a was measured and 
normalized against cell count. The results showed that the uptake was dose-dependent 
in all three cell lines (Figure 1a). Importantly, a much higher uptake was seen in the skin 
cancer cell line A431 compared to the bladder cancer cell lines T24 and AY-27 (Figure 
1a). The endocytotic rate is cell type dependent [49], and this may account for 
differences in cellular TPCS2a uptake as seen in the these cell lines. 
According to the principle of PCI, the applied doses of both photosensitizer and 
light (termed photodynamic dose in this paper) are supposed to be sub-lethal, leading 
mainly to damage to the endosomal/lysosomal membrane. Therefore, we set out to 
determine the sub-lethal photodynamic doses before evaluating PCI-bleomycin efficacy. 
No dark toxicity, TPCS2a buffer toxicity (Tween 80 and 50 mM Tris buffer), or light 
toxicity was observed in any of the cell lines under the experimental conditions (data 
not shown), thus the cytotoxicity is dependent upon light activation of the TPCS2a 
molecules. The results showed that T24 cells were resistant to activation by blue light 
although they had similar TPCS2a uptake as the AY-27 cells that were very light 
sensitive (Figure 1b). A431 cells, which accumulated more TPCS2a molecules than the 
two other cell lines, were medium sensitive to light activation (Figure 1b). Light doses 
that gave low (0-20%) reduction in cell survival in this experiment (Figure 1b, arrows) 
were selected for the PCI-bleomycin experiments, but in the following experiments a 
further three times reduction of the TPCS2a concentration was applied in order to further 
reduce the background cytotoxicity. In summary, these results show that the cell lines 
accumulate different levels of TPCS2a, but that this did not directly correlate with their 
light sensitivity. 
Next, we tested the bleomycin sensitivity of the different cell lines. We treated the 
cells with bleomycin for 4 hours, and measured the cell growth after 48 hours. A431 
was the most, and AY-27 the least sensitive cell line (Figure 1c).  
8 
 
C
el
l s
ur
vi
va
l f
ra
ct
io
n,
%
 
 
Figure 1. Cellular uptake of TPCS2a is dose-dependent, its cytotoxicity is dependent upon dose 
of blue light, and bleomycin cytotoxicity is cell type-dependent. (A) Cellular accumulation at 
increasing concentrations of TPCS2a in A431, T24 and AY-27 cells. After 18 h the TPCS2a 
fluorescence was normalized to fluorescence intensity per cell by DRAQ5-staining. The data are 
from one representative experiment out of two (mean of 12 wells). (B) Cytotoxicity of 
increasing blue light doses (435 nm) in A431, T24 and AY-27 cells exposed to 0.3 µg ml-1 
TPCS2a for 18 h. The data are from one representative experiment out of three (mean of 24 wells 
± SD). Light doses selected for further PCI experiments are shown with arrows. (C) Dose 
response to bleomycin determined as cell growth after 48 h. A431, T24 and AY-27 cells were 
treated with different bleomycin doses for 4 h. The data are from one representative experiment 
out of four (mean from 48 wells ± SD).  
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Figure 2. PCI enhances cytotoxic effect of bleomycin in all three cell lines. Cell survival 
fractions were determined 48 h after incubation with 0.1 µg ml-1 TPCS2a for 18 h, 50 IU ml-1 
bleomycin or fresh medium for 4 h, and illumination (light doses as indicated in Figure 1b) in 
sequence. The data are from one representative experiment out of three (mean of 24 wells ± SD). 
P-values were calculated using two-tailed Student’s t-test and the values (p<0.0001, presented 
with asterisk) indicated significant differences between bleomycin and PCI-bleomycin 
treatments. 
 
 
3.2 The effect of bleomycin is increased in combination with PCI  
 
To determine the efficacy of PCI-bleomycin in the three cell lines, sub-lethal doses of 
light (see arrows in Figure 1b) and TPCS2a (0.1 µg ml-1) were used. P-values were 
calculated using two-tailed Student’s t-test and the values (p<0.0001) indicated that 
differences in cytotoxicity between bleomycin versus PCI-bleomycin treatment were 
highly significant. In line with the PCI concept, sub-lethal photodynamic doses were 
applied. In addition, the PDT effect included in PCI-bleomycin treatment in each cell 
line was less than its PDT control due to an additional washing (see section 2.6 in 
Methods). The results showed that bleomycin cytotoxicity was enhanced up to 20% by 
PCI, independent of cell type (Figure 2). This is likely due to increased uptake of 
bleomycin in the cells. At the selected conditions, A431 cells were more sensitive than 
the bladder cancer cells (44% surviving cells versus 55%, respectively, Figure 2). This 
likely reflects that this cell line had highest uptake of TPCS2a in addition to being the 
most sensitive towards bleomycin (Figure 1a and 1c). These results are in agreement 
with recent results reported by Arentsen et al. [28]. 
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3.3 Inhibition of bleomycin hydrolase did not increase the cytotoxicity of 
PCI-bleomycin treatment 
 
Different sensitivity towards bleomycin could be due to differences in uptake of the 
drug, differences in how the cells process the drug or repair the DNA damages induced 
by the drug. Bleomycin hydrolase (BLMH) is a cytosolic enzyme which has been 
shown to inactivate bleomycin before it enters the nucleus, and is thus believed to 
contribute to bleomycin resistance [11,12,30]. When measuring the BLMH expression 
in the three cell lines, we found that AY-27 cell line expressed more BLMH than the 
other two cells lines (almost 2x, Figure 3a). No change in BLMH levels from the 
BLMH inhibitor E-64 was observed. AY-27 was the most bleomycin-resistant cell line 
(Figure 1c), also in presence of E-64 (Figure 3b), suggesting that BLMH is not 
important for the resistance of AY-27 towards bleomycin. The changes in sensitivity 
towards bleomycin in the other cell lines were also minimal following addition of E-64 
(Figure 3b), thus BLMH is most likely not important for bleomycin sensitivity of these 
cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Bleomycin hydrolase is strongly expressed in AY-27 cells but the protease inhibitor 
E-64 does not sensitize AY-27 to bleomycin. (A) Western blots of BLMH expression in K562 
(positive control), A431, T24 and AY-27 cells. E-64 treated cells are included as control. PCNA 
expression level is used as loading control. The image is from one representative experiment out 
of three. (B) Bleomycin cytotoxicity at two concentrations (5 and 50 IU ml-1) with and without 
E-64 treatment (concentrations used are listed in Table 1). Cell survival fractions were 
determined 48 h after 4 h-treatment of the drug(s). The data are from one representative 
experiment out of three (mean of 24 wells ± SD). 
K-5
62 p
osit
ive
AY
27 c
ontr
ol
AY
27 E
-64
 trea
ted
T24
 con
trol
T24
 E-6
4 tr
eate
d
A43
1 co
ntro
l
A43
1 E
-64
 trea
ted
BLMH
PCNA
53kDa
29kDa
A.
C
el
l s
ur
vi
va
l f
ra
ct
io
n,
%
A4
31
  b
leo
my
cin
(5 
IU
 m
l-
1 ) 
A4
31
  b
leo
my
cin
(5 
IU
 m
l-
1 ) +
 E-
64
A4
31
  b
leo
my
cin
(50
 IU
 m
l-
1 ) 
A4
31
  b
leo
my
cin
(50
 IU
 m
l-
1 )  +
 E-
64
T2
4  
ble
om
yc
in(
5 I
U 
ml
-1 ) 
T2
4  
ble
om
yc
in(
5 I
U 
ml
-1 )  
+ E
-64
T2
4  
ble
om
yc
in(
50
 IU
 m
l-
1 ) 
T2
4  
ble
om
yc
in(
50
 IU
 m
l-
1 )  +
 E-
64
AY
27
  b
leo
my
cin
(5 
IU
 m
l-
1 ) 
AY
27
  b
leo
my
cin
(5 
IU
 m
l-
1 )  +
 E-
64
AY
27
  b
leo
my
cin
(50
 IU
 m
l-
1 ) 
AY
27
 bl
eo
my
cin
(50
 IU
 m
l-
1 ) +
 E-
64
0
20
40
60
80
100
B.
11 
 
3.4 Impairing DNA damage responses during PCI-bleomycin treatment increased 
the efficacy 
 
Bleomycin binds to DNA strands resulting in both single stranded and double stranded 
DNA breaks. We measured the levels of DNA damage induced by bleomycin alone and 
by PCI-bleomycin using comet assays. An increase in DNA damage by PCI-bleomycin 
versus only bleomycin would strongly indicate increased uptake of bleomycin in the 
cells. We also measured the DNA repair rate in each cell line. Because it takes 15 min to 
detach cells, the earliest time points for DNA damage evaluation were after 15 min. 
Cells were left to repair for additional 15 and 30 min (30 and 45 min in total, 
respectively) (Figure 4a). Statistical analysis was performed using two-tailed Student’s 
t-test. Highly significant differences in DNA damage levels between treatments 
(p<0.0001) are shown with asterisks in Figure 4. Bleomycin-induced DNA damage was 
observed in all cell lines, but the levels at different time points varied between the cell 
lines. Bleomycin alone induced more DNA damage and the damage was removed more 
slowly in T24 and A431 than in AY-27 cells, consistent with the observation that AY-27 
was more resistant to bleomycin. Furthermore, the results showed that PCI-bleomycin 
induced a higher level of DNA damage than bleomycin alone in all three cell lines 
(Figure 4a), supporting increased import of bleomycin. The highest increase in levels of 
DNA damage was seen in AY-27 cells, and importantly no reduction in the level of 
DNA damage could be detected 45 minutes after PCI-bleomycin treatment in this cell 
line, suggesting that the repair capacity was saturated. The observation that cell survival 
after 48 hours was 55% (see Figure 2) shows that a large fraction of the cells were 
eventually repaired, but at later time points.  
The novel peptide drug ATX-101 has the potential to reduce several aspects of the 
cellular defense systems, including DNA repair, and is therefore enhancing the efficacy 
of several chemotherapeutics [33,34,35]. We tested if ATX-101 could increase the 
efficacy of PCI-bleomycin, and found that ATX-101 enhanced the PCI-bleomycin 
efficacy with 14.7%, 30.5%, and 20.7% in A431, T24, and AY-27 cells respectively, 
showing statistically significant differences (Figure 4b). The cytotoxic effects of the 
double combinations ATX-101-bleomycin and ATX-101-TPCS2a-PDT are similar or 
lower than PCI-bleomycin, and lower than the triple combination 
ATX-101-PCI-bleomycin (data not shown). Any PDT effect in these PCI combination 
treatments was reduced due to one additional washing. The additive effects of ATX-101 
were stronger in the bladder cancer cells than in the skin cancer cells under these 
experimental conditions (Figure 4b). Because the bladder cancer cells were less 
sensitive towards bleomycin both with regard to cell survival and induction of DNA 
damage (Figure 1 and 4), these results suggest that the cellular DNA repair capacity is a 
crucial factor of the efficacy of bleomycin, and therefore also the efficacy of 
PCI-bleomycin. As expected from the results in Figure 3b, addition of E-64 did not 
affect PCI-bleomycin efficacy. 
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Figure 4. PCI elevates bleomycin-induced DNA damages and ATX-101 enhances 
PCI-bleomycin cytotoxicity. (A) Bleomycin and PCI-bleomycin induced DNA damages. Comet 
assay was performed at different intervals after incubation with 0.1 µg ml-1 TPCS2a (18 h), 50 
IU ml-1 bleomycin (4 h), and illumination (light doses as indicated in Figure 1b) in sequence, or 
with the bleomycin treatment only. The data are from one representative experiment out of two 
experiments (mean of 500/700 cells ± SD). P-values were calculated using two-tailed Student’s 
t-test and the values (p<0.0001, presented with asterisk) indicated that the level of DNA damage 
between bleomycin treatment and PCI-bleomycin, or between different time intervals of the 
same treatment, were significant different. (B) Cell growth after treatment with PDT, bleomycin, 
ATX-101, PCI-bleomycin, and PCI-bleomycin in combination with E-64 or ATX-101. Cell 
survival fractions were determined 48 h after incubation with TPCS2a (18 h), bleomycin 
with/without ATX-101/E-64 (4 h), and light exposure in sequence (drug and light doses are 
shown in Table 1). Any PDT effect in the PCI combination treatments was reduced due to one 
additional washing (see section 2.6 in Materials and Methods). The data are from one 
representative experiments out of three (mean of 12/24 wells ± SD). P-values were calculated 
using Student’s t-test and the values (p<0.0001, presented with asterisk) indicated that cell 
growth after bleomycin-bleomycin and PCI-bleomycin-ATX-101 treatment were significantly 
different. 
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Conclusions  
 
This is a fundamental study of specific aspects of the PCI technique. Using sub-lethal 
photodynamic doses, our results show that the cytotoxic effect of bleomycin is 
enhanced by TPCS2a-mediated PCI in the tested bladder cancer cells, although these cell 
lines show clear differences with respect to sensitivity to photosensitizer uptake, light 
dose, and DNA repair capacity. We show that the PCI technique elevates 
bleomycin-induced DNA damage levels in all three cell lines, strongly suggesting that 
more bleomycin molecules enter the nuclei compared to treatment with bleomycin as a 
single agent. Thus, the membrane barrier to bleomycin seems to be bypassed by the PCI 
technique. We have further demonstrated that application of a cocktail of 
PCI-bleomycin and ATX-101, under condition where individual drug levels have no or 
low toxicity, reaches a promising therapeutic effect in the human bladder cancer cells 
T24 which is two-fold stronger than in the reference cell line, the human skin cancer 
cells A431. Combining PCI-chemotherapy treatments with inhibitors of DNA repair 
therefore seems to be a promising therapeutic strategy for increased efficacy “on site”.  
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The results shown in Figure 1S, 2S and 3S are repetitive or supplementary to the figures 
in the main paper, thus they are presented here as Supplementary Information. These 
results were used to determine an optimal time point (48 h) and support for the 
cytotoxicity assays (section 2.6 in Materials and Methods of the main paper). 
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Figure 1S (Supplementary). The long-term bleomycin cytotoxicity in the three cell 
lines AY-27, T24 and A431. Cells were seeded out into 25 cm2 culture flasks (1×106 
cells/flask) and treated with bleomycin (4 h) at indicated concentrations (5, 50, and 
100 IU ml-1) after cell attachment. The cells were re-plated into 96-well plates (1000 
cells/well) with parallels. Cell survival fraction was determined by resazurin survival 
assay from the next day until the seventh. The data are from one representative 
experiments out of two (mean of 12/24 wells ± SD). 
 
 
 
 
 
 
Figure 2S (Supplementary). Cell survival after bleomycin treatment in T24 and AY-
27 cell line. Cells were seeded out into 25 cm2 culture flasks (1×106 cells/flask) and 
treated with bleomycin (4 h) at indicated concentrations (5, 50, and 200 IU ml-1) after 
cell attachment. The cells were re-plated into petri dishes (100 cells/dish) with parallels. 
The fraction was determined and calibrated with the amount of colonies using a 
standard clonogenic assay. The time for colony forming was seven days for AY-27 cells 
and ten days for T24 cells. 
 
 
  
 
 
 
 
Figure 3S (Supplementary). Elimination of TPCS2a in AY-27 cells. Attached cells in 
96-well plate were incubated with TPCS2a (18 h) at different concentrations and washed 
with culture medium (100 µl/well) at every chase of 10-15 min. Chased medium was 
moved to a new 96-well plate in the same well position.  The amount of released 
TPCS2a and cellular retention after 8th washing were determined by fluorescence 
measurement using FLUOStar Omega microplate reader (410 nm/640 nm, ±10 nm).  
  
  
 
 
  
 
 
  
 
 
Paper 4 
 
1 
 
Manuscript 
 
Studies of the photosensitizer disulfonated meso-tetraphenyl chlorin in 
an orthotopic rat bladder tumor model 
 
 
Yan Bagloa,*, Qian Pengb, Lars Hagena, Kristian Bergc, Anders Høgsetd, Finn Drabløsa, 
Odrun A. Gederaasa 
 
a Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University 
of Science and Technology, N-7491 Trondheim, Norway 
b Department of Pathology, the Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-
0310 Oslo, Norway 
c Department of Radiation Biology, the Norwegian Radium Hospital, Oslo University Hospital, 
Montebello, N-0310 Oslo, Norway  
d PCI Biotech AS, Strandveien 55, N-1366 Lysaker, Norway 
 
 
*Corresponding author: 
Yan Baglo 
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU 
Postbox 8905, N7491 Trondheim, Norway 
Telephone:  0047 72826606             E-mail: yan.baglo@ntnu.no 
 
  
2 
 
Summary 
 
Background 
 
Photochemical internalization (PCI) is a novel technology for the release of a 
therapeutic molecule from endocytic vesicles into the cytosol of a cell. The release of 
molecules occurs after activation of an endocytic membrane-embedded photosensitizer 
by light. In this study uptake and localization of the photosensitizer disulfonated 
tetraphenyl chlorin (TPCS2a) were explored to optimize a PCI protocol in an orthotopic 
rat bladder tumor model.  
 
Methods 
 
Female Fischer F344 rats were intravesically instilled with 0.4×106 AY-27 transitional 
carcinoma cells before allowing tumor growth for 14 days. The photosensitizer TPCS2a 
was intravesically instilled at different concentrations, and bladders were excised after 
different time intervals. The retention, penetration, and localization of intratumoral 
TPCS2a were explored ex vivo using fluorescence spectroscopy and fluorescence 
microscopy to determine an optimal PCI protocol. These results were compared to 
histological analysis of necrotic areas after activation of intratumoral TPCS2a by red 
light (652 nm, 0.5 J/cm2).  
 
Results 
 
A superficial distribution pattern of the photosensitizer TPCS2a was seen in bladder 
tumor tissue, and TPCS2a was almost cleared from the tumors after 72 hours. The 
highest retention of TPCS2a was found at 24 hours after instillation when using a 
concentration of 3 mg/ml. 
 
Conclusion 
 
An optimal PCI protocol was defined for the tumor model, including a 24-hour TPCS2a-
to-light interval and a dose of 3 mg/ml TPCS2a. This protocol will be utilized for the 
study of PCI-enhanced therapeutic effects on non-muscle invasive bladder cancer, using 
a potent chemotherapeutic under an optimal light dose. 
 
Keywords 
 
Photochemical internalization; photodynamic therapy; rat orthotopic bladder tumor 
model; non-muscle invasive bladder cancer; disulfonated meso-tetraphenyl chlorin  
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Introduction 
 
In Norway, bladder cancer has been one of the five most common cancer types for men 
during the past decade [1]. Approximately 70-80% of diagnosed bladder cancers 
worldwide are non-muscular invasive bladder cancer (NMIBC) consisting of carcinoma 
in situ, stage Ta and T1 tumors. NMIBC is normally removed by surgery during a 
cystoscopy under general anesthesia, known as transurethral resection of bladder tumors 
(TURBT). Unfortunately, the high rate of recurrence and progression after TURBT 
means that adjuvant treatments may usually be required, such as intravesical 
chemotherapy using mitomycin C, epirubicin, or doxorubicin and/or immunotherapy 
using Bacillus Calmette-Guérin (BCG) vaccine [2,3,4,5]. However, recurrence rates still 
remain high, and progression is not eliminated after the combined therapies. Side effects 
including bladder irritation, skin rash, frequency and pain are often seen with the 
chemo- and immunotherapy [6]. To improve the total intravesical agent uptake and 
hence chemotherapeutic efficacy, various experimental approaches have been evaluated, 
including enhancing the agent delivery to bladder tumor tissue using electromotive 
therapy and photochemical internalization (PCI), enhancing cell membrane permeability 
using intravesical hyperthermia [7,8,9]. Hexaminolevulinate-guided transurethral 
resection has been shown to significantly improve detection of Ta and T1 lesions and 
reduce recurrences [10]. In this study, photochemical internalization (PCI) [11] have 
been studied in vivo to enhance the effect of therapeutic agents for NMIBC.  
 
PCI has been developed from photodynamic therapy (PDT) [12], but is designed to 
favor the delivery of a therapeutic molecule without inactivating the molecule or 
lethally damaging the cell. The cell killing effect therefore results predominantly from 
the therapeutic molecule, rather than the photodynamic treatment [13]. This is of 
particular importance for the delivery of genes and siRNA [14]. However, PCI is based 
on the same photochemical principles as PDT. PCI can be looked upon as a three-stage 
process. The first stage is the selective accumulation of an amphiphilic photosensitizer 
in the tumor endosomal or lysosomal membranes via endocytosis, in the absence of 
light. The second stage is the accumulation of a therapeutic molecule in the endocytic 
vesicles, also in the absence of light. In the last stage, the photosensitizer is activated by 
light of the appropriate wavelength and intensity. Using a sub-lethal photodynamic dose, 
activated photosensitizer evokes a response only in the endosomal and lysosomal 
membranes by reacting with molecular oxygen leading to membrane rupture and release 
of the molecules [11]. PCI could be combined with different therapeutic 
macromolecules or molecules with limited ability to penetrate the cell membrane, but 
PCI has also been shown to enhance therapeutic efficacy of some conventional 
cytotoxic therapies, with reduced side effects as the therapeutic site is limited to the 
illuminated area [15,16].   
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NMIBC is potentially well suited for effective treatment by PDT or PCI because it is 
easily accessible for both intravesical instillation and illumination. In addition, it is 
possible to irradiate the whole bladder and hence provide access to multifocal tumors 
[17]. As no difference in light penetration is observed between tumor and normal 
bladder tissue, the photodynamic responses upon illumination of the bladder will 
depend on the localization and accumulation of the photosensitizer within the tumor 
[18]. In this study, the potent photosensitizer disulfonated tetraphenyl chlorin (TPCS2a) 
was utilized to explore its tissue localization and accumulation in a rat bladder tumor 
model [19,20,21,22], to establish an optimal protocol for the first stage of PCI.  
 
TPCS2a is an amphiphilic chlorin produced from disulfonate tetraphenyl phorphyrin 
(TPPS2a) [15,23]. The absorption spectrum of TPCS2a has been investigated in organic 
media and shown to be only slightly affected by the properties of the organic solvents. It 
is observed that TPCS2a has absorption maximum at 650-653 nm and emission 
maximum at 654-657 nm in organic solvents [24,25]. As a fluorophore, TPCS2a is found 
to have stronger light absorption in the red wavelength region and to be more efficient 
for in vivo applications than its corresponding porphyrin TPPS2a [23,24,25,26,27]. 
TPCS2a was approved for use in clinical studies in 2008, and a phase I clinical trial of 
TPCS2a-mediated PCI of bleomycin in head-and-neck cancer showed no severe side 
effects associated with the treatment. The efficacy and safety of the modality are 
currently being evaluated in a phase II clinical intervention trial [28,29]. In animal 
studies, TPCS2a-mediated PCI of the chemotherapeutic agent bleomycin has been 
investigated as an adjunct to radiotherapy and surgery by Norum et al. [30,31], showing 
that PCI induces synergistic therapeutic effects in a human sarcoma model. PCI is also 
proposed to have potential competence to bypass the development of drug resistance 
induced by repeated exposure to therapeutics [15]. Very recently, PCI-enhanced 
vaccination using TPCS2a was demonstrated to strongly increase stimulation of CD8 T-
cell responses preventing tumor growth in a mouse skin tumor model [32]. With rapid 
development of TPCS2a usage in PCI, it has become of great interest in the possible 
treatment of bladder cancer [7,8]. 
 
 
Materials and Methods 
 
Cell suspension 
 
Rat bladder transitional carcinoma cells (AY-27) [33] were maintained in the same 
RPMI-1640 culture medium and conditions as described in our earlier study [34]. 
Immediately before intravesical inoculation of AY-27 cells into rat bladder, single 
cell suspension was prepared at a desired density with RPMI-1640 medium 
supplement with glutamine (5%) and stored on ice until instillation.  
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Photosensitizer  
 
The photosensitizer TPCS2a (30 mg/ml, Amphinex®) disaggregated in Tween 80 
and 50 mM Tris buffer [35] was provided by PCI Biotech AS (Lysaker, Norway) 
and stored at 4 °C in aliquots. The solution was diluted into desired concentrations 
with 50 mM phosphate buffer (pH 8.5) for inoculation in rat bladder. For cell 
incubation, the solution was diluted first with 50 mM Tris buffer (pH 8.5) and 
then with culture medium immediately before use [8]. All work with TPCS2a was 
performed under subdued light or light protection. 
 
Animals 
 
Female rats (Fischer inbred F344, 8-10 weeks old, body mass 160-180 grams) 
were used in all experiments. The animals were housed in standard conditions 
under conventional pathogen-free microbiological status, as described by Arum et 
al. [21]. Every six rats were housed in a standard cage and fed with standard rat 
food pellets and tap water. Rat bladder was modeled as a sphere with a volume of 
0.3 ml in order to determine volume of a single instillation [20]. All animal 
experiments were approved by Norwegian National Animal Research Authority 
(NARA). 
 
Orthotopic bladder tumor model 
 
After weighing of body mass, the rats were numbered, and allocated into control 
and treated groups according to experimental designs (see later). The tumor model 
has been described previously [19,20,21]. Briefly, under anesthesia each rat 
received 0.4×106 AY-27 cells intravesically through an 18 gauge plastic cannula 
after acidic and alkaline conditioning [21]. A standard dose of temgesic for pain 
relieve was given as required after recovery. The rats were further housed for 14 
days allowing tumor growth according to earlier histological investigations by 
Larsen et al. [20]. The tumor stages in this model have been evaluated to be 
similar to human urinary carcinoma at stage T1-3 WHO grade 3 [21].  
 
Intravesical TPCS2a administration 
 
Each bladder was quickly washed three times with 0.9% salt water through an 18 
gauge plastic cannula, while the rat was under anesthesia. Instillation of TPCS2a 
solution (0.3 ml) at desired concentration was followed by incubation for two 
hours in the dark, while the rat body was rotated 90 degrees every 30 minutes 
allowing homogenous uptake of the photosensitizer into the whole bladder. Finally, 
the rats were housed under light protection until ex vivo fluorescent measurement. 
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Fluorescent intensity measurement 
 
JETI PDT fluorometer (JETI Technische Instrumente GmbH, German) is a 
miniaturized fiber-optic spectrometer for the detection of fluorescence in the 
wavelength range of 550 nm to 800 nm, using a single excitation wavelength. A 
violet LED lamp with a peak wavelength at 405 nm was used for excitation. The 
instrument is able to measure fluorescence emission from TPCS2a, where 
fluorescence can be excited at 405 nm, and the measurements were performed 
with an external 200 µm diameter optical fiber. Subsequent to calibration, a series 
of fluorescence intensity data were collected from 550 nm to 800 nm using the 
software of the PDT fluorometer (V.1.2).  
 
Each bladder was excised under anesthesia and opened from the urethra. The rats 
were then sacrificed. After flat fixing the opened bladder upon a cardboard with 
the mucosal layer exposed, fluorescence measurement was performed from the 
mucosal layer on at least five random areas by JETI PDT fluorometer. After 
measurement, the tissue was quickly frozen in liquid nitrogen and stored at -80 °C 
before sectioning.  
 
Illumination with red light 
 
Intravesical illumination was performed using a laser fiber (BioLitech AG, 
Germany) coupled to an optometer (P-9710-1/P-9710-2, Gigahertz-Optic GmbH, 
Germany). The intensity of the laser (652 nm) was measured and controlled with 
the optometer until light delivery was stable after pre-warming the optometer (30 
min) and the laser (15 min). The exposure to the whole bladder wall with red light 
(652 nm, 0.5 J/cm2) was performed by inserting the fiber through an 18 gauge 
plastic cannula after inflating bladder with 0.3 ml salt water.  
 
Frozen sections 
 
Tissue blocks were made with tissue OCT compound (Tissue-Tek®, Sakura 
Finetek USA) from a piece of frozen bladder and frozen with liquid nitrogen. 
Tissue frozen sections (5 µm) were cross sectioned through bladder walls under 
light protection using Leica cryostat (CM3050S, Leica Biosystems Nussloch 
GmbH, Germany) at -20 °C. The frozen sections were collected to a glass slide 
and stored at -80 °C until microscope examination or haematoxylin erythrosine 
saffron (HES) staining using a standard protocol for histological frozen sections.  
 
Tissue paraffin  
 
Bladder tumor tissue was immersed in 4% formaldehyde until paraffin embedding. 
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After cross sectioning of the tissue through bladder walls, the sections (4 µm) 
were HES stained in an automatic slide stainer (Tissue-Tek®, PrismaTM, Sakura 
Finetek USA, Inc.) using a standard protocol for histological paraffin sections.  
 
Intratumoral localization of TPCS2a  
 
Localization of TPCS2a in the frozen sections of bladder tumor tissue was 
visualized using an Olympus IX71 inverted fluorescence microscope (410 nm 
BP/590 nm LP). Each frozen tumor tissue section was covered with Dako 
fluorescent mounting medium (Dako Danmark A/S) before being thawed. Images 
were taken by a CCD camera (XM10), using a 4× objective, and a Cell^P Image 
visualization software. A neighboring section was HES-stained in the automatic 
slide stainer using a standard protocol for frozen sections. Histological 
examination was performed in a microscope (Nikon Eclipse 80i) and images were 
taken by a digital Sight camera with the NIS-Elements F3.0 software. 
 
Microscopic fluorescence photometry 
 
TPCS2a fluorescence measurements were done by microscopic fluorescence 
photometry using a microscope (Nikon Eclipse E800) with a 100 W mercury lamp 
and a highly light-sensitive thermo-electrically cooled charge-coupled device 
camera (ORCAII-ER, Hamamatsu, Japan). The resolution was 1280×1024 pixels 
with a dynamic range of 12 bits per pixel. The images were taken with a 4× 
objective and a filter combination composed of a 380-420 nm excitation filter, a 
430 nm beam splitter and a 605±55 nm band-pass emission filter. A rectangular 
area superimposing the tumor zone from the superficial to deep part was made on 
each fluorescence image. The fluorescence intensity within the selected area was 
then quantified as a function of depth of the tumor by an image processing unit 
(Aqua Cosmos software). In the measurements, each mean value of specific 
TPCS2a fluorescence intensity was calculated from the pixels at the exact same 
depth location; the mean values were then plotted as a function of the depth of the 
tumor by SigmaPlot 10 (Systat Software Inc., CA).   
 
Experimental design  
 
Protocol A. Assessment of tissue TPCS2a at different instilled concentrations  
 
A total of 37 rats were allocated into one of the six groups: (1) control, 4 rats 
(without any treatments); (2) tumor, 5 rats (inoculated with AY-27 cells only); (3) 
1 mg/ml TPCS2a, 7 rats; (4) 2 mg/ml TPCS2a, 7 rats; (5) 3 mg/ml TPCS2a, 7 rats; 
and (6) 5 mg/ml TPCS2a, 7 rats. Groups 2-6 were intravesical inoculated with 
4×106 AY-27 cells. After housing for 14 days, groups 3-6 received intravesical 
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instillation of TPCS2a at the noted concentrations and the animals were housed for 
72 hours under light protection. In the end, all bladders were excised and 
fluorescence intensity was measured immediately using a JETI fluorometer. An 
optimal TPCS2a concentration was chosen from these experiments for the use in 
protocol B. 
 
Protocol B. Assessment of tissue TPCS2a at different time intervals  
 
Nineteen rats were allocated into one of the six groups: (1) control, 1 rat; (2) 
tumor, 1 rat; (3) 4 hours retention time, 4 rats; (4) 24 hours retention time, 4 rats; 
(5) 48 hours retention time, 5 rats; and (6) 72 hours retention time, 4 rats. After 
establishing tumor in Groups 2-6 (see protocol A), group 3-6 received intravesical 
instillation of TPCS2a at the optimal concentration (chosen from experiments in 
protocol A) and the animals were housed for further 4, 24, 48 or 72 hours 
respectively under light protection. Group 3-5 were excised with bladder at each 
determined time; while Group 6 and the control groups were excised with bladder 
at the last experiment day. Fluorescence intensity was measured immediately 
using the JETI fluorometer. An optimal TPCS2a distribution time in tissue, i.e. 
TPCS2a-to-light time interval, was chosen from these experiments for the use in 
protocol C. 
 
Protocol C. Assessment of necrotic area when using the optimal TPCS2a 
concentration and TPCS2a-light interval 
 
Eight rats established with bladder tumor (see protocol A) were intravesical 
instilled with TPCS2a at the optimal concentration (protocol A) and housed for the 
optimal time (protocol B). Bladders were intravesically exposed to red light (laser, 
652 nm, 0.5 J/cm2) in salt water. Then, all bladders were excised after housing the 
rats for additional 19 days.  
 
All bladder tumor tissue samples except the photodynamically treated ones were 
frozen at -80 °C until tissue sectioning for histological analysis and fluorescence 
microscope in order to explore TPCS2a localization and penetration in the bladder 
tumor tissue. The photodynamically treated tissue samples were immersed in 4% 
formaldehyde until paraffin sectioning. 
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Results 
 
Tumor characteristics in the model  
 
The bladder consists of three layers: the mucous layer of epithelial cells 
(urothelium), the underlying submucosa, and the outer muscular layer. Bladder 
tumors were visually present in all inoculated rats (see Table 1). Histology showed 
that the tumors were multifocal and developed in either stage T1 or T2 with varied 
tumor size. In Figure 1, bladder histology shows clear tumor characteristics in the 
model system.  
 
 
Table 1 Tumor development for each experiment  
Experiment  Number of control rats 
Number of 
inoculated rats 
Rats with 
tumor present 
Rats without 
tumor 
present 
Number of 
dead rats 
A 4 33 33 0 0 
B 1 18 18 0 0 
C 0 8 7 1 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Histology of rat bladder tumors developed for 14 days after intravesical inoculation 
with AY-27 cells. (A) Normal urothelium (N) and multifocal bladder tumors (T) (1×100). (B) 
Bladder tumor in stage T2 (1×20). The bladder was inoculated with 0.4×106 AY-27 cells. The 
images were taken in microscope (Nikon Eclipse 80i) using a Digital Sight Camera, showing 
HES sections (5 µm). The upper part is the mucosal layer and the lower part in image B is the 
muscular layer of the bladder. 
 
  
N 
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Determination of intratumoral TPCS2a with fluorescence spectroscopy 
 
The amount of retentive TPCS2a in bladder tumor tissue was measured ex vivo by 
a JETI PDT fluorometer. In accordance with absorbance and fluorescence spectra 
of TPCS2a in organic solvents [24], the molecules of TPCS2a were excited at 
405 nm in bladder tumor tissue and maximum fluorescence emission was detected 
at 654-656 nm, in which a peak at 655 nm was dominant. Fluorescence spectra of 
TPCS2a obtained from control, tumor control and TPCS2a-treated bladder samples 
in this study are shown in Figure 2, in which only the TPCS2a-treated sample 
presents the typical TPCS2a fluorescence spectrum [24]. Thus, for the data 
collection in this study, only relative fluorescence intensity (RFI) at the peak of 
654-656 nm from the typical TPCS2a spectrum was recorded to present the 
amount of retentive TPCS2a in the measured tissue, and calibrated to integration 
time 200 ms of the instrument. For TPCS2a-free tissue, such as control and tumor 
control in Figure 2, the value of RFI was set to zero in subsequent experiments 
(see Figure 3).  
 
 
 
 
             wavelength, nm
550 600 650 700 750 800
-500
0
500
1000
1500
2000
control
tumor control
TPCS2a treated
 
 
Figure 2. Fluorescence emission spectra of TPCS2a in bladder tumor tissues. Data were 
obtained from JETI PDT fluorometer at calibrated integration time of 200 ms. 
Fluorescence of TPCS2a was excited at 405 nm by JETI equipped laser. TPCS2a 
fluorescence was detected ex vivo only from TPCS2a-treated bladder tumor tissue, not the 
controls. 
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TPCS2a uptake and elimination in tissue 
 
To explore an optimal concentration of TPCS2a and optimal TPCS2a-to-light time 
interval for the PCI protocol in the tumor model, two animal trials were performed 
(protocol A and B in Methods). The retentive TPCS2a in tumor tissue as measured 
under different treatment conditions is shown in Figure 3. The photosensitizer 
retention in bladder tumor tissue was first explored at 72 h after intravesical 
instillation using four different concentrations of TPCS2a (1, 2, 3 and 5 mg/ml; 
protocol A in Methods). Means of relative fluorescence intensity (RFI) of TPCS2a 
were measured and calculated as 1.8, 11.9, 15.7 and 22.8 respectively, with 
increasing concentration of TPCS2a, showing a clear dose-dependency (Figure 
3A). One animal with extremely high uptake was observed in the group treated 
with 5 mg/ml TPCS2a. However, significant difference of the mean was neither 
observed between the groups treated with 2 and 3 mg/ml, nor between the groups 
treated with 3 and 5 mg/ml TPCS2a (two-tailed unpaired t-test, p value > 0.05). 
Based on this, 3 mg/ml was chosen for further study on four different retention 
time intervals (4, 24, 48 and 72 h; protocol B in Methods). Mean of retentive 
TPCS2a was obtained as 427, 669, 236, and 1.7 RFI respectively with increasing 
time after administration (Figure 3B). The maximum retentive TPCS2a was seen at 
24 h after intravesical instillation, and elimination of TPCS2a occurred thereafter. 
Tissue TPCS2a was almost cleared after 72 hours (Figure 3B). A time interval of 
24 h was therefore chosen for the animal trial using protocol C (see Figure 6).  
 
 
Figure 3. Uptake and retention of TPCS2a in bladder tumor tissues. (A) Relative 
florescence intensity (RFI) of TPCS2a measured 72 h after intravesical instillation at 
concentration of 1, 2, 3, and 5 mg/ml respectively (protocol A); (B) RFI of TPCS2a with 
an originally instilled concentration of 3 mg/ml measured at retention time of 4, 24, 48, 
and 72 h respectively (protocol B). Data were obtained from a JETI PDT fluorometer at 
calibrated integration time of 200 ms. Mean RFI of each group is shown as a horizontal 
line. Please observe the difference in vertical scale between A and B. 
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Localization of intratumoral TPCS2a  
 
To investigate the distribution and localization of TPCS2a in bladder tumor tissue, 
frozen sections of the tumor samples with strongest RFI from each treated group 
(Fig. 3B) were selected, together with the control samples, to be investigated by 
fluorescence microscopy using a 590 nm long-pass emission filter. Frozen 
sections and their corresponding HES sections from one tumor control and one 
treated sample (4 h of retention time) are shown in Figure 4. We are showing the 
fluorescent image of the sample after 4 h retention time, rather than 24 h, which 
was the optimal TPCS2a-to-light interval (Figure 3B), because of weaker 
fluorescence in the 24 h sample as a result of accidental photobleaching during 
sample sectioning. However, the sample after 4 h retention time had very similar 
measured RFI as the sample after 24 h retention time (Figure 3B) and very similar 
fluorescent distribution pattern. Comparison of the frozen section with its 
corresponding HES section and the control sample shows that TPCS2a was located 
in the tumor surface of the mucosal layer, and that the distribution of TPCS2a is 
superficial (Figure 4C). No fluorescence of TPCS2a was detected in the tumor 
control sample (Figure 4A). Since the emission filter used is 590 nm long-pass, in 
order to confirm that the fluorescent compound was likely to be TPCS2a (emission 
peak at 654-657 nm) [24,25], the neighboring frozen sections from the same 
samples were examined with a band-pass filter (605 ± 55 nm) in a separate 
experiment, and the penetration depth was calculated by a semi-quantitative 
approach (see Figure 5). 
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Figure 4. Fluorescence (A, C) and transmission (B, D) microphotographs of bladder 
tumors taken from a control sample (without TPCS2a) (A, B) or from a TPCS2a-treated 
sample (3 mg/ml, 4 h). The fluorescence images of frozen tissue sections (5 µm) were 
taken from an Olympus IX71 inverted fluorescence microscope (410 nm BP/590 nm LP) 
using a CCD camera (X10) with a 4× objective; while the transmission images of HES-
stained neighboring tissue sections (5 µm,) were taken from a Nikon Eclipse 80i 
microscope with a digital Sight camera using a 20× objective. The fluorescence images 
were enlarged to the same scale as the transmission images. The same histological 
orientation of the fluorescent and transmission images is indicated with the green arrows 
for the tumor areas (the mucosal layer of the bladder wall).  
A. 
B. 
C. 
D.
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Penetration of TPCS2a  
 
The PCI technology only functions within regions of tumor tissue that contain 
photosensitizer. It is therefore important to understand how deeply TPCS2a can 
penetrate into bladder tumor tissue after intravesical instillation. This was 
investigated using microscopic fluorescence photometry (Figure 5). The mean of 
TPCS2a fluorescence intensity (see Methods) measured at each distance from the 
starting point (green arrows) was plotted as a function of tissue depth, confirming 
that TPCS2a penetration was superficial, less than 0.2 mm (Figure 5F).   
 
 
 
Figure 5. Fluorescence intensity of TPCS2a against the depth of tumor. (A) and (B) are 
from the neighboring tissue sections of a control sample (without TPCS2a); while (D) and 
(E) are from the neighboring tissue sections of a TPCS2a-treated sample (3 mg/ml, 4 h). 
The fluorescence images of the frozen tissue sections (5 µm, A and D) and transmission 
images of the HES-stained tissue sections (5 µm, B and E) were taken from the 
microscope (Nikon Eclipse E800) with a thermo-electrically cooled CCD camera 
using a 4× objective. The fluorescence intensity of TPCS2a within the rectangular areas 
was quantified with the software of AquaCosmos and plotted for the control sample (C) 
and the TPCS2a-treated sample (F). The left side of the rectangular areas is the mucosal 
layer of the bladder wall (i.e. the tumor surface). The graphs of tissue distribution were 
plotted with the SigmaPlot® 10 software. 
A. 
D. 
B. 
C. 
E. F. 
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Light activation of TPCS2a in tissue 
 
So far the distribution of TPCS2a in tissue has been estimated using fluorescence. 
It is possible that this underestimates concentrations due to photobleaching 
occurring during sample sectioning, and due to sensitivity of the instrument used 
for fluorescence measurement. In order to investigate more precise location and 
penetration of the photosensitizer under the presumed optimal protocol 
determined using fluorescence measurements (Figure 3), a third animal trial was 
performed (Protocol C in Methods). Here the retentive TPCS2a was activated 
using red light (652 nm, 0.5 J/cm2). This will cause a limited necrosis, which may 
be used to estimate the distribution of TPCS2a in tissue. Necrosis was present in 4 
rat bladders and one sample is shown in Figure 6. Histology of the sample shows 
that necrotic lesions (more than 0.5 mm, black arrows) were found at the surface 
of the mucosal layer of the bladder wall, where TPCS2a was located. The, 
maximum necrotic thickness was measured to be around 1 mm (Figure 6, blue 
arrow). 
 
 
 
 
Figure 6. Histology of tumor-bearing bladder sample after intravesical illumination. The 
photodynamic response was mediated with TPCS2a (3 mg/ml), TPCS2a-to-light interval of 
24 h, and red light (652 nm, 0.5 J/cm2). The induced necrotic area is shown to be 
superficial (pointed to by black arrows) and maximum necrotic thickness is about 1 mm 
(depth of the blue arrow). The image was taken in a Nikon Eclipse 80i microscope using 
a Digital Sight Camera (1×20). 
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Discussion 
 
The PCI technology has been shown to be a potentially effective modality for 
cancer treatment [13]. However, the technology is complex with action 
mechanisms involving both photosensitizer, light, and drug. In particular, after 
choosing a photosensitizer (PS) and light source, the outcome of the PCI modality 
is additionally influenced by the photosensitizer dose, PS-to-light time interval, 
light dosimetry, and presence of molecular oxygen [36]. Thus, the evaluation of 
PCI efficacy requires the modality to be appropriate and optimized. Our previous 
in vitro studies have demonstrated that the AY-27 cell line is very sensitive to 
both TPCS2a concentration and light dose, and that the photodynamic cytotoxicity 
depends upon light activation of cellularly accumulated TPCS2a molecules [8]. 
Our present results show that the retentive TPCS2a concentration in tissue is 
proportional to the original administered doses (Figure 3A). Because most rats 
receiving 5 mg/ml TPCS2a showed similar retentive level as groups with 2 or 
3 mg/ml, we decided to use 3 mg/ml as an optimal concentration of TPCS2a in this 
tumor model. It is desirable to do PCI at a low PS concentration to reduce side 
effects, but going below 3 mg/ml seems to give more cases with very low PS 
uptake (Figure 3A).  
 
It has been supposed that urine formation may be the main reason for drug 
elimination in the rat bladder model after intravesical drug instillation. Other 
mechanisms are also known to be involved, such as removal via blood vessels and 
possibly molecular degradation [37]. Our results show that the concentration of 
TPCS2a in tissue reached maximum within 24 hours after intravesical instillation, 
followed by elimination until clearance from the tissue after 72 hours. Although 
fluorescence intensity was relative strong at the time interval of 4h, it was not 
suitable for animal experiment due to limited time for anesthesia. Thus, we 
decided to use 24 hours as an optimal TPCS2a-to-light time interval in the tumor 
model. 
 
Histological examination showed that the tumors grew from the mucosal layer of 
bladder wall in a multifocal pattern, and developed to Stage T1 or T2 in the tumor 
model (Figure 1). Although tumor size was different between rats, the localization 
and penetration of TPCS2a in tissue was superficial in the mucosal layer as 
demonstrated by both fluorescence microscopy (Figure 4 and 5) and histological 
identification of necrotic area (Figure 6). The depth of the necrotic area (at least 
0.5 mm) is somewhat deeper than the depth measured by fluorescence (less than 
0.2 mm). This may be due to photobleaching, sensitivity of the JETI PDT 
florometer, and high sensitivity of AY-27 cells to TPCS2a and light dose (our 
results in another submitted manuscript). However, both methods show that the 
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affected area is superficial. 
 
In summary, we have established a PCI protocol for the TPCS2a photosensitizer 
for studies of a rat bladder tumor model. The optimal TPCS2a concentration is 
3 mg/ml and optimal time for intravesical illumination for drug release (i.e. 
TPCS2a-to-light interval) is 24 h after TPCS2a instillation. As the location and 
penetration of TPCS2a are shown to be superficial in the rat bladder tumor model, 
further studies on improvement of tissue penetration and optimization of light 
dose are required. 
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